{
  "08c6e9a5-120c-47d2-9f1e-3b708eb8ea05_SpecialistAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"test-patient-001\",\\n  \"demographics\": {\\n    \"age\": 65,\\n    \"gender\": \"Male\"\\n  },\\n  \"current_condition\": {\\n    \"description\": \"Presenting with chest pain and shortness of breath\",\\n    \"duration\": \"3 days\",\\n    \"severity\": \"moderate\"\\n  },\\n  \"medical_history\": [\\n    {\\n      \"condition\": \"Hypertension\",\\n      \"duration\": \"10 years\"\\n    },\\n    {\\n      \"condition\": \"Type 2 Diabetes\",\\n      \"duration\": \"5 years\"\\n    }\\n  ],\\n  \"ehr_analysis\": {\\n    \"summary\": \"This analysis is based on limited information.  The absence of data on smoking status, family history, current medications, and detailed social history limits a complete assessment.  A full clinical examination and further investigations are crucial to determine the definitive diagnosis and appropriate treatment plan.  This report should not be considered a substitute for a comprehensive medical evaluation by a qualified healthcare professional.\",\\n    \"details\": {\\n      \"summary\": \"This analysis is based on limited information.  The absence of data on smoking status, family history, current medications, and detailed social history limits a complete assessment.  A full clinical examination and further investigations are crucial to determine the definitive diagnosis and appropriate treatment plan.  This report should not be considered a substitute for a comprehensive medical evaluation by a qualified healthcare professional.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"\",\\n        \"comorbidity_impact\": \"**  Optimal management of hypertension and T2DM is essential for overall patient well-being and to reduce the risk of complications.\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"**EHR Analysis Agent Report - Patient ID: test-patient-001**\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Demographics:** 65-year-old male.  Age is a significant risk factor for cardiovascular disease.\\\\n* **Medical History:**  10-year history of hypertension and 5-year history of Type 2 Diabetes Mellitus (T2DM). Both are major risk factors for cardiovascular events.  Poorly controlled T2DM, as evidenced by HbA1c of 7.2%, further increases risk.\\\\n* **Current Condition:**  Onset of moderate chest pain and shortness of breath 3 days prior to presentation. This acute symptom presentation warrants immediate investigation.  The combination of chest pain and shortness of breath raises strong suspicion for cardiac ischemia or other life-threatening conditions.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Presenting Complaint:** Acute onset of moderate chest pain and shortness of breath.  This requires urgent evaluation to rule out acute coronary syndrome (ACS), pulmonary embolism (PE), or other critical conditions.\\\\n* **Laboratory Findings:**  Elevated HbA1c (7.2%) indicates poorly controlled T2DM. Elevated LDL cholesterol (140 mg/dL) signifies hyperlipidemia, another significant cardiovascular risk factor.\\\\n* **Comorbidities:** Hypertension and T2DM significantly increase the risk of cardiovascular complications.  The interaction of these conditions necessitates careful consideration of treatment options.\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:** Advanced age increases the likelihood of cardiovascular disease and reduced physiological reserve.\\\\n* **Hypertension:**  A major risk factor for coronary artery disease (CAD), stroke, and heart failure.\\\\n* **Type 2 Diabetes Mellitus:**  Increases the risk of CAD, stroke, peripheral artery disease, and nephropathy.  Poor glycemic control exacerbates these risks.\\\\n* **Hyperlipidemia:**  Contributes significantly to atherosclerosis and the development of CAD.\\\\n* **Smoking Status:**  Information not provided.  Smoking is a crucial risk factor that needs to be ascertained.\\\\n* **Family History:** Information not provided.  Family history of cardiovascular disease would further increase risk assessment.\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nWithout a formal ECOG (Eastern Cooperative Oncology Group) performance status assessment or a similar functional assessment, a precise evaluation is limited. However, based on the acute presentation of chest pain and shortness of breath, it is reasonable to assume a significantly reduced performance status, potentially ECOG 2-4, until further evaluation clarifies the severity and underlying cause of symptoms.  The patient\\'s ability to perform activities of daily living is likely compromised.\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\nThe patient\\'s presentation necessitates immediate and comprehensive investigation.  The high likelihood of a critical cardiovascular event demands urgent action.  Initial investigations should include:\\\\n\\\\n* **Electrocardiogram (ECG):** To assess for evidence of myocardial ischemia or arrhythmias.\\\\n* **Cardiac biomarkers (troponin, CK-MB):** To rule out myocardial infarction (MI).\\\\n* **Chest X-ray:** To evaluate for pulmonary pathology, such as pneumonia or pulmonary edema.\\\\n* **D-dimer:** To assess the risk of pulmonary embolism.\\\\n* **Further investigations may be necessary depending on initial findings** (e.g., echocardiogram, coronary angiography, computed tomography pulmonary angiography).\\\\n\\\\n**Treatment Planning Considerations:**\\\\n\\\\nTreatment will depend heavily on the results of the above investigations.  However, given the comorbidities, careful consideration must be given to:\\\\n\\\\n* **Potential drug interactions:**  Multiple medications will likely be required to manage the acute condition and the underlying comorbidities.  Careful attention to potential drug interactions is crucial.\\\\n* **Comorbidity management:**  Optimal management of hypertension and T2DM is essential for overall patient well-being and to reduce the risk of complications.\\\\n* **Patient preferences and shared decision-making:**  Treatment decisions should always involve the patient and consider their individual preferences and values.\\\\n\\\\n\\\\n**Limitations and Uncertainties:**\\\\n\\\\nThis analysis is based on limited information.  The absence of data on smoking status, family history, current medications, and detailed social history limits a complete assessment.  A full clinical examination and further investigations are crucial to determine the definitive diagnosis and appropriate treatment plan.  This report should not be considered a substitute for a comprehensive medical evaluation by a qualified healthcare professional.\"\\n    }\\n  },\\n  \"imaging_analysis\": {\\n    \"summary\": \"**Imaging Analysis Agent Report - Patient ID: test-patient-001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Agent Report - Patient ID: test-patient-001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"Details not specified\",\\n        \"nodal_status\": \"\",\\n        \"metastatic_status\": \"\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"Imaging findings analyzed\"\\n        ]\\n      },\\n      \"treatment_implications\": []\\n    }\\n  },\\n  \"pathology_analysis\": {\\n    \"summary\": \"**Pathology Analysis Agent Report - Patient ID: test-patient-001**\",\\n    \"details\": {\\n      \"summary\": \"**Pathology Analysis Agent Report - Patient ID: test-patient-001**\",\\n      \"histology\": \"**\",\\n      \"molecular_profile\": {\\n        \"key_mutations\": \"Key mutations not specified\",\\n        \"immunotherapy_markers\": \"\",\\n        \"other_markers\": {}\\n      },\\n      \"therapeutic_implications\": [\\n        \"The elevated cardiac biomarkers strongly suggest the need for urgent investigation to rule out acute myocardial infarction or other forms of acute coronary syndrome.  Immediate management should focus on stabilizing the patient\\'s condition and conducting the following:\",\\n        \"**Electrocardiogram (ECG):** To assess for ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI).\",\\n        \"**Further cardiac enzyme monitoring:** Serial measurements of troponin and CK-MB are crucial to assess the extent and evolution of myocardial damage.\",\\n        \"**Chest X-ray:** To evaluate for pulmonary edema or other pulmonary pathology.\",\\n        \"**Echocardiogram:** To assess cardiac function and identify potential structural abnormalities.\",\\n        \"**Coronary angiography:**  If ECG and echocardiogram findings are suggestive of significant coronary artery disease, coronary angiography is essential to visualize the coronary arteries and determine the need for revascularization procedures (percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)).\",\\n        \"*7. Recommendations for Additional Testing:**\",\\n        \"Given the incomplete data and the suspicion of cardiovascular disease, the following additional tests are strongly recommended:\",\\n        \"**Complete blood count (CBC):** Although initially reported as normal, repeat CBC is recommended to monitor for any changes.\",\\n        \"**Comprehensive metabolic panel (CMP):** To assess renal function, electrolyte balance, and glucose control.\",\\n        \"**Lipid profile:** To assess cholesterol levels and risk factors for atherosclerosis.\",\\n        \"**Cardiac MRI:**  To assess myocardial viability, scar tissue, and the extent of myocardial damage.\",\\n        \"**Assessment of risk factors:** Detailed information regarding smoking status, family history of cardiovascular disease, current medications, and social history is essential for a complete risk stratification.\",\\n        \"*8. Limitations and Uncertainties:**\",\\n        \"This analysis is based on limited laboratory data and lacks crucial clinical information (e.g., detailed history, physical examination findings, imaging results).  The absence of tissue-based pathological analysis significantly limits the ability to provide a definitive diagnosis and tailored treatment plan.  This report should be considered preliminary and must be integrated with a comprehensive clinical evaluation to formulate an appropriate management strategy.  The information provided should not be used as the sole basis for clinical decision-making.\",\\n        \"*9.  Pathological Diagnosis (Provisional):**\",\\n        \"Based on the limited data, a provisional diagnosis of possible acute coronary syndrome (ACS) is suggested.  Further investigations are absolutely necessary to confirm or refute this diagnosis and to identify the specific cause of the patient\\'s symptoms.\"\\n      ]\\n    }\\n  },\\n  \"guideline_recommendations\": [\\n    {\\n      \"guideline\": \"**  These guidelines provide a structured approach to evaluating patients presenting with chest pain, emphasizing a systematic approach to ruling out life-threatening conditions.\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"*2. Evidence-Based Treatment Options:**\",\\n        \"**ACS Management:**  This may involve antiplatelet therapy (aspirin, P2Y12 inhibitors), anticoagulation (heparin), and potentially reperfusion therapy (PCI or CABG) if coronary angiography reveals significant coronary artery disease.\",\\n        \"**Hypertension Management:**  This will likely involve continued or adjusted antihypertensive medication, aiming for optimal blood pressure control.\",\\n        \"**Diabetes Management:**  This will involve managing blood glucose levels through lifestyle modifications and/or medication.\",\\n        \"*3. Clinical Trial Eligibility:**\"\\n      ]\\n    },\\n    {\\n      \"guideline\": \"**\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"*5. Special Considerations:**\",\\n        \"**Polypharmacy:**  The patient\\'s multiple comorbidities will likely require multiple medications.  Careful consideration of potential drug interactions is essential.\",\\n        \"**Patient Preferences:**  Treatment decisions should be made in collaboration with the patient, considering his preferences and values.\",\\n        \"**Geriatric Considerations:**  The patient\\'s age requires careful consideration of potential age-related physiological changes and medication side effects.\",\\n        \"*Recommendations:**\",\\n        \"**Immediate Investigations:**  ECG, cardiac biomarkers (troponin, CK-MB), chest X-ray, and D-dimer are urgently needed.  Further investigations (echocardiogram, coronary angiography) may be necessary depending on initial findings.\",\\n        \"**Complete Medical History:**  Gather detailed information about smoking status, family history, current medications, and social history.\"\\n      ]\\n    },\\n    {\\n      \"guideline\": \"**  Once investigations are complete and a diagnosis is established, apply the appropriate guidelines for ACS, hypertension, and type 2 diabetes.\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"**Clinical Trial Exploration:**  Explore clinical trial eligibility based on the definitive diagnosis.\",\\n        \"**Multidisciplinary Approach:**  Involve a multidisciplinary team (cardiology, endocrinology, etc.) for optimal management.\",\\n        \"*Limitations and Uncertainties:**\",\\n        \"This analysis is based on limited information.  The lack of detailed clinical data, including physical examination findings and imaging results, prevents a definitive diagnosis and treatment plan.  The recommendations above are preliminary and subject to change based on further investigations and clinical findings.\"\\n      ]\\n    }\\n  ]\\n}', 'task': 'Synthesize all available information and provide an expert clinical assessment including treatment recommendations, risk stratification, and special considerations. Consider both patient-specific factors and guideline recommendations.'}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'overall_assessment': '**', 'treatment_considerations': ['* **Unknown Medication List:**  Understanding current medications is vital to avoid drug interactions and optimize treatment.  This is especially critical given the likely need for multiple medications to manage the acute condition and comorbidities.', '**4. Treatment Options:**', 'The immediate priority is stabilization and rapid diagnosis.  Treatment depends entirely on the results of the urgently needed investigations.', '* **Acute Management (Pending Investigations):**  Oxygen therapy, intravenous fluids, and monitoring of vital signs are essential.  Early initiation of aspirin and potentially other antiplatelet agents (e.g., ticagrelor, prasugrel) may be considered based on clinical suspicion and ECG findings, but should be guided by experienced clinicians.  Anticoagulation with heparin may be necessary if PE is suspected.', '* **ACS Management:**  PCI or CABG if coronary angiography reveals significant coronary artery disease.  Medical management includes antiplatelet therapy, anticoagulation, and beta-blockers.'], 'risk_assessment': '**', 'proposed_approach': 'Individualized approach recommended.', 'follow_up_recommendations': ['*10. Limitations and Uncertainties:**', 'This assessment is based on limited information.  The absence of detailed history, physical examination findings, and complete laboratory results prevents a definitive diagnosis and precise treatment plan.  The recommendations are preliminary and subject to change based on further investigations and clinical findings.  A comprehensive clinical evaluation is absolutely necessary.']}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "991390b7-e3e8-4f36-ad6f-eda915d264e4_SpecialistAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"medical_history\": [\\n    {\\n      \"condition\": \"Type 2 Diabetes\",\\n      \"diagnosed\": \"2015-06-15\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Metformin 1000mg BID\",\\n      \"control\": \"Good, HbA1c 6.8%\"\\n    },\\n    {\\n      \"condition\": \"Hypertension\",\\n      \"diagnosed\": \"2016-03-22\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Lisinopril 20mg daily\",\\n      \"control\": \"Well-controlled, BP avg 128/78\"\\n    },\\n    {\\n      \"condition\": \"Osteoarthritis\",\\n      \"diagnosed\": \"2018-11-30\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"PRN NSAIDs\",\\n      \"affected_joints\": [\\n        \"knees\",\\n        \"hands\"\\n      ]\\n    }\\n  ],\\n  \"ehr_analysis\": {\\n    \"summary\": \"Based on the presented information, a preliminary assessment suggests a Karnofsky Performance Status (KPS) score of 60-70%. This is an educated guess based on the reported fatigue, weight loss, and moderate to severe cough.  A more precise assessment requires a detailed functional assessment evaluating activities of daily living (ADLs).  The ECOG performance status would likely be 2.\",\\n    \"details\": {\\n      \"summary\": \"Based on the presented information, a preliminary assessment suggests a Karnofsky Performance Status (KPS) score of 60-70%. This is an educated guess based on the reported fatigue, weight loss, and moderate to severe cough.  A more precise assessment requires a detailed functional assessment evaluating activities of daily living (ADLs).  The ECOG performance status would likely be 2.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"**  This patient requires urgent further investigation to confirm the diagnosis and stage the potential lung cancer. A multidisciplinary team (MDT) approach involving pulmonology, oncology, radiology, pathology, and potentially thoracic surgery is essential for optimal patient care.  The comorbidities need to be carefully managed throughout the treatment process.  Regular monitoring of performance status is crucial for adapting the treatment plan as needed.\",\\n        \"comorbidity_impact\": \"**  The patient\\'s Type 2 Diabetes and hypertension will necessitate careful monitoring and adjustments to medications during and after cancer treatment.  The osteoarthritis may influence pain management strategies.  Close collaboration with endocrinology and cardiology will be crucial.\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"**EHR Analysis Agent Report: Patient ID MDT2024001**\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:** The patient, a 62-year-old Caucasian female, presents with a persistent cough (onset January 15, 2024) initially described as moderate to severe, progressing to include blood-tinged sputum.  Significant associated symptoms include unintentional weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats \\\\u2013 all highly suggestive of malignancy.\\\\n\\\\n* **Medical History:**  The patient has a history of well-controlled Type 2 Diabetes (since 2015), well-controlled hypertension (since 2016), and osteoarthritis (since 2018).  These comorbidities will influence treatment choices and require careful monitoring.  Her former smoking status (quit 10 years ago) remains a significant risk factor.\\\\n\\\\n* **Social and Functional Factors:**  The patient is retired, suggesting potential availability for treatment but also potentially increased vulnerability due to reduced social support and physical activity.  Further social history is required to confirm this.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Primary Complaint:** Persistent cough with hemoptysis.\\\\n* **Physical Exam:** Significant findings include decreased breath sounds in the right upper lobe and right supraclavicular lymphadenopathy \\\\u2013 highly suspicious for lung cancer.  Vital signs are relatively stable, although the slightly elevated blood pressure warrants monitoring.\\\\n* **Laboratory Results:**  The complete blood count (CBC) shows normal hemoglobin, white blood cell count, and platelets, which is not definitive but doesn\\'t immediately suggest severe anemia or infection.  Liver function tests (LFTs) are mildly elevated (ALT 28 U/L, AST 32 U/L), which may be related to the underlying condition or medications, necessitating further investigation.  Albumin is within the normal range.  Renal function is normal (creatinine 0.9 mg/dL).\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:** 62 years old (increased risk for lung cancer).\\\\n* **Gender:** Female (although lung cancer is more common in males, it\\'s still a significant risk).\\\\n* **Smoking History:** Former smoker (significant risk factor, even after cessation).\\\\n* **Symptoms:**  Classic presentation suggestive of lung cancer: cough, hemoptysis, weight loss, fatigue, anorexia, night sweats.\\\\n* **Physical Exam:** Right supraclavicular lymphadenopathy is a serious warning sign.\\\\n\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nBased on the presented information, a preliminary assessment suggests a Karnofsky Performance Status (KPS) score of 60-70%. This is an educated guess based on the reported fatigue, weight loss, and moderate to severe cough.  A more precise assessment requires a detailed functional assessment evaluating activities of daily living (ADLs).  The ECOG performance status would likely be 2.\\\\n\\\\n\\\\n**5. Clinical Implications and Treatment Planning:**\\\\n\\\\nThe clinical presentation strongly suggests the possibility of lung cancer.  The right supraclavicular lymphadenopathy points towards advanced disease potentially involving mediastinal lymph nodes.  Further investigations are urgently required:\\\\n\\\\n* **Imaging:** High-resolution computed tomography (HRCT) of the chest is essential to confirm the presence of a lung mass, assess its size, location, and relationship to surrounding structures, and evaluate for mediastinal lymph node involvement.  A PET-CT scan would be beneficial for staging.\\\\n* **Bronchoscopy:**  To obtain tissue samples for histopathological examination (biopsy) and cytology.  This is crucial for definitive diagnosis and determining the type and subtype of lung cancer.\\\\n* **Thoracic Surgery Consultation:**  For potential biopsy and/or surgical intervention depending on the findings.\\\\n* **Oncology Consultation:** To discuss treatment options based on the staging and histological findings, which may include chemotherapy, targeted therapy, immunotherapy, or radiation therapy, or a combination.\\\\n\\\\n**Comorbidities\\' Impact on Treatment:**  The patient\\'s Type 2 Diabetes and hypertension will necessitate careful monitoring and adjustments to medications during and after cancer treatment.  The osteoarthritis may influence pain management strategies.  Close collaboration with endocrinology and cardiology will be crucial.\\\\n\\\\n**Medication Interactions:**  A thorough review of all current medications (Metformin, Lisinopril, PRN NSAIDs) is necessary to assess potential interactions with any planned cancer therapies.\\\\n\\\\n**Limitations and Uncertainties:** The diagnosis remains presumptive pending further investigations.  The severity of the lung cancer and its impact on prognosis cannot be definitively determined without further diagnostic testing and staging.\\\\n\\\\n\\\\n**Conclusion:**  This patient requires urgent further investigation to confirm the diagnosis and stage the potential lung cancer. A multidisciplinary team (MDT) approach involving pulmonology, oncology, radiology, pathology, and potentially thoracic surgery is essential for optimal patient care.  The comorbidities need to be carefully managed throughout the treatment process.  Regular monitoring of performance status is crucial for adapting the treatment plan as needed.\"\\n    }\\n  },\\n  \"imaging_analysis\": {\\n    \"summary\": \"**Imaging Analysis Report: Patient ID MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Report: Patient ID MDT2024001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"**  If there is uncertainty about the extent of the primary tumor or the involvement of smaller lymph nodes.\",\\n        \"nodal_status\": \"** These are crucial for accurate staging of mediastinal lymph nodes.  This is necessary to confirm the N-stage and refine the overall staging.\",\\n        \"metastatic_status\": \"\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The finding is highly suggestive of a primary lung malignancy.  The limited resolution prevents precise characterization of the lesion.\",\\n          \"* **CT Chest (2024-02-05):**  Confirms a 3.8 x 3.2 cm spiculated mass in the right upper lobe.  Multiple enlarged right hilar and mediastinal lymph nodes are present.  No evidence of distant metastases is identified. Mild emphysematous changes are noted in the upper lobes.  The spiculated margins of the mass are concerning for malignancy.\",\\n          \"* **PET-CT (2024-02-12):**  Shows a right upper lobe mass with a maximum standardized uptake value (SUVmax) of 12.4, indicating high metabolic activity consistent with malignancy.  FDG-avid right hilar and mediastinal lymph nodes are present, with a maximum SUVmax of 8.2, further supporting the diagnosis of lymph node involvement.  No evidence of distant metastatic disease is detected.\",\\n          \"* **Primary Lesion:** 3.8 x 3.2 cm (CT Chest)\",\\n          \"* **SUVmax of Primary Lesion:** 12.4 (PET-CT)\",\\n          \"Based on the imaging findings, the patient presents with a large primary lung mass in the right upper lobe with involvement of regional lymph nodes (hilar and mediastinal).  There is no evidence of distant metastases.  This imaging profile is most consistent with **Stage IIIA Non-Small Cell Lung Cancer (NSCLC)** according to the 8th edition TNM staging system.  However, this is a preliminary assessment pending histopathological confirmation of the diagnosis and precise nodal staging which requires tissue sampling and potentially mediastinoscopy or endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA).\",\\n          \"The primary lesion is located in the right upper lobe, close to the hilum and major vessels. The extent of lymph node involvement needs further clarification through invasive procedures to determine the exact N category. The close proximity of the tumor to major vessels could influence surgical resectability. The mild emphysema might impact surgical planning and post-operative recovery.\"\\n        ]\\n      },\\n      \"treatment_implications\": []\\n    }\\n  },\\n  \"pathology_analysis\": {\\n    \"summary\": \"**\",\\n    \"details\": {\\n      \"summary\": \"**\",\\n      \"histology\": \"**\",\\n      \"molecular_profile\": {\\n        \"key_mutations\": \"**4. Biomarker Status:**\",\\n        \"immunotherapy_markers\": \"\",\\n        \"other_markers\": {\\n          \"KRAS\": \"**  Sotorasib and adagrasib are FDA-approved targeted therapies specifically designed to inhibit KRAS G12C mutant proteins.  These should be considered as first-line treatment options given the strong molecular driver.\"\\n        }\\n      },\\n      \"therapeutic_implications\": [\\n        \"The provided data does not specify the grade or differentiation of the adenocarcinoma.  Further histopathological review of the biopsy specimen, including assessment of nuclear pleomorphism, mitotic rate, and architectural features, is necessary to determine the grade and level of differentiation. This information is crucial for prognosis and treatment planning.\",\\n        \"Molecular testing reveals a *KRAS* G12C mutation.  *EGFR*, *ALK*, and *ROS1* are wild type (no rearrangements detected).  The presence of a *KRAS* G12C mutation is a significant finding, as it identifies a targetable oncogenic driver.\",\\n        \"PD-L1 expression is 80%, indicating a high likelihood of response to immunotherapy.  This is a significant positive biomarker for treatment selection.\",\\n        \"**5. Therapeutic Targets and Implications:**\",\\n        \"* **KRAS G12C Inhibitors:**  Sotorasib and adagrasib are FDA-approved targeted therapies specifically designed to inhibit KRAS G12C mutant proteins.  These should be considered as first-line treatment options given the strong molecular driver.\",\\n        \"* **Immunotherapy:**  Given the high PD-L1 expression (80%), immunotherapy with a PD-1 or PD-L1 inhibitor (e.g., pembrolizumab, nivolumab, atezolizumab) could be highly effective either as monotherapy or in combination with a KRAS G12C inhibitor.  The high PD-L1 expression supports the use of immunotherapy, even in the context of a *KRAS* mutation.  Combination therapy may offer synergistic effects.\",\\n        \"* **Chemotherapy:**  While targeted therapy and immunotherapy are preferred given the molecular profile, chemotherapy might be considered in specific circumstances, such as in cases of resistance to targeted therapy.\",\\n        \"* **Comprehensive genomic profiling:**  Consideration of broader next-generation sequencing (NGS) panels to screen for other potential actionable mutations beyond the *KRAS* G12C mutation.  This can identify additional therapeutic targets if the initial treatment fails.\",\\n        \"* **Assessment of performance status:**  A formal assessment of the patient\\'s Karnofsky Performance Status (KPS) and Eastern Cooperative Oncology Group (ECOG) performance status is essential for tailoring treatment decisions and managing treatment-related toxicities.\",\\n        \"This patient presents with a lung adenocarcinoma with a *KRAS* G12C mutation and high PD-L1 expression.  This molecular profile suggests a favorable prognosis and opens up several effective treatment options, primarily KRAS G12C inhibitors and immunotherapy, potentially used in combination.  However, a complete histopathological evaluation and further staging are crucial to refine the treatment plan and provide accurate prognostic information.  The MDT should carefully consider all findings and the patient\\\\u2019s overall health to develop a personalized treatment strategy.  Regular monitoring of response to therapy and potential toxicities is essential.\"\\n      ]\\n    }\\n  },\\n  \"guideline_recommendations\": [\\n    {\\n      \"guideline\": \"**\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"*3. Special Populations and Evidence Levels:**\",\\n        \"*4. Evidence-Based Treatment Options:**\"\\n      ]\\n    },\\n    {\\n      \"guideline\": \"**\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"*7. Recommendations:**\",\\n        \"**Detailed Staging:**  Complete staging, including mediastinoscopy or EBUS-TBNA if necessary, is critical for definitive staging and accurate treatment planning.\",\\n        \"**Multidisciplinary Team (MDT) Meeting:**  An urgent MDT meeting involving pulmonology, oncology, thoracic surgery, pathology, and radiology is essential to discuss the case and formulate a personalized treatment plan.\",\\n        \"**Treatment Plan:**  A tailored treatment plan should prioritize KRAS G12C inhibitors and immunotherapy, with careful consideration of potential combinations.  Close monitoring for treatment response and toxicity is crucial.\",\\n        \"**Comorbidity Management:**  A detailed plan for managing the patient\\'s comorbidities (diabetes, hypertension, osteoarthritis) should be implemented to minimize treatment-related complications.\",\\n        \"**Clinical Trial Consideration:**  The patient should be assessed for eligibility in relevant clinical trials.\",\\n        \"**Supportive Care:**  Comprehensive supportive care, including pain management, nutritional support, and psychological counseling, should be provided to improve quality of life.\",\\n        \"*8.  Limitations and Uncertainties:**\",\\n        \"*9. Documentation:**\"\\n      ]\\n    }\\n  ]\\n}', 'task': 'Synthesize all available information and provide an expert clinical assessment including treatment recommendations, risk stratification, and special considerations. Consider both patient-specific factors and guideline recommendations.'}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'overall_assessment': '**  Close monitoring of treatment response, toxicity, and performance status is crucial.  This includes regular blood tests, imaging studies (CT scans), and clinical assessments.', 'treatment_considerations': ['Patient MDT2024001 is a 62-year-old Caucasian female presenting with a concerning constellation of symptoms highly suggestive of advanced non-small cell lung cancer (NSCLC).  The imaging (CT chest and PET-CT) reveals a 3.8 x 3.2 cm spiculated mass in the right upper lobe with significant hilar and mediastinal lymph node involvement.  Pathology confirms a lung adenocarcinoma with a *KRAS* G12C mutation and a high PD-L1 expression (80%).  This represents a significant finding, as it identifies a targetable oncogenic driver and a strong predictor of immunotherapy response.  The clinical stage is preliminarily assessed as IIIA NSCLC, pending definitive nodal staging via mediastinoscopy or EBUS-TBNA.  Her comorbidities (Type 2 Diabetes, hypertension, osteoarthritis) will require careful management throughout the treatment process.  Her KPS is estimated at 60-70%, reflecting her symptomatic burden.  A comprehensive functional assessment is necessary to refine this score.', '**4. Treatment Options:**', 'Given the *KRAS* G12C mutation and high PD-L1 expression, the treatment strategy should prioritize targeted therapy and immunotherapy.', '* **First-line Treatment:**  A combination of a KRAS G12C inhibitor (sotorasib or adagrasib) and a PD-1/PD-L1 inhibitor (pembrolizumab, nivolumab, or atezolizumab) is the preferred approach based on current evidence.  This combination is likely to provide the best chance of achieving durable disease control and improved survival.', '* **Alternative Strategies:** If the patient is not a suitable candidate for combination therapy due to comorbidities or performance status, monotherapy with either a KRAS G12C inhibitor or a PD-1/PD-L1 inhibitor could be considered.  Chemotherapy would be a less favorable option given the available targeted therapies.'], 'risk_assessment': '', 'proposed_approach': 'Individualized approach recommended.', 'follow_up_recommendations': ['*9. Limitations and Uncertainties:**', 'The current assessment relies on available data and is subject to change based on the results of the mediastinoscopy or EBUS-TBNA and further histopathological evaluation.  Prognostication is dependent on accurate staging and response to treatment.', '*In summary:** Patient MDT2024001 requires urgent definitive staging and initiation of treatment with a KRAS G12C inhibitor and a PD-1/PD-L1 inhibitor.  A multidisciplinary approach is crucial for optimizing treatment and managing her comorbidities.  Close monitoring of treatment response and quality of life is essential.']}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "e594fda1-7c91-45c2-9394-fc7360d58e04_SpecialistAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"medical_history\": [\\n    {\\n      \"condition\": \"Type 2 Diabetes\",\\n      \"diagnosed\": \"2015-06-15\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Metformin 1000mg BID\",\\n      \"control\": \"Good, HbA1c 6.8%\"\\n    },\\n    {\\n      \"condition\": \"Hypertension\",\\n      \"diagnosed\": \"2016-03-22\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Lisinopril 20mg daily\",\\n      \"control\": \"Well-controlled, BP avg 128/78\"\\n    },\\n    {\\n      \"condition\": \"Osteoarthritis\",\\n      \"diagnosed\": \"2018-11-30\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"PRN NSAIDs\",\\n      \"affected_joints\": [\\n        \"knees\",\\n        \"hands\"\\n      ]\\n    }\\n  ],\\n  \"ehr_analysis\": {\\n    \"summary\": \"Based on the presented information, a preliminary assessment suggests a performance status of ECOG 2-3.  The patient is experiencing significant symptoms (fatigue, weight loss, cough) impacting her daily activities.  Further assessment using a validated performance status scale (e.g., ECOG, Karnofsky) is necessary for a definitive assessment.\",\\n    \"details\": {\\n      \"summary\": \"Based on the presented information, a preliminary assessment suggests a performance status of ECOG 2-3.  The patient is experiencing significant symptoms (fatigue, weight loss, cough) impacting her daily activities.  Further assessment using a validated performance status scale (e.g., ECOG, Karnofsky) is necessary for a definitive assessment.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"\",\\n        \"comorbidity_impact\": \"** The patient has well-controlled Type 2 Diabetes Mellitus (diagnosed 2015), well-controlled hypertension (diagnosed 2016), and osteoarthritis (diagnosed 2018). These comorbidities will need careful consideration during treatment planning due to potential drug interactions and impact on overall tolerance.\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"## EHR Analysis Agent Report: Patient MDT2024001\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:** The patient, a 62-year-old Caucasian female, presents with a persistent cough (onset January 15th, 2024) initially characterized as moderate to severe, now complicated by occasional blood-tinged sputum.  This is accompanied by significant unintentional weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats \\\\u2013 all highly suggestive of a serious underlying condition, potentially malignancy.\\\\n\\\\n* **Comorbidities:** The patient has well-controlled Type 2 Diabetes Mellitus (diagnosed 2015), well-controlled hypertension (diagnosed 2016), and osteoarthritis (diagnosed 2018). These comorbidities will need careful consideration during treatment planning due to potential drug interactions and impact on overall tolerance.\\\\n\\\\n* **Social and Functional Factors:** The patient is a retired teacher, suggesting a potentially stable social support network but also potential limitations in physical activity due to osteoarthritis.  Her retirement status may impact her ability to tolerate intensive treatment regimens.\\\\n\\\\n* **Risk Factors:**  Former smoker (quit 10 years ago) increases the risk of lung cancer.  Age (62) also places her within a high-risk age group for various malignancies.  The combination of weight loss, cough, hemoptysis, and lymphadenopathy significantly increases suspicion for lung cancer.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Primary Complaint:** Persistent cough with hemoptysis.\\\\n* **Physical Exam:**  Significant findings include decreased breath sounds in the right upper lobe, right supraclavicular lymphadenopathy, and unintentional weight loss. These findings strongly suggest a possible right upper lobe lung mass.\\\\n* **Laboratory Results:**  While the complete blood count (CBC) shows no overt anemia (hemoglobin 12.8 g/dL), the liver function tests (LFTs) show mildly elevated AST (32 U/L) and ALT (28 U/L), which warrants further investigation.  Albumin levels are within the normal range.  Creatinine is normal.\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:** 62 years old (increased risk for various cancers)\\\\n* **Smoking History:** Former smoker (increased risk of lung cancer)\\\\n* **Weight Loss:** Significant unintentional weight loss (5kg in 3 months) \\\\u2013 a major red flag for malignancy.\\\\n* **Hemoptysis:** Presence of blood in sputum.\\\\n* **Lymphadenopathy:** Right supraclavicular lymphadenopathy \\\\u2013 suggestive of metastatic disease.\\\\n* **Fatigue, Anorexia, Night Sweats:**  Constitutional symptoms highly suggestive of malignancy.\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nBased on the presented information, a preliminary assessment suggests a performance status of ECOG 2-3.  The patient is experiencing significant symptoms (fatigue, weight loss, cough) impacting her daily activities.  Further assessment using a validated performance status scale (e.g., ECOG, Karnofsky) is necessary for a definitive assessment.\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\nThe clinical presentation strongly suggests the possibility of lung cancer.  The right upper lobe findings, lymphadenopathy, and constitutional symptoms warrant urgent further investigation.\\\\n\\\\n**Further Investigations:**\\\\n\\\\n* **Chest X-ray:** To confirm the presence and extent of the suspected lung lesion.\\\\n* **Computed Tomography (CT) Scan of the Chest and Abdomen/Pelvis:** To further characterize the lung lesion, assess for mediastinal involvement, and evaluate for distant metastases.\\\\n* **Bronchoscopy with Bronchoalveolar Lavage (BAL) and Biopsy:**  To obtain tissue for definitive pathological diagnosis.\\\\n* **Positron Emission Tomography (PET) Scan:** To assess for distant metastases and to stage the disease.\\\\n* **Further Blood Tests:**  Tumor markers (CEA, CYFRA 21-1) may be considered.\\\\n\\\\n\\\\n**Treatment Planning:**\\\\n\\\\nTreatment planning will depend heavily on the pathological diagnosis, staging, and the patient\\'s performance status.  Options may include surgery, chemotherapy, radiation therapy, targeted therapy, or a combination thereof.  Management of comorbidities (diabetes, hypertension, osteoarthritis) will be crucial throughout the treatment process.  Close monitoring of medication interactions will be essential.  A multidisciplinary team (MDT) approach involving pulmonologists, oncologists, radiologists, pathologists, and potentially other specialists is crucial for optimal patient care.\\\\n\\\\n**Limitations and Uncertainties:**\\\\n\\\\nThis analysis is based on limited information.  A definitive diagnosis and treatment plan require further investigations as outlined above.  The severity of comorbidities and their impact on treatment tolerance remain to be fully assessed.\\\\n\\\\n**Patient-Centered Care:**\\\\n\\\\nThroughout the diagnostic and treatment process, patient preferences, values, and goals must be considered and integrated into the care plan.  Open communication and shared decision-making are essential to ensure optimal patient-centered care.\"\\n    }\\n  },\\n  \"imaging_analysis\": {\\n    \"summary\": \"## Imaging Analysis Report: Patient MDT2024001\",\\n    \"details\": {\\n      \"summary\": \"## Imaging Analysis Report: Patient MDT2024001\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"** 3.8 x 3.2 cm (CT Chest)\",\\n        \"nodal_status\": \"** This is highly recommended to obtain tissue samples for definitive diagnosis and to further characterize the mediastinal lymph node involvement.  This will allow for precise staging and surgical planning.\",\\n        \"metastatic_status\": \"**  Given the physical exam findings, further evaluation of the supraclavicular lymphadenopathy with ultrasound or CT is warranted to assess for potential metastatic spread.\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The impression of a highly suspicious primary lung malignancy is consistent with subsequent imaging.\",\\n          \"* **CT Chest (2024-02-05):** Confirms a 3.8 x 3.2 cm spiculated mass in the right upper lobe, consistent with malignancy.  Multiple enlarged right hilar and mediastinal lymph nodes are identified. No evidence of distant metastases is seen. Mild emphysematous changes are noted in the upper lobes.\",\\n          \"* **PET-CT (2024-02-12):**  Shows an SUVmax of 12.4 in the right upper lobe mass, confirming its high metabolic activity.  FDG-avid right hilar and mediastinal lymph nodes are present (SUVmax 8.2), indicating likely metastatic involvement. No evidence of distant metastatic disease is detected.\",\\n          \"* **Primary lesion:** 3.8 x 3.2 cm (CT Chest)\",\\n          \"Based on the imaging findings, the patient presents with a right upper lobe lung mass with significant mediastinal lymph node involvement and no evidence of distant metastases.  This strongly suggests a Stage IIIA non-small cell lung cancer (NSCLC) according to the 8th edition TNM staging system.  Further clarification regarding precise nodal involvement (N2 vs N3) may require further imaging or pathological assessment.  The exact T-stage (T1-T4) will require pathological confirmation following biopsy. However, based on the size of the lesion, a T2-T3 classification is likely.  Therefore, a preliminary staging assessment is **Stage IIIA (T2-3 N2 M0)**, acknowledging the possibility of refinement upon histopathological analysis.\",\\n          \"The primary lesion is located in the right upper lobe, close to the hilum, with direct involvement of regional hilar and mediastinal lymph nodes.  The proximity of the tumor to the hilum and the extent of nodal involvement are crucial factors in treatment planning, particularly regarding surgical resectability. The mild emphysema may impact surgical approach and post-operative recovery.  The presence of right supraclavicular lymphadenopathy on physical exam warrants correlation with imaging findings.  It is possible that this is a result of the primary disease, but other possibilities need to be considered.\"\\n        ]\\n      },\\n      \"treatment_implications\": []\\n    }\\n  },\\n  \"pathology_analysis\": {\\n    \"summary\": \"**Pathology Analysis Agent Report: Patient MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Pathology Analysis Agent Report: Patient MDT2024001**\",\\n      \"histology\": \"**\",\\n      \"molecular_profile\": {\\n        \"key_mutations\": \"**4. Biomarker Status:**\",\\n        \"immunotherapy_markers\": \"**  Consideration should be given to a combination of a KRAS G12C inhibitor (sotorasib or adagrasib) and a PD-1/PD-L1 inhibitor.  The high PD-L1 expression strongly supports the inclusion of immunotherapy.\",\\n        \"other_markers\": {}\\n      },\\n      \"therapeutic_implications\": [\\n        \"The provided data does not specify the grade or differentiation of the adenocarcinoma.  This information is crucial for prognosis and treatment planning and should be obtained from the full pathology report.  Further analysis of the biopsy specimen, including assessment of nuclear atypia, mitotic rate, and architectural features, is necessary to determine the grade.\",\\n        \"Molecular testing reveals a *KRAS* G12C mutation.  This is a significant finding, as it identifies a targetable oncogenic driver mutation.  The absence of EGFR, ALK, and ROS1 rearrangements excludes the use of tyrosine kinase inhibitors (TKIs) targeting these pathways.\",\\n        \"* **PD-L1:**  High PD-L1 expression (80%) is observed. This indicates a potential response to immunotherapy, specifically PD-1/PD-L1 inhibitors.  The high expression level suggests a greater likelihood of benefit from immunotherapy compared to lower expression levels.\",\\n        \"**5. Therapeutic Targets:**\",\\n        \"Given the molecular and biomarker profile, the primary therapeutic target is the *KRAS* G12C mutation.  Sotorasib and adagrasib are FDA-approved targeted therapies specifically designed to inhibit KRAS G12C.  The high PD-L1 expression suggests that a combination therapy incorporating a PD-1/PD-L1 inhibitor (e.g., pembrolizumab, nivolumab) alongside a KRAS G12C inhibitor may be highly beneficial.\",\\n        \"* **First-line therapy:**  Consideration should be given to a combination of a KRAS G12C inhibitor (sotorasib or adagrasib) and a PD-1/PD-L1 inhibitor.  The high PD-L1 expression strongly supports the inclusion of immunotherapy.\",\\n        \"* **Alternative strategies:** If the patient is ineligible for or does not tolerate the combination therapy, monotherapy with either a KRAS G12C inhibitor or a PD-1/PD-L1 inhibitor could be considered, although the combination approach is generally preferred given the data.\",\\n        \"* **Close monitoring:**  Close monitoring for treatment response and toxicity is essential.  Regular imaging and clinical assessments are needed to track disease progression and the effects of therapy.\",\\n        \"1. **Complete pathology report:**  Obtain the full pathology report to determine the grade and differentiation of the adenocarcinoma.  This will refine the prognosis and inform treatment decisions.\",\\n        \"2. **Comprehensive genomic profiling:** While KRAS G12C is identified, a more comprehensive genomic profile may reveal other targetable mutations or biomarkers that could influence treatment decisions.\",\\n        \"4. **Further staging investigations:**  While imaging suggests Stage IIIA, definitive staging requires complete pathological assessment of lymph node involvement.  This is crucial for treatment planning (surgery vs. non-surgical options).\",\\n        \"**Disclaimer:** This analysis is based on the provided data and represents a preliminary assessment.  A complete and definitive treatment plan requires a comprehensive review of all clinical information, radiological findings, and the complete pathology report within a multidisciplinary team setting.  The recommendations herein should be considered in consultation with the patient and her treating oncologist.\"\\n      ]\\n    }\\n  },\\n  \"guideline_recommendations\": [\\n    {\\n      \"guideline\": \"**  This is the primary guideline to inform treatment decisions for NSCLC.  Specific sections relevant to this case include those addressing Stage IIIA NSCLC, *KRAS* mutations, and PD-L1 expression.  The NCCN guidelines emphasize a multidisciplinary approach, incorporating surgical, radiation, chemotherapy, and targeted therapy options based on staging, molecular profiling, and patient performance status.\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"**FDA-approved treatments for KRAS G12C-mutated NSCLC:**  The FDA approvals of sotorasib and adagrasib for *KRAS* G12C-mutated NSCLC will be central to treatment recommendations.\"\\n      ]\\n    },\\n    {\\n      \"guideline\": \"** The patient\\'s well-controlled comorbidities (Type 2 Diabetes, hypertension, osteoarthritis) will influence treatment choices.  The guidelines for managing these conditions will be consulted to minimize drug interactions and optimize treatment tolerability.\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"*3. Special Populations and Considerations:**\",\\n        \"*4. Evidence Levels:**\",\\n        \"The recommendations are based on high-level evidence:\"\\n      ]\\n    },\\n    {\\n      \"guideline\": \"** These guidelines represent expert consensus based on the available evidence from randomized controlled trials and observational studies.\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"**FDA approvals of KRAS G12C inhibitors:**  These approvals are based on robust clinical trial data demonstrating significant improvements in progression-free survival and overall survival.\",\\n        \"**Immunotherapy efficacy in NSCLC:**  The efficacy of PD-1/PD-L1 inhibitors in NSCLC is well-established through numerous large-scale clinical trials.\",\\n        \"*5. Clinical Trial Options:**\",\\n        \"*Recommendations:**\"\\n      ]\\n    },\\n    {\\n      \"guideline\": \"** The recommendation is based on high-level evidence from NCCN guidelines, FDA-approved therapies, and numerous clinical trials demonstrating the efficacy of KRAS G12C inhibitors and immunotherapy in NSCLC.\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"**Clinical trial considerations:**  Exploration of clinical trials investigating novel combinations or agents is warranted to consider potentially superior treatment options.\",\\n        \"**Special considerations:**  Close monitoring of comorbidities (diabetes, hypertension, osteoarthritis) is essential throughout treatment, including careful medication management to avoid interactions and optimize tolerability.  Regular assessment of performance status is necessary to adjust treatment intensity as needed.\",\\n        \"**Documentation of deviations:**  No deviations from standard practice are anticipated at this time, but this will remain under review as the patient\\'s treatment progresses.  Any deviations will be carefully documented and justified based on clinical findings and patient-specific factors.\",\\n        \"*Disclaimer:** This analysis is a preliminary assessment based on the available data.  A definitive treatment plan requires a comprehensive review by a multidisciplinary team (MDT) including the patient\\'s preferences and values.  The recommendations herein should be considered in consultation with the patient and her treating oncologist.  Further investigations, including complete pathological assessment and potentially additional imaging, may be necessary to refine staging and optimize treatment decisions.\"\\n      ]\\n    }\\n  ]\\n}', 'task': 'Synthesize all available information and provide an expert clinical assessment including treatment recommendations, risk stratification, and special considerations. Consider both patient-specific factors and guideline recommendations.'}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'overall_assessment': '**  Regular clinical assessments, including physical examination, blood tests, and performance status evaluation, will be essential to monitor treatment-related side effects and overall health.', 'treatment_considerations': ['Patient MDT2024001 is a 62-year-old Caucasian female presenting with a concerning clinical picture highly suggestive of Stage IIIA non-small cell lung cancer (NSCLC).  The key findings include a 3.8 x 3.2 cm right upper lobe mass with significant mediastinal lymph node involvement,  hemoptysis, weight loss, fatigue, and constitutional symptoms.  Imaging (CT and PET-CT) confirms the presence of a large, metabolically active mass with nodal involvement, and absence of distant metastases.  Pathology reveals a KRAS G12C mutation and high PD-L1 expression (80%).  Her comorbidities (well-controlled Type 2 Diabetes, hypertension, and osteoarthritis) will require careful consideration in treatment planning.  Her ECOG performance status is estimated to be 2-3, indicating moderate to severe symptom burden impacting daily activities.  A definitive ECOG/Karnofsky score is needed for precise assessment.', '**4. Treatment Options:**', 'Given the KRAS G12C mutation and high PD-L1 expression, the most appropriate first-line treatment strategy is a combination of targeted therapy and immunotherapy.', '* **Recommended Treatment:**  Combination therapy with a KRAS G12C inhibitor (sotorasib or adagrasib) and a PD-1/PD-L1 inhibitor (pembrolizumab or nivolumab).  This approach is supported by strong evidence from clinical trials demonstrating significant improvements in outcomes for patients with this specific molecular profile.', '* **Alternative Strategies (if combination therapy is not tolerated or contraindicated):**  Monotherapy with either a KRAS G12C inhibitor or a PD-1/PD-L1 inhibitor could be considered, though combination therapy is preferred.'], 'risk_assessment': '**', 'proposed_approach': 'Individualized approach recommended.', 'follow_up_recommendations': []}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "9bb0c567-a29c-4d59-97c5-98d55b7cdb1f_SpecialistAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"medical_history\": [\\n    {\\n      \"condition\": \"Type 2 Diabetes\",\\n      \"diagnosed\": \"2015-06-15\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Metformin 1000mg BID\",\\n      \"control\": \"Good, HbA1c 6.8%\"\\n    },\\n    {\\n      \"condition\": \"Hypertension\",\\n      \"diagnosed\": \"2016-03-22\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Lisinopril 20mg daily\",\\n      \"control\": \"Well-controlled, BP avg 128/78\"\\n    },\\n    {\\n      \"condition\": \"Osteoarthritis\",\\n      \"diagnosed\": \"2018-11-30\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"PRN NSAIDs\",\\n      \"affected_joints\": [\\n        \"knees\",\\n        \"hands\"\\n      ]\\n    }\\n  ],\\n  \"ehr_analysis\": {\\n    \"summary\": \"This analysis is based on the provided information.  A complete assessment requires a thorough physical examination, additional investigations (as outlined above), and potentially further history taking, including family history of cancer.  The absence of family history information limits the risk stratification.  The exact stage and histology of any potential malignancy are unknown at this time.  The patient\\'s performance status requires formal assessment.\",\\n    \"details\": {\\n      \"summary\": \"This analysis is based on the provided information.  A complete assessment requires a thorough physical examination, additional investigations (as outlined above), and potentially further history taking, including family history of cancer.  The absence of family history information limits the risk stratification.  The exact stage and histology of any potential malignancy are unknown at this time.  The patient\\'s performance status requires formal assessment.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"**  Treatment will depend on the stage and histology of the cancer.  Options might include surgery, chemotherapy, radiotherapy, targeted therapy, or a combination. The patient\\'s comorbidities (T2DM, hypertension, osteoarthritis) will influence treatment selection and require close monitoring for potential adverse effects and interactions.  The patient\\'s performance status will also be a major factor in determining treatment intensity and feasibility.  Multidisciplinary team (MDT) discussion involving oncologists, pulmonologists, radiologists, and pathologists is crucial for optimal management.\",\\n        \"comorbidity_impact\": \"** The patient has well-controlled Type 2 Diabetes Mellitus (T2DM) and Hypertension, managed with Metformin and Lisinopril respectively.  She also has Osteoarthritis affecting her knees and hands. These comorbidities will need careful consideration during treatment planning due to potential drug interactions and impact on overall tolerance.  Her good glycemic control (HbA1c 6.8%) is positive.\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"**EHR Analysis Agent Report: Patient MDT2024001**\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:** The patient, a 62-year-old Caucasian female, presents with a concerning symptom constellation starting January 15th, 2024.  The primary complaint is a persistent cough with occasional hemoptysis (blood-tinged sputum), accompanied by significant unintentional weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats. This symptom cluster strongly suggests a possible malignancy, particularly lung cancer.\\\\n\\\\n* **Comorbidities:** The patient has well-controlled Type 2 Diabetes Mellitus (T2DM) and Hypertension, managed with Metformin and Lisinopril respectively.  She also has Osteoarthritis affecting her knees and hands. These comorbidities will need careful consideration during treatment planning due to potential drug interactions and impact on overall tolerance.  Her good glycemic control (HbA1c 6.8%) is positive.\\\\n\\\\n* **Social and Functional Factors:**  The patient is a retired teacher, suggesting a potentially stable social support system, but also a potential reduction in physical activity compared to her previous occupation.  Her functional status needs further assessment to determine her capacity to tolerate treatment.\\\\n\\\\n* **Risk Factors:**  The patient\\'s former smoking history (quit 10 years ago) is a significant risk factor for lung cancer.  Age (62) also increases the risk.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Symptoms:**  The persistent cough with hemoptysis, significant weight loss, fatigue, decreased appetite, and night sweats are highly suggestive of a serious underlying condition, most likely lung cancer.\\\\n\\\\n* **Physical Examination:**  Decreased breath sounds in the right upper lobe and right supraclavicular lymphadenopathy strongly support the suspicion of lung malignancy.  Vital signs are relatively stable, although slightly elevated blood pressure (132/82) should be monitored.\\\\n\\\\n* **Laboratory Results:**  The complete blood count (CBC) shows normal hemoglobin, white blood cell count, and platelets, which does not rule out malignancy but doesn\\'t suggest a severe anemia or infection.  Liver function tests (ALT and AST) are mildly elevated, which warrants further investigation and could be related to the underlying condition or medications.  Albumin is within the normal range.  Creatinine is normal.\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Smoking history:** Former smoker (quit 10 years ago) \\\\u2013 significant risk factor for lung cancer.\\\\n* **Age:** 62 years \\\\u2013 increased risk for various malignancies.\\\\n* **Family history:**  (Not provided, but crucial information missing for complete risk assessment)\\\\n\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nA full performance status assessment (e.g., ECOG or Karnofsky) is needed to determine the patient\\'s ability to tolerate various treatment regimens.  Based on the reported symptoms (significant fatigue, weight loss), a preliminary assessment suggests a potentially compromised performance status. This needs formal evaluation.\\\\n\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\n* **Differential Diagnosis:** The most likely diagnosis is lung cancer. Other possibilities, though less likely given the presentation, include tuberculosis, lung infection, and other granulomatous diseases.  Further investigation is crucial.\\\\n\\\\n* **Investigations:**  Urgent chest imaging (CT scan of the chest with contrast) is essential to confirm the diagnosis and stage the disease.  Bronchoscopy with biopsy is likely necessary for tissue diagnosis and cytology.  Further investigations may include PET scan depending on the initial imaging findings.\\\\n\\\\n* **Treatment Planning:**  Treatment will depend on the stage and histology of the cancer.  Options might include surgery, chemotherapy, radiotherapy, targeted therapy, or a combination. The patient\\'s comorbidities (T2DM, hypertension, osteoarthritis) will influence treatment selection and require close monitoring for potential adverse effects and interactions.  The patient\\'s performance status will also be a major factor in determining treatment intensity and feasibility.  Multidisciplinary team (MDT) discussion involving oncologists, pulmonologists, radiologists, and pathologists is crucial for optimal management.\\\\n\\\\n* **Medication Considerations:**  Careful monitoring of the patient\\'s current medications (Metformin, Lisinopril, PRN NSAIDs) is necessary, particularly for potential drug interactions with cancer therapies.\\\\n\\\\n\\\\n**Limitations and Uncertainties:**\\\\n\\\\nThis analysis is based on the provided information.  A complete assessment requires a thorough physical examination, additional investigations (as outlined above), and potentially further history taking, including family history of cancer.  The absence of family history information limits the risk stratification.  The exact stage and histology of any potential malignancy are unknown at this time.  The patient\\'s performance status requires formal assessment.\\\\n\\\\n\\\\n**Conclusion:**\\\\n\\\\nThis patient requires urgent further investigation to confirm the suspected diagnosis and stage the disease.  A multidisciplinary team approach is essential for optimal management, taking into account her comorbidities and performance status to ensure patient-centered care.\"\\n    }\\n  },\\n  \"imaging_analysis\": {\\n    \"summary\": \"**Imaging Analysis Report: Patient MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Report: Patient MDT2024001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"** 12.4 (PET-CT)\",\\n        \"nodal_status\": \"** N2 (ipsilateral mediastinal lymph node involvement).  The presence of enlarged hilar and mediastinal lymph nodes confirmed on CT and PET-CT indicates N2 disease.\",\\n        \"metastatic_status\": \"** M0 (no evidence of distant metastases on CT and PET-CT).\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The findings are highly suggestive of a primary lung malignancy.  The resolution is limited, preventing precise characterization of the mass.\",\\n          \"* **CT Chest (2024-02-05):**  Confirms a 3.8 x 3.2 cm spiculated mass in the right upper lobe.  Multiple enlarged right hilar and mediastinal lymph nodes are present.  No evidence of distant metastases is identified. Mild emphysematous changes are noted in the upper lobes. The spiculated nature of the mass is concerning for malignancy.\",\\n          \"* **PET-CT (2024-02-12):**  Shows a right upper lobe mass with an SUVmax of 12.4, indicating high metabolic activity consistent with malignancy.  FDG-avid right hilar and mediastinal lymph nodes are present, with an SUVmax of 8.2, further supporting the diagnosis of lymph node involvement.  No evidence of distant metastatic disease is detected.\",\\n          \"* **Primary lesion:** 3.8 x 3.2 cm (CT Chest)\",\\n          \"* **SUVmax of primary lesion:** 12.4 (PET-CT)\",\\n          \"* **T:** T3 ( > 7cm or invades chest wall, diaphragm, mediastinum)  or possibly T4 (invasion of mediastinum or other structures) based on the size and location of the mass and the involvement of the hilar lymph nodes.  Precise T-staging requires further assessment with bronchoscopy and potentially surgical exploration.\",\\n          \"The mass is located in the right upper lobe, close to the hilum and in proximity to mediastinal structures.  The involvement of hilar and mediastinal lymph nodes suggests potential local invasion. The relationship of the tumor to major vessels and bronchi needs further delineation.  This proximity to critical structures will influence surgical resectability.\"\\n        ]\\n      },\\n      \"treatment_implications\": []\\n    }\\n  },\\n  \"pathology_analysis\": {\\n    \"summary\": \"**\",\\n    \"details\": {\\n      \"summary\": \"**\",\\n      \"histology\": \"**\",\\n      \"molecular_profile\": {\\n        \"key_mutations\": \"**4. Biomarker Status:**\",\\n        \"immunotherapy_markers\": \"** The high PD-L1 expression suggests that immunotherapy with a PD-1/PD-L1 inhibitor (e.g., pembrolizumab, nivolumab) could be a highly effective treatment option, either as monotherapy or in combination with other agents.\",\\n        \"other_markers\": {\\n          \"ALK\": \"** No rearrangement.\",\\n          \"ROS1\": \"** No rearrangement.\"\\n        }\\n      },\\n      \"therapeutic_implications\": [\\n        \"*10. Recommendations for Additional Testing:**\",\\n        \"**Complete histopathological assessment:**  Detailed review of the biopsy specimen to determine the grade and differentiation of the adenocarcinoma using established grading systems.\",\\n        \"**Comprehensive staging:**  Further imaging including CT and PET-CT scans are needed to fully assess the extent of the disease and determine a precise TNM stage.  This will involve evaluating the relationship of the tumor to critical structures and assessing for distant metastases.\",\\n        \"**Performance status assessment:**  Formal assessment of the patient\\'s performance status (e.g., ECOG or Karnofsky) is essential to guide treatment decisions.\",\\n        \"**Further clinical assessment:**  A thorough review of the patient\\'s medical history, including family history of cancer, is needed for comprehensive risk stratification.  This is critical to determine underlying risk factors and guide treatment decisions.\",\\n        \"*Disclaimer:** This report is based solely on the provided data and is for informational purposes only.  It does not constitute a formal medical diagnosis or treatment plan.  A complete clinical evaluation by a qualified medical professional is necessary for accurate diagnosis and appropriate management of the patient.\"\\n      ]\\n    }\\n  },\\n  \"guideline_recommendations\": [\\n    {\\n      \"guideline\": \"**\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"The patient\\'s characteristics (age, gender, smoking history, comorbidities, stage of disease, and histology) will be used to tailor treatment recommendations based on the above guidelines.  Her good control of Type 2 Diabetes is a positive factor.  However, her age and comorbidities will necessitate careful consideration of treatment toxicity. The presence of significant fatigue and weight loss suggests a potentially compromised performance status, which will influence treatment intensity.\",\\n        \"*3. Special Populations Considerations:**\",\\n        \"*4. Evidence Levels:**\",\\n        \"Treatment recommendations will be based on high-level evidence from randomized controlled trials (RCTs) and meta-analyses where available.  For certain aspects of management, expert opinion and consensus statements may be necessary.\",\\n        \"*5. Clinical Trial Options:**\",\\n        \"*Recommendations:**\"\\n      ]\\n    },\\n    {\\n      \"guideline\": \"**\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"**Definitive Treatment:**  Given the Stage IIIB disease and the location of the tumor, surgical resection is unlikely to be curative.  Therefore, the focus would be on systemic therapies aiming for optimal disease control and improved patient outcomes.\",\\n        \"**Immunotherapy:**  The potential high PD-L1 expression makes immunotherapy a highly promising treatment option.  Pembrolizumab or nivolumab as first-line therapy are supported by high-level evidence.\",\\n        \"**Chemotherapy:**  Platinum-based doublet chemotherapy (e.g., cisplatin or carboplatin combined with pemetrexed or docetaxel) may be considered as an alternative or in combination with immunotherapy, depending on the final pathology and molecular results.\",\\n        \"**Targeted Therapy:**  If the final pathology reveals specific driver mutations (e.g., EGFR, KRAS), targeted therapy may be an option.\",\\n        \"*2. Evidence Levels:**\",\\n        \"*3. Clinical Trial Considerations:**\",\\n        \"*4. Special Considerations:**\",\\n        \"**Comorbidities:**  Close monitoring of blood glucose levels and blood pressure is essential, especially with the use of chemotherapy or immunotherapy, which can impact these parameters.  Treatment plans must account for potential drug interactions between cancer therapies and the patient\\'s existing medications (Metformin, Lisinopril).\",\\n        \"**Performance Status:**  A formal ECOG or Karnofsky performance status assessment is crucial to guide treatment intensity and choice.\",\\n        \"**Supportive Care:**  Supportive care measures, including pain management, nutritional support, and management of fatigue, are essential to improve patient quality of life.\",\\n        \"*5. Documentation of Deviations:**\",\\n        \"*Next Steps:**\",\\n        \"Obtain final pathology results, including detailed histological analysis and complete molecular profiling (EGFR, ALK, ROS1, etc.).\",\\n        \"Perform a formal performance status assessment (ECOG or Karnofsky).\",\\n        \"Explore clinical trial eligibility.\",\\n        \"Present the case at a multidisciplinary tumor board to finalize treatment planning, considering the patient\\'s specific circumstances and preferences.\"\\n      ]\\n    }\\n  ]\\n}', 'task': 'Synthesize all available information and provide an expert clinical assessment including treatment recommendations, risk stratification, and special considerations. Consider both patient-specific factors and guideline recommendations.'}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'overall_assessment': '**', 'treatment_considerations': ['Patient MDT2024001 is a 62-year-old female former smoker presenting with a concerning constellation of symptoms highly suggestive of lung cancer: persistent cough with hemoptysis, significant weight loss, fatigue, decreased appetite, and night sweats.  Imaging (CXR, CT chest, PET-CT) reveals a 3.8 x 3.2 cm spiculated mass in the right upper lobe (SUVmax 12.4), with involvement of ipsilateral mediastinal lymph nodes (N2), consistent with Stage IIIB lung cancer (T3/T4 N2 M0).  While the exact T-stage requires further clarification pending bronchoscopy and potentially surgical exploration, the current imaging strongly suggests unresectable disease.  The preliminary pathology report suggests adenocarcinoma with high PD-L1 expression, which significantly impacts treatment choices.  Her well-controlled type 2 diabetes, hypertension, and osteoarthritis are significant comorbidities requiring careful consideration in treatment planning.  A formal performance status assessment (ECOG/Karnofsky) is crucial to determine treatment intensity.', '* **Age:** 62 years  influences treatment tolerance and overall prognosis.', '**4. Treatment Options:**', 'Given the likely unresectability of the tumor and the high PD-L1 expression, the primary treatment focus should be systemic therapy.', '* **First-line treatment:**  Pembrolizumab or nivolumab monotherapy is the preferred first-line treatment option based on current evidence and the high PD-L1 expression.  This aligns with current NCCN guidelines for stage IIIB non-small cell lung cancer (NSCLC) with high PD-L1 expression.'], 'risk_assessment': '**', 'proposed_approach': 'Individualized approach recommended.', 'follow_up_recommendations': ['**Obtain complete pathology results:**  Including detailed histological analysis and comprehensive molecular profiling (EGFR, KRAS, etc.).', '**Formal performance status assessment:**  ECOG or Karnofsky performance status.', '**Initiate first-line immunotherapy:**  Pembrolizumab or Nivolumab.', '**Multidisciplinary Team (MDT) discussion:**  Present the case at an MDT meeting to finalize treatment planning and ensure optimal patient care.', '**Consider clinical trial enrollment:**  Explore eligibility for relevant clinical trials.', '*10. Limitations and Uncertainties:**']}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "0279bebc-10df-4927-a301-eab91d18c3bd_SpecialistAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"medical_history\": [\\n    {\\n      \"condition\": \"Type 2 Diabetes\",\\n      \"diagnosed\": \"2015-06-15\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Metformin 1000mg BID\",\\n      \"control\": \"Good, HbA1c 6.8%\"\\n    },\\n    {\\n      \"condition\": \"Hypertension\",\\n      \"diagnosed\": \"2016-03-22\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Lisinopril 20mg daily\",\\n      \"control\": \"Well-controlled, BP avg 128/78\"\\n    },\\n    {\\n      \"condition\": \"Osteoarthritis\",\\n      \"diagnosed\": \"2018-11-30\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"PRN NSAIDs\",\\n      \"affected_joints\": [\\n        \"knees\",\\n        \"hands\"\\n      ]\\n    }\\n  ],\\n  \"ehr_analysis\": {\\n    \"summary\": \"** The current information is limited.  A definitive diagnosis cannot be made without further investigations.  The severity of the patient\\'s comorbidities and their impact on treatment tolerance needs further assessment.\",\\n    \"details\": {\\n      \"summary\": \"** The current information is limited.  A definitive diagnosis cannot be made without further investigations.  The severity of the patient\\'s comorbidities and their impact on treatment tolerance needs further assessment.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"\",\\n        \"comorbidity_impact\": \"**  Treatment options will depend heavily on the results of the imaging and biopsy, including the stage and histological subtype of the cancer.  Treatment may involve surgery, chemotherapy, radiation therapy, targeted therapy, or a combination thereof.  The patient\\'s comorbidities (T2DM and hypertension) need careful consideration in treatment selection and management to minimize potential complications.  Her current medications will need to be reviewed for potential interactions with anticancer agents.  A multidisciplinary team (MDT) approach involving oncologists, pulmonologists, radiologists, pathologists, and potentially other specialists (e.g., endocrinologist for diabetes management) is essential for optimal management.\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"**EHR Analysis Agent Report - Patient ID: MDT2024001**\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:** The patient, a 62-year-old Caucasian female, presents with a persistent cough, occasionally producing blood-tinged sputum, starting on 2024-01-15.  This is accompanied by significant unintentional weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats \\\\u2013 all highly suggestive of a serious underlying illness, possibly malignancy.  The worsening cough and hemoptysis are particularly concerning.\\\\n\\\\n* **Medical History:**  The patient has a history of well-controlled Type 2 Diabetes Mellitus (T2DM), well-controlled hypertension, and osteoarthritis.  These comorbidities will need careful consideration during treatment planning due to potential drug interactions and increased risk of complications.  Her history of smoking, though she quit 10 years ago, remains a significant risk factor.\\\\n\\\\n* **Current Medications:** Metformin, Lisinopril, and PRN NSAIDs.  These medications need to be considered in the context of potential new treatments, particularly given the potential need for cytotoxic chemotherapy which can have interactions with these drugs.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Presenting Complaint:** Persistent cough with hemoptysis, significant weight loss, fatigue, decreased appetite, and night sweats.\\\\n\\\\n* **Physical Examination:**  The physical exam reveals concerning findings: decreased breath sounds in the right upper lobe, and right supraclavicular lymphadenopathy, strongly suggesting a possible lung malignancy.  Vital signs are relatively stable, although the slightly elevated blood pressure warrants monitoring.\\\\n\\\\n* **Laboratory Results:**  The complete blood count (CBC) is unremarkable, showing no significant anemia, leukocytosis, or thrombocytopenia.  Liver function tests (LFTs) are mildly elevated (ALT 28 U/L, AST 32 U/L), which could be related to the underlying condition or medications, but are not significantly alarming in isolation.  Albumin levels are within the normal range.  Renal function, as indicated by creatinine, is normal.\\\\n\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:** 62 years old, placing her in a higher risk category for various cancers.\\\\n* **Gender:** Female (lung cancer incidence is lower in females but this is a significant symptom presentation).\\\\n* **Smoking History:** Former smoker (although quit 10 years ago, past smoking significantly increases lung cancer risk).\\\\n* **Weight Loss:** Significant unintentional weight loss is a major red flag for malignancy.\\\\n* **Symptoms:**  The combination of cough, hemoptysis, weight loss, fatigue, and night sweats is highly suggestive of lung cancer.\\\\n* **Physical Exam:** Decreased breath sounds and lymphadenopathy further support the suspicion of lung cancer.\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nBased on the information provided, a preliminary assessment of performance status using the Eastern Cooperative Oncology Group (ECOG) scale would likely be between 2 and 3. The patient is experiencing significant fatigue, weight loss, and decreased appetite, impacting her daily activities. A more precise assessment requires a more detailed functional assessment.\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\nThe clinical picture strongly suggests the possibility of lung cancer.  Further investigations are urgently required, including:\\\\n\\\\n* **Imaging:**  High-resolution computed tomography (HRCT) of the chest is crucial to visualize the lung lesions and assess their extent, including lymph node involvement.  A CT scan of the abdomen and pelvis may also be necessary to rule out distant metastases.\\\\n* **Biopsy:**  A tissue biopsy (e.g., bronchoscopy with transbronchial needle aspiration or percutaneous needle biopsy) is essential to obtain a definitive diagnosis and determine the histological subtype of the cancer. This will allow for accurate staging and tailored treatment planning.\\\\n* **Further Lab Tests:**  Consideration should be given to additional tests, such as serum tumor markers (e.g., CEA, CYFRA 21-1), depending on the imaging findings.\\\\n\\\\n\\\\n**Treatment Planning:**  Treatment options will depend heavily on the results of the imaging and biopsy, including the stage and histological subtype of the cancer.  Treatment may involve surgery, chemotherapy, radiation therapy, targeted therapy, or a combination thereof.  The patient\\'s comorbidities (T2DM and hypertension) need careful consideration in treatment selection and management to minimize potential complications.  Her current medications will need to be reviewed for potential interactions with anticancer agents.  A multidisciplinary team (MDT) approach involving oncologists, pulmonologists, radiologists, pathologists, and potentially other specialists (e.g., endocrinologist for diabetes management) is essential for optimal management.\\\\n\\\\n\\\\n**Limitations and Uncertainties:** The current information is limited.  A definitive diagnosis cannot be made without further investigations.  The severity of the patient\\'s comorbidities and their impact on treatment tolerance needs further assessment.\\\\n\\\\n\\\\n**Patient-Centered Care:**  The patient\\'s preferences and values should be central to all treatment decisions.  Open communication and shared decision-making are crucial to ensure that the treatment plan aligns with her goals and expectations.  Psychosocial support should be offered to address the emotional and psychological impact of her condition.\"\\n    }\\n  },\\n  \"imaging_analysis\": {\\n    \"summary\": \"**Imaging Analysis Report - Patient ID: MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Report - Patient ID: MDT2024001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"** 3.8 x 3.2 cm (CT Chest)\",\\n        \"nodal_status\": \"** Multiple enlarged right hilar and mediastinal lymph nodes (CT Chest and PET-CT).  SUVmax of 8.2 in involved nodes (PET-CT).\",\\n        \"metastatic_status\": \"** Although the PET-CT was negative for distant metastases, a dedicated CT scan of the abdomen and pelvis could be considered for a more comprehensive assessment, particularly if there are clinical findings suggestive of distant disease.\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The findings are highly suggestive of a primary lung malignancy.  The resolution is limited, preventing precise characterization of the mass.\",\\n          \"* **CT Chest (2024-02-05):**  Reveals a 3.8 x 3.2 cm spiculated mass in the right upper lobe, consistent with a malignant neoplasm.  Multiple enlarged right hilar and mediastinal lymph nodes are present.  No evidence of distant metastases is identified. Mild emphysematous changes are noted in the upper lobes.\",\\n          \"* **PET-CT (2024-02-12):** Confirms the presence of a right upper lobe mass with an SUVmax of 12.4, indicative of high metabolic activity consistent with malignancy.  FDG-avid right hilar and mediastinal lymph nodes are present, with an SUVmax of 8.2, suggesting metastatic involvement. No evidence of distant metastatic disease is seen.\",\\n          \"* **Primary Lesion:** 3.8 x 3.2 cm (CT Chest)\",\\n          \"The primary lesion is located in the right upper lobe, close to the hilum.  The involvement of hilar and mediastinal lymph nodes suggests spread within the regional lymphatic system.  The relationship of the tumor to major vessels and bronchi will be crucial for surgical planning, if surgery is considered.  The mild emphysema may influence surgical resectability and post-operative recovery.\"\\n        ]\\n      },\\n      \"treatment_implications\": []\\n    }\\n  },\\n  \"pathology_analysis\": {\\n    \"summary\": \"**Pathology Analysis Agent Report - Patient ID: MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Pathology Analysis Agent Report - Patient ID: MDT2024001**\",\\n      \"histology\": \"**  Complete review of H&E stained slides to determine the grade and subtype of the adenocarcinoma (e.g., acinar, papillary, lepidic, etc.). This will refine the prognostic assessment.\",\\n      \"molecular_profile\": {\\n        \"key_mutations\": \"**4. Biomarker Status:**\",\\n        \"immunotherapy_markers\": \"80%\",\\n        \"other_markers\": {}\\n      },\\n      \"therapeutic_implications\": [\\n        \"The provided data does not include information regarding the grade and differentiation of the adenocarcinoma.  This information is crucial for prognosis and treatment planning.  Review of the hematoxylin and eosin (H&E) stained slides by a pathologist is necessary to determine the grade and differentiation.\",\\n        \"The molecular testing reveals a *KRAS* G12C mutation.  This is a significant finding as it identifies a targetable oncogenic driver mutation.  The absence of EGFR, ALK, and ROS1 rearrangements excludes these as drivers in this case.\",\\n        \"* **PD-L1:**  The tumor shows 80% PD-L1 expression.  This high expression level strongly suggests that the patient may benefit from immunotherapy, specifically PD-1/PD-L1 inhibitors.\",\\n        \"* **KRAS G12C:** The presence of the *KRAS* G12C mutation indicates a specific targetable mutation.  Sotorasib and adagrasib are FDA-approved therapies specifically targeting this mutation.\",\\n        \"**5. Therapeutic Targets:**\",\\n        \"Based on the current data, the key therapeutic targets are:\",\\n        \"* **KRAS G12C mutation:**  Treatment with a KRAS G12C inhibitor (sotorasib or adagrasib) should be strongly considered as a first-line treatment option.\",\\n        \"* **High PD-L1 expression:**  Given the high PD-L1 expression (80%), immunotherapy with a PD-1/PD-L1 inhibitor may be considered as a first-line or subsequent treatment option, either as monotherapy or in combination with chemotherapy or a KRAS G12C inhibitor.  The optimal sequencing of these agents needs further discussion within the MDT considering the patient\\'s overall condition and comorbidities.\",\\n        \"The patient is a candidate for targeted therapy with a KRAS G12C inhibitor (sotorasib or adagrasib) and/or immunotherapy with a PD-1/PD-L1 inhibitor. The optimal treatment strategy requires consideration of the patient\\'s overall health status, performance status (ECOG score), and comorbidities.  A multidisciplinary team (MDT) discussion is crucial for personalized treatment planning.\",\\n        \"2. **Staging Investigations:**  Thorough staging is essential before treatment.  This includes a detailed review of the existing imaging studies (CT Chest, PET-CT) to confirm the stage and extent of disease, specifically to assess for any distant metastasis not currently identified.  It is recommended to conduct a CT scan of the abdomen and pelvis to fully exclude distant metastasis.\",\\n        \"3. **Microsatellite Instability (MSI) and Tumor Mutational Burden (TMB) testing:**  These tests could provide additional information to guide treatment choices, particularly in relation to immunotherapy.\",\\n        \"4. **Comprehensive Comorbidity Assessment:** A thorough assessment of the patient\\'s comorbidities (T2DM, hypertension, osteoarthritis) and their impact on treatment tolerance is critical for safe and effective treatment.  A consultation with an endocrinologist or cardiologist may be warranted.\",\\n        \"**Disclaimer:** This report is based on the information provided.  A complete and accurate diagnosis and treatment plan require a comprehensive clinical evaluation and integration of all available data within a multidisciplinary team setting.  This analysis should not be considered a substitute for professional medical advice.\"\\n      ]\\n    }\\n  },\\n  \"guideline_recommendations\": [\\n    {\\n      \"guideline\": \"**\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"*2. Evidence-Based Treatment Options:**\",\\n        \"**KRAS G12C Inhibitors:** Sotorasib or adagrasib are FDA-approved and represent first-line treatment options for patients with metastatic NSCLC harboring the KRAS G12C mutation.  (Evidence Level: 1A - based on large randomized controlled trials).\",\\n        \"**Immunotherapy (PD-1/PD-L1 Inhibitors):**  The high PD-L1 expression (80%) strongly suggests that immunotherapy with a PD-1/PD-L1 inhibitor (e.g., pembrolizumab, atezolizumab) would be beneficial, either as monotherapy or in combination with chemotherapy or a KRAS G12C inhibitor.  (Evidence Level: 1A - based on large randomized controlled trials showing benefit in high PD-L1 expressing NSCLC).\",\\n        \"**Combination Therapy:**  Combining a KRAS G12C inhibitor with immunotherapy is a promising strategy, though further data is needed to optimize the combination.  (Evidence Level: 1B - based on ongoing clinical trials showing promising results).\",\\n        \"*3. Clinical Trial Eligibility:**\",\\n        \"*4. Special Considerations:**\",\\n        \"**Comorbidities:**  The patient\\'s Type 2 Diabetes and hypertension require careful management to minimize treatment-related toxicities.  Close collaboration with an endocrinologist and cardiologist is crucial.  Medication adjustments might be needed to avoid drug interactions with anticancer agents.\",\\n        \"**Performance Status:**  A thorough assessment of the patient\\'s performance status (ECOG) is essential.  This will help in selecting appropriate treatment intensity and managing potential side effects.\",\\n        \"**Age:**  While age is not a contraindication to targeted therapy or immunotherapy, it\\'s important to consider potential age-related factors influencing treatment tolerance and overall outcome.\",\\n        \"*5. Documentation of Deviations from Standard Practice:**\",\\n        \"*6. Recommendations:**\",\\n        \"**Staging Completion:**  A CT scan of the abdomen and pelvis is recommended to rule out distant metastases, completing the staging process.\",\\n        \"**Multidisciplinary Team (MDT) Discussion:**  A comprehensive MDT discussion involving oncologists, pulmonologists, radiologists, pathologists, an endocrinologist, and potentially a cardiologist is essential to develop a personalized treatment plan.\",\\n        \"**Treatment Plan:**  Based on the MDT discussion, the initial treatment could include either a KRAS G12C inhibitor (sotorasib or adagrasib) or a combination of a KRAS G12C inhibitor and immunotherapy (PD-1/PD-L1 inhibitor).  The choice will depend on factors such as the patient\\'s performance status, comorbidities, and preferences.\",\\n        \"**Clinical Trial Exploration:**  The MDT should explore the possibility of clinical trial participation, considering the patient\\'s characteristics and eligibility criteria.\",\\n        \"**Close Monitoring:**  Close monitoring of treatment response, side effects, and comorbidity management is crucial throughout the treatment course.\",\\n        \"*Disclaimer:** This analysis is based on the information provided.  A definitive diagnosis and treatment plan require a comprehensive clinical evaluation and integration of all available data within a multidisciplinary team setting.  This analysis should not be considered a substitute for professional medical advice.\"\\n      ]\\n    }\\n  ]\\n}', 'task': 'Synthesize all available information and provide an expert clinical assessment including treatment recommendations, risk stratification, and special considerations. Consider both patient-specific factors and guideline recommendations.'}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'overall_assessment': '**  Close monitoring of disease progression, treatment response, and side effects is crucial, including regular blood tests, imaging studies, and clinical assessments.', 'treatment_considerations': [\"This 62-year-old female presents with a concerning clinical picture highly suggestive of advanced non-small cell lung cancer (NSCLC), likely adenocarcinoma, given the imaging findings and pathology results.  The persistent cough with hemoptysis, significant weight loss, fatigue, and night sweats, coupled with right upper lobe mass, hilar and mediastinal lymphadenopathy, and high metabolic activity on PET-CT, strongly support this diagnosis. The presence of a *KRAS* G12C mutation and high PD-L1 expression (80%) identifies specific targetable therapeutic opportunities.  Her comorbidities (Type 2 Diabetes, Hypertension, Osteoarthritis) require careful consideration in treatment planning and monitoring.  While distant metastases haven't been definitively ruled out (requiring a CT abdomen/pelvis), the current data points towards locally advanced or possibly stage IIIB disease.\", '* **Staging:** Currently clinically staged as locally advanced (likely stage IIIB) pending completion of CT abdomen/pelvis to definitively exclude distant metastases.  The presence of mediastinal lymph node involvement significantly impacts treatment options and prognosis.', '* **Molecular Profile:**  The *KRAS* G12C mutation and high PD-L1 expression are key drivers informing treatment selection.  Absence of EGFR, ALK, and ROS1 mutations is significant as it eliminates other targeted therapy options.  MSI and TMB testing should be considered to further refine treatment strategy.', '* **Age:** 62 years   within the age range where aggressive treatment is generally considered.  However, age-related comorbidities and potential treatment toxicities need careful consideration.', '* **Comorbidities:** Well-controlled Type 2 Diabetes (HbA1c 6.8%), well-controlled hypertension, and osteoarthritis.  These comorbidities increase the risk of treatment-related complications and require careful medication management to minimize drug interactions.  Close collaboration with endocrinology and cardiology is crucial.'], 'risk_assessment': '**', 'proposed_approach': '**Disclaimer:** This report represents my expert opinion based on the information provided.  A definitive diagnosis and treatment plan require a comprehensive clinical evaluation and integration of all available data within a multidisciplinary team setting.  This analysis should not be considered a substitute for professional medical advice.', 'follow_up_recommendations': []}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "43bdffb8-6195-47c9-ac2d-d2dd3b1bc67c_SpecialistAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"medical_history\": [\\n    {\\n      \"condition\": \"Type 2 Diabetes\",\\n      \"diagnosed\": \"2015-06-15\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Metformin 1000mg BID\",\\n      \"control\": \"Good, HbA1c 6.8%\"\\n    },\\n    {\\n      \"condition\": \"Hypertension\",\\n      \"diagnosed\": \"2016-03-22\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Lisinopril 20mg daily\",\\n      \"control\": \"Well-controlled, BP avg 128/78\"\\n    },\\n    {\\n      \"condition\": \"Osteoarthritis\",\\n      \"diagnosed\": \"2018-11-30\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"PRN NSAIDs\",\\n      \"affected_joints\": [\\n        \"knees\",\\n        \"hands\"\\n      ]\\n    }\\n  ],\\n  \"ehr_analysis\": {\\n    \"summary\": \"The diagnosis remains presumptive until confirmed by histopathological examination.  The extent of disease and the patient\\'s response to treatment are uncertain at this stage.  A comprehensive psychosocial assessment is required to address the patient\\'s emotional and functional needs.\",\\n    \"details\": {\\n      \"summary\": \"The diagnosis remains presumptive until confirmed by histopathological examination.  The extent of disease and the patient\\'s response to treatment are uncertain at this stage.  A comprehensive psychosocial assessment is required to address the patient\\'s emotional and functional needs.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"**  The case requires immediate discussion within an MDT (including oncologists, pulmonologists, radiologists, and pathologists) to formulate a comprehensive and individualized treatment plan.  Treatment options will depend on the stage of the cancer, histological subtype, and the patient\\'s overall performance status and comorbidities.\",\\n        \"comorbidity_impact\": \"\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"**EHR Analysis Agent Report: Patient ID MDT2024001**\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:** The patient, a 62-year-old Caucasian female, presents with a persistent cough with occasional hemoptysis (blood-tinged sputum) starting on January 15th, 2024.  This is accompanied by significant unintentional weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats \\\\u2013 all suggestive of a serious underlying condition, potentially malignancy.\\\\n\\\\n* **Medical History:**  The patient has a history of well-controlled Type 2 Diabetes Mellitus (T2DM), well-controlled hypertension, and osteoarthritis.  These comorbidities will need careful consideration in treatment planning due to potential drug interactions and increased risk of complications.\\\\n\\\\n* **Social and Functional Factors:** The patient is a retired teacher, suggesting a previously active lifestyle, now potentially impacted by her current illness.  Her social support network is unknown and requires further assessment.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Symptoms:**  The primary complaint of a persistent cough with hemoptysis, coupled with significant weight loss, fatigue, decreased appetite, and night sweats, strongly points towards a concerning diagnosis, most likely lung cancer.  The presence of right supraclavicular lymphadenopathy further supports this suspicion.\\\\n\\\\n* **Physical Exam:** Decreased breath sounds in the right upper lobe and right supraclavicular lymphadenopathy are highly suggestive of a right-sided lung pathology.\\\\n\\\\n* **Investigations:**  Initial lab results show relatively normal complete blood count (CBC) and liver function tests (LFTs), which do not definitively rule out malignancy but do not indicate severe anemia or significant liver involvement at this stage.  Further investigations are crucial, including chest imaging (CT scan with contrast), sputum cytology, and potentially bronchoscopy with biopsy for definitive diagnosis and staging.\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:** 62 years old \\\\u2013 placing her within a high-risk age group for lung cancer.\\\\n* **Smoking History:** Former smoker (quit 10 years ago) \\\\u2013 significantly increases the risk of lung cancer even after cessation.  The duration of smoking is not specified and would be a crucial piece of information.\\\\n* **Family History:**  Family history of lung cancer or other cancers is unknown and needs to be elicited.\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nBased on the reported symptoms (significant weight loss, fatigue, decreased appetite), a preliminary assessment of performance status using the Eastern Cooperative Oncology Group (ECOG) scale would likely place the patient in either ECOG performance status 2 (requiring occasional assistance with daily activities) or possibly 3 (requiring significant assistance).  A more precise assessment requires a comprehensive physical examination and functional assessment.\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\nThe clinical presentation strongly suggests the possibility of lung cancer.  The presence of hemoptysis, weight loss, and supraclavicular lymphadenopathy raises concerns for advanced disease.  The patient\\'s comorbidities (T2DM and hypertension) will require careful management during any subsequent treatment.  The osteoarthritis may influence pain management and the choice of certain medications.\\\\n\\\\n\\\\n**Further Investigations and Management Plan:**\\\\n\\\\n* **Imaging:** High-resolution CT scan of the chest with contrast is urgently needed to evaluate the lung lesions and lymph nodes.\\\\n* **Bronchoscopy with Biopsy:**  This is crucial for obtaining tissue for histopathological examination and definitive diagnosis.\\\\n* **Sputum Cytology:**  Should be performed to screen for malignant cells.\\\\n* **PET Scan:**  May be considered for staging if lung cancer is confirmed.\\\\n* **Multidisciplinary Team (MDT) Discussion:**  The case requires immediate discussion within an MDT (including oncologists, pulmonologists, radiologists, and pathologists) to formulate a comprehensive and individualized treatment plan.  Treatment options will depend on the stage of the cancer, histological subtype, and the patient\\'s overall performance status and comorbidities.\\\\n\\\\n\\\\n**Limitations and Uncertainties:**\\\\n\\\\nThe diagnosis remains presumptive until confirmed by histopathological examination.  The extent of disease and the patient\\'s response to treatment are uncertain at this stage.  A comprehensive psychosocial assessment is required to address the patient\\'s emotional and functional needs.\\\\n\\\\n\\\\n**Conclusion:**\\\\n\\\\nThis patient requires urgent further investigation for suspected lung cancer.  A multidisciplinary approach is essential for optimal management.  The patient\\'s comorbidities need careful consideration in treatment planning.  Close monitoring of her clinical status and careful management of her diabetes and hypertension are crucial throughout the treatment process.\"\\n    }\\n  },\\n  \"imaging_analysis\": {\\n    \"summary\": \"**Imaging Analysis Report: Patient ID MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Report: Patient ID MDT2024001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"** 3.8 x 3.2 cm (CT Chest).\",\\n        \"nodal_status\": \"**  If surgical resection is planned, EBUS or mediastinoscopy might be considered for more precise lymph node sampling and staging, potentially altering the surgical approach.  This would be decided upon in consultation with the thoracic surgeon.\",\\n        \"metastatic_status\": \"** Although the PET-CT did not reveal any distant metastases, a brain MRI might be considered to rule out brain metastases, especially if the patient demonstrates neurological symptoms.  This is not routinely required in this initial staging assessment but is an option depending on clinical presentation.\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The findings are highly suggestive of a primary lung malignancy.  This initial imaging served as a screening tool and prompted further investigation.\",\\n          \"* **CT Chest (2024-02-05):**  Confirms a 3.8 x 3.2 cm spiculated mass in the right upper lobe, consistent with a primary lung cancer.  Multiple enlarged right hilar and mediastinal lymph nodes are identified. No evidence of distant metastases is observed. Mild emphysematous changes are present in the upper lobes.  The spiculated margins of the primary lesion are suggestive of malignancy.\",\\n          \"* **PET-CT (2024-02-12):**  Shows a right upper lobe mass with a maximum standardized uptake value (SUVmax) of 12.4, indicating high metabolic activity consistent with malignancy.  FDG-avid right hilar and mediastinal lymph nodes are present, with a maximum SUVmax of 8.2, confirming the presence of metastatic disease in regional lymph nodes.  No evidence of distant metastatic disease is seen.\",\\n          \"* **Primary Lesion:** 3.8 x 3.2 cm (CT Chest).\",\\n          \"The primary lesion is located in the right upper lobe, close to the hilum.  The involvement of hilar and mediastinal lymph nodes indicates locoregional spread.  The anatomical location necessitates careful consideration during surgical planning, potentially requiring lobectomy or pneumonectomy.  The proximity to major vessels and bronchi needs to be assessed pre-operatively with high-resolution imaging.\"\\n        ]\\n      },\\n      \"treatment_implications\": [\\n        \"The imaging strongly suggests a need for multidisciplinary management, including medical oncology, thoracic surgery, radiation oncology, and potentially other specialists.  Treatment options could include surgery (potentially lobectomy or pneumonectomy), chemotherapy, radiotherapy, or a combination thereof, depending on the pathological findings, patient\\'s performance status, and comorbidities.  This will be determined after a comprehensive MDT discussion.\"\\n      ]\\n    }\\n  },\\n  \"pathology_analysis\": {\\n    \"summary\": \"**Pathology Analysis Agent Report: Patient ID MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Pathology Analysis Agent Report: Patient ID MDT2024001**\",\\n      \"histology\": \"**\",\\n      \"molecular_profile\": {\\n        \"key_mutations\": \"**  While KRAS G12C is a primary driver mutation, additional molecular testing might be considered to detect additional mutations or alterations that could influence treatment choices or predict response.\",\\n        \"immunotherapy_markers\": \"**10. Recommendations for Additional Testing:**\",\\n        \"other_markers\": {}\\n      },\\n      \"therapeutic_implications\": [\\n        \"*6. Pathological Diagnosis:**\"\\n      ]\\n    }\\n  },\\n  \"guideline_recommendations\": [\\n    {\\n      \"guideline\": \"**\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"*3. Special Populations and Considerations:**\",\\n        \"*4. Evidence Levels and Treatment Options:**\"\\n      ]\\n    },\\n    {\\n      \"guideline\": \"**  If the tumor is resectable, surgical resection (lobectomy or pneumonectomy) may be considered, based on the NCCN guidelines.  This would be followed by adjuvant chemotherapy and/or radiotherapy depending on the pathological findings and stage.  The extent of surgery will depend on the precise location of the tumor and lymph node involvement.  Pre-operative assessment with EBUS or mediastinoscopy might be needed to accurately stage the disease.\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"**Chemotherapy:**  Platinum-based doublet chemotherapy (e.g., cisplatin/etoposide or carboplatin/paclitaxel) is a standard treatment option for advanced-stage NSCLC.  Targeted therapy may be considered if specific driver mutations are identified (e.g., EGFR, ALK, ROS1).\",\\n        \"**Immunotherapy:**  Immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab) are used in advanced NSCLC, especially in patients with high PD-L1 expression.  This will be determined by the molecular profiling results.\",\\n        \"**Radiation Therapy:**  Radiation therapy may be used as a primary treatment or in combination with other modalities (chemoradiotherapy) depending on the stage and location of the tumor.\",\\n        \"*5. Clinical Trial Eligibility:**\"\\n      ]\\n    },\\n    {\\n      \"guideline\": \"**\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"*7. Recommendations:**\",\\n        \"**Urgent multidisciplinary team (MDT) discussion:**  This is crucial to coordinate the diagnostic and treatment plan.\",\\n        \"**Complete pathological analysis:**  This includes histology, molecular profiling (KRAS, EGFR, ALK, ROS1, PD-L1), and immunohistochemistry.\",\\n        \"**Staging investigations:**  Further imaging (EBUS/mediastinoscopy may be considered to refine nodal staging, brain MRI if neurological symptoms appear).\"\\n      ]\\n    },\\n    {\\n      \"guideline\": \"**  This will be tailored to the patient\\'s specific characteristics, including histology, stage, molecular profile, and performance status.\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"**Close monitoring of comorbidities:**  Careful management of diabetes and hypertension is essential throughout treatment.\",\\n        \"**Psychosocial support:**  Addressing the emotional and functional needs of the patient.\",\\n        \"**Exploration of clinical trial eligibility:**  Identification of suitable trials based on the patient\\'s characteristics.\",\\n        \"*8. Limitations and Uncertainties:**\"\\n      ]\\n    }\\n  ]\\n}', 'task': 'Synthesize all available information and provide an expert clinical assessment including treatment recommendations, risk stratification, and special considerations. Consider both patient-specific factors and guideline recommendations.'}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'overall_assessment': '**', 'treatment_considerations': ['This 62-year-old female presents with a highly suggestive clinical picture of advanced lung cancer.  The persistent cough with hemoptysis, significant weight loss, fatigue, and right supraclavicular lymphadenopathy, coupled with imaging findings (3.8 x 3.2 cm right upper lobe mass with hilar and mediastinal lymph node involvement on CT and PET-CT), strongly indicate a malignant process.  The preliminary imaging suggests Stage III lung cancer, but definitive staging awaits pathological confirmation and potentially further investigations like EBUS/mediastinoscopy.  Her medical history includes well-controlled Type 2 Diabetes Mellitus and hypertension, which will necessitate careful consideration during treatment planning.  A comprehensive psychosocial assessment is crucial given the severity of her diagnosis and its potential impact on her quality of life.', '* **Molecular Profile:** Unknown at this stage;  comprehensive molecular testing (including KRAS, EGFR, ALK, ROS1, PD-L1) is essential to guide treatment decisions and predict response to targeted therapies and immunotherapy.', '* **Comorbidities:** Well-controlled Type 2 Diabetes Mellitus and hypertension.  Osteoarthritis may influence pain management and medication choices.', '* **Social Support:** Unknown and requires assessment.  This is crucial for managing the emotional and practical challenges associated with cancer treatment.', '**4. Treatment Options:**'], 'risk_assessment': '', 'proposed_approach': 'Individualized approach recommended.', 'follow_up_recommendations': ['**Urgent MDT Meeting:** To formulate a comprehensive treatment plan.', '**Bronchoscopy with Biopsy:** For definitive diagnosis and tissue sampling.', '**EBUS/Mediastinoscopy:** For precise nodal staging.', '**Brain MRI (if indicated):** To rule out brain metastases.', '**Regular Monitoring:**  Of her clinical status, including symptoms, performance status, and comorbidities.', '**Psychosocial Support:**  Ongoing assessment and support.', '*9. Limitations and Uncertainties:**', \"The diagnosis remains presumptive until confirmed by histopathological examination. The precise stage and the patient's response to treatment remain uncertain at this stage.  The effectiveness of any chosen treatment will depend on various factors, including the specific histology and molecular profile of the tumor.  Therefore, close monitoring and adjustments to the treatment plan may be necessary.\"]}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "bdaf8997-4cd7-4936-a7d7-b055d1f8234f_SpecialistAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"medical_history\": [\\n    {\\n      \"condition\": \"Type 2 Diabetes\",\\n      \"diagnosed\": \"2015-06-15\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Metformin 1000mg BID\",\\n      \"control\": \"Good, HbA1c 6.8%\"\\n    },\\n    {\\n      \"condition\": \"Hypertension\",\\n      \"diagnosed\": \"2016-03-22\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Lisinopril 20mg daily\",\\n      \"control\": \"Well-controlled, BP avg 128/78\"\\n    },\\n    {\\n      \"condition\": \"Osteoarthritis\",\\n      \"diagnosed\": \"2018-11-30\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"PRN NSAIDs\",\\n      \"affected_joints\": [\\n        \"knees\",\\n        \"hands\"\\n      ]\\n    }\\n  ],\\n  \"ehr_analysis\": {\\n    \"summary\": \"Based on the information provided, a preliminary assessment suggests a Karnofsky Performance Status (KPS) score of 60-70%. This is an educated estimate based on the reported fatigue, weight loss, and the severity of the cough, which significantly impacts her daily activities. A more accurate assessment would require a more detailed functional assessment.  However, this suggests she may be able to tolerate some forms of treatment, but aggressive interventions might need careful consideration and monitoring.\",\\n    \"details\": {\\n      \"summary\": \"Based on the information provided, a preliminary assessment suggests a Karnofsky Performance Status (KPS) score of 60-70%. This is an educated estimate based on the reported fatigue, weight loss, and the severity of the cough, which significantly impacts her daily activities. A more accurate assessment would require a more detailed functional assessment.  However, this suggests she may be able to tolerate some forms of treatment, but aggressive interventions might need careful consideration and monitoring.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"**  Treatment will depend on the histological diagnosis and staging of the cancer.  Options might include surgery, chemotherapy, radiotherapy, targeted therapy, or a combination thereof.  Careful consideration must be given to her comorbidities (T2DM, hypertension, osteoarthritis) to minimize potential drug interactions and adverse effects.  The patient\\'s performance status will also guide treatment intensity and choice.  A multidisciplinary team (MDT) approach involving oncologists, pulmonologists, radiologists, pathologists, and potentially other specialists, is essential for optimal management.\",\\n        \"comorbidity_impact\": \"**  The patient has well-controlled Type 2 Diabetes Mellitus (T2DM) managed with Metformin and well-controlled hypertension managed with Lisinopril.  She also has osteoarthritis affecting her knees and hands. These comorbidities will need careful consideration during treatment planning, particularly regarding potential drug interactions and the overall tolerance of aggressive therapies.\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"**EHR Analysis Agent Report: Patient MDT2024001**\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:** The patient, a 62-year-old Caucasian female, presents with a concerning 2-month history of persistent cough, initially dry but now producing occasional blood-tinged sputum.  This is accompanied by significant unintentional weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats \\\\u2013 all classic features suggestive of underlying malignancy.  The onset of symptoms is relatively recent, raising concerns about rapid disease progression.\\\\n\\\\n* **Comorbidities:**  The patient has well-controlled Type 2 Diabetes Mellitus (T2DM) managed with Metformin and well-controlled hypertension managed with Lisinopril.  She also has osteoarthritis affecting her knees and hands. These comorbidities will need careful consideration during treatment planning, particularly regarding potential drug interactions and the overall tolerance of aggressive therapies.\\\\n\\\\n* **Social and Functional Factors:** The patient is a retired teacher, suggesting a previously active lifestyle.  Her current symptoms significantly impact her functional status, given the fatigue, weight loss, and persistent cough.  This needs assessment to determine her ability to tolerate treatment and participate in rehabilitation.\\\\n\\\\n* **Risk Factors:**  Her history of smoking (former smoker, quit 10 years ago) increases her risk of lung cancer. Age (62) is also a significant risk factor.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Primary Complaint:** Persistent cough with hemoptysis.\\\\n* **Physical Exam:**  Significant findings include decreased breath sounds in the right upper lobe and right supraclavicular lymphadenopathy, highly suggestive of intrathoracic pathology, possibly malignancy.\\\\n* **Laboratory Results:**  The complete blood count (CBC) shows normal hemoglobin, white blood cell count, and platelets, which doesn\\'t exclude malignancy but doesn\\'t reveal significant anemia or infection.  Liver function tests (LFTs) are mildly elevated (AST 32 U/L, ALT 28 U/L), which warrants further investigation but could be related to the underlying condition or medications.  The albumin level is within the normal range.  Renal function, as assessed by creatinine, is normal.\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:** 62 years\\\\n* **Smoking History:** Former smoker\\\\n* **Symptoms:**  Persistent cough with hemoptysis, weight loss, fatigue, night sweats, decreased appetite, and lymphadenopathy.  These are all strong indicators of potential malignancy.\\\\n\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nBased on the information provided, a preliminary assessment suggests a Karnofsky Performance Status (KPS) score of 60-70%. This is an educated estimate based on the reported fatigue, weight loss, and the severity of the cough, which significantly impacts her daily activities. A more accurate assessment would require a more detailed functional assessment.  However, this suggests she may be able to tolerate some forms of treatment, but aggressive interventions might need careful consideration and monitoring.\\\\n\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\nThe clinical presentation strongly suggests the possibility of lung cancer.  The right supraclavicular lymphadenopathy points towards advanced disease.  The blood-tinged sputum further supports this suspicion.  The patient requires urgent further investigations, including:\\\\n\\\\n* **Chest X-ray:** To confirm the findings on physical examination.\\\\n* **CT Chest with contrast:** To accurately stage the disease and evaluate the extent of involvement.\\\\n* **Bronchoscopy with bronchoalveolar lavage (BAL) and biopsy:**  To obtain tissue for histopathological examination and cytology.  This is crucial for definitive diagnosis and subtyping of the malignancy.\\\\n* **PET-CT scan:**  To assess for distant metastases.\\\\n* **Further blood tests:** Consider tumor markers such as CEA and CYFRA 21-1, although these are not definitive for diagnosis.\\\\n\\\\n**Treatment Planning:**  Treatment will depend on the histological diagnosis and staging of the cancer.  Options might include surgery, chemotherapy, radiotherapy, targeted therapy, or a combination thereof.  Careful consideration must be given to her comorbidities (T2DM, hypertension, osteoarthritis) to minimize potential drug interactions and adverse effects.  The patient\\'s performance status will also guide treatment intensity and choice.  A multidisciplinary team (MDT) approach involving oncologists, pulmonologists, radiologists, pathologists, and potentially other specialists, is essential for optimal management.\\\\n\\\\n**Limitations and Uncertainties:**  This analysis is based on limited information.  A definitive diagnosis and treatment plan can only be established after completing the recommended investigations and discussions within the MDT.\\\\n\\\\n\\\\n**Conclusion:** This patient requires urgent specialist referral for further evaluation and management of suspected lung cancer.  The MDT approach is crucial for optimizing her care.\"\\n    }\\n  },\\n  \"imaging_analysis\": {\\n    \"summary\": \"**Imaging Analysis Report: Patient MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Report: Patient MDT2024001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"**  The primary tumor (T) is larger than 3cm, suggesting a T2 classification or potentially a T3 if there is involvement of the main bronchus or visceral pleura (this requires further clarification from the CT report).\",\\n        \"nodal_status\": \"**  These procedures are crucial for definitive staging of mediastinal lymph nodes.  Imaging alone cannot definitively determine the presence of microscopic involvement.  Tissue sampling is necessary for accurate nodal staging.\",\\n        \"metastatic_status\": \"** No distant metastases (M0).\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The impression of a highly suspicious primary lung malignancy is consistent with subsequent imaging.\",\\n          \"* **CT Chest (2024-02-05):** Confirms a 3.8 x 3.2 cm spiculated mass in the right upper lobe, characteristic of malignancy.  Multiple enlarged right hilar and mediastinal lymph nodes are present.  No evidence of distant metastases is identified.  Mild emphysematous changes are noted in the upper lobes.\",\\n          \"* **PET-CT (2024-02-12):** Shows a right upper lobe mass with a maximum standardized uptake value (SUVmax) of 12.4, indicating high metabolic activity consistent with malignancy.  FDG-avid right hilar and mediastinal lymph nodes are present, with a maximum SUVmax of 8.2, confirming their involvement.  No evidence of distant metastatic disease is observed.\",\\n          \"* **Primary lesion:** 3.8 x 3.2 cm (CT Chest)\",\\n          \"* **SUVmax of primary lesion:** 12.4 (PET-CT)\",\\n          \"The primary lesion is located in the right upper lobe, close to the hilum, with involvement of hilar and mediastinal lymph nodes. The proximity of the tumor to the mediastinum and the presence of mediastinal lymphadenopathy are crucial considerations for surgical resectability and treatment planning.  The mild emphysema might impact surgical feasibility.\"\\n        ]\\n      },\\n      \"treatment_implications\": []\\n    }\\n  },\\n  \"pathology_analysis\": {\\n    \"summary\": \"**Pathology Analysis Agent Report: Patient MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Pathology Analysis Agent Report: Patient MDT2024001**\",\\n      \"histology\": \"**\",\\n      \"molecular_profile\": {\\n        \"key_mutations\": \"**  If available, molecular testing should be performed on additional tissue samples to confirm the KRAS G12C mutation and to look for other potential driver mutations.\",\\n        \"immunotherapy_markers\": \"**  A PD-1/PD-L1 inhibitor (pembrolizumab or nivolumab) should be strongly considered, potentially as a single agent or in combination with chemotherapy or targeted therapy.  The high PD-L1 expression makes this a strong option.\",\\n        \"other_markers\": {\\n          \"KRAS\": \"**  A KRAS G12C inhibitor (sotorasib or adagrasib) is the preferred first-line targeted therapy.\"\\n        }\\n      },\\n      \"therapeutic_implications\": [\\n        \"**Stage of Disease:** The imaging suggests locally advanced disease (likely Stage IIIA or IIIB), but surgical resection may be considered if deemed feasible based on further assessment of resectability by thoracic surgery.  The proximity of the tumor to the mediastinum and the presence of mediastinal lymphadenopathy must be carefully evaluated for resectability.\",\\n        \"**Treatment Options:**  Options include:\"\\n      ]\\n    }\\n  },\\n  \"guideline_recommendations\": [\\n    {\\n      \"guideline\": \"**\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"The primary guideline relevant to this case is the National Comprehensive Cancer Network (NCCN) Guidelines for Lung Cancer.  Specific guidelines within this framework will be applied based on the final histological diagnosis and staging.  Further, guidelines for managing the patient\\'s comorbidities (Type 2 Diabetes, Hypertension, Osteoarthritis) will be considered throughout the treatment process.  Unfortunately, the `guideline_reference` tool lacks the specificity to directly access and interpret these guidelines.  To provide the most accurate recommendations, I would need access to the full NCCN guidelines and other relevant oncology resources.\",\\n        \"*2. Patient Characteristics and Matching:**\",\\n        \"*3. Special Populations and Considerations:**\",\\n        \"*4. Evidence Levels and Treatment Options:**\",\\n        \"**Surgical Resection:**  Surgical resection (lobectomy, pneumonectomy, etc.) remains a cornerstone of treatment for resectable NSCLC.  However, the proximity of the tumor to the mediastinum and mediastinal lymph node involvement raise concerns about resectability.  A multidisciplinary discussion with thoracic surgery is crucial to determine surgical feasibility.  This is a high-evidence intervention supported by numerous randomized controlled trials demonstrating improved survival compared to non-surgical approaches in resectable disease.\",\\n        \"**Chemotherapy:**  Platinum-based doublet chemotherapy (e.g., cisplatin/etoposide, carboplatin/paclitaxel) is a standard treatment for unresectable locally advanced NSCLC.  The choice of regimen depends on the patient\\'s performance status and comorbidities.  This approach has well-established efficacy, with multiple phase III trials demonstrating significant survival benefits.\",\\n        \"**Radiation Therapy:**  Concurrent chemoradiotherapy is often used for unresectable locally advanced NSCLC.  This approach combines chemotherapy with radiation therapy, aiming to improve local control and overall survival.  The evidence supporting this approach is strong, with several randomized controlled trials showcasing its effectiveness.\",\\n        \"**Targeted Therapy:** The pathology report suggests a KRAS G12C mutation.  If confirmed, a KRAS G12C inhibitor (sotorasib or adagrasib) would be a first-line targeted therapy option. This is a high-evidence approach based on clinical trials demonstrating significant clinical benefit in this specific molecular subtype.\",\\n        \"**Immunotherapy:**  High PD-L1 expression is mentioned; hence, a PD-1/PD-L1 inhibitor (pembrolizumab or nivolumab) should be strongly considered, potentially as a single agent or in combination with chemotherapy or targeted therapy. The evidence supporting immunotherapy is substantial, with clinical trials demonstrating improved outcomes for patients with PD-L1 positive tumors.\",\\n        \"*5. Clinical Trial Eligibility:**\",\\n        \"*6. Special Considerations and Deviations:**\",\\n        \"**Comorbidities:** Careful monitoring of blood glucose and blood pressure is essential during treatment.  The choice of chemotherapy regimen and supportive care will need to account for her osteoarthritis and potential drug interactions.\",\\n        \"**Performance Status:**  Treatment intensity must be adjusted based on the patient\\'s tolerance. Regular assessment of performance status is crucial.\",\\n        \"**Resectability:** The decision regarding surgical resection requires a thorough evaluation by a thoracic surgeon.\",\\n        \"*7. Recommendations:**\",\\n        \"**Urgent Multidisciplinary Team (MDT) Meeting:**  An MDT meeting involving oncologists, pulmonologists, thoracic surgeons, radiologists, and pathologists is crucial to determine the optimal treatment strategy.\",\\n        \"**Definitive Histological Diagnosis and Molecular Profiling:**  Complete pathological analysis with immunohistochemistry and molecular testing (including KRAS mutation analysis and PD-L1 expression) is paramount.\",\\n        \"**Treatment Plan:** Based on the MDT discussion and the results of the pathology and molecular testing, a personalized treatment plan will be developed.  This plan might involve surgery, chemotherapy, targeted therapy, immunotherapy, or a combination thereof.\",\\n        \"**Close Monitoring:**  Close monitoring of the patient\\'s response to treatment, including regular assessments of performance status, blood counts, and organ function, is essential.\",\\n        \"**Supportive Care:**  Appropriate supportive care, including pain management, nutritional support, and management of comorbidities, will be vital.\",\\n        \"**Clinical Trial Consideration:**  The patient should be evaluated for eligibility in relevant clinical trials.\",\\n        \"*Limitations and Uncertainties:**\",\\n        \"This analysis is based on the information provided.  Further investigations and the MDT discussion are necessary to confirm the diagnosis, refine the staging, and finalize the treatment plan.  The absence of detailed guideline information through the `guideline_reference` tool limits the precision of the guideline-specific recommendations.\"\\n      ]\\n    }\\n  ]\\n}', 'task': 'Synthesize all available information and provide an expert clinical assessment including treatment recommendations, risk stratification, and special considerations. Consider both patient-specific factors and guideline recommendations.'}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'overall_assessment': '**', 'treatment_considerations': ['Patient MDT2024001 is a 62-year-old Caucasian female presenting with a concerning constellation of symptoms highly suggestive of advanced non-small cell lung cancer (NSCLC).  The persistent cough with hemoptysis, significant weight loss, fatigue, night sweats, and right supraclavicular lymphadenopathy, coupled with imaging findings demonstrating a large right upper lobe mass and mediastinal lymphadenopathy, paint a strong picture of locally advanced disease.  The imaging suggests a T2-T3 N2 M0 classification (further confirmation needed via surgical staging).  While the PET-CT shows no distant metastases (M0), the extent of local/regional disease requires immediate and comprehensive multidisciplinary management.  Her well-controlled comorbidities (Type 2 Diabetes, Hypertension, Osteoarthritis) will require careful consideration during treatment planning to minimize potential adverse events and drug interactions.  Her estimated Karnofsky Performance Status (KPS) of 60-70% indicates that she can likely tolerate moderate-intensity treatment, but aggressive interventions should be carefully monitored.  The preliminary pathology report suggests a KRAS G12C mutation and high PD-L1 expression, opening up targeted therapy and immunotherapy avenues.', '* **Molecular Profile:** Preliminary data suggests a KRAS G12C mutation and high PD-L1 expression, which significantly impacts treatment options.  Confirmation is crucial.', '* **Comorbidities:** Well-controlled Type 2 Diabetes Mellitus (Metformin), Hypertension (Lisinopril), and Osteoarthritis (PRN NSAIDs).  These will influence treatment choice and require close monitoring.', '* **Performance Status:** Estimated KPS 60-70%, suggesting moderate functional impairment but potential tolerance for certain treatments.', '**4. Treatment Options:**'], 'risk_assessment': '**', 'proposed_approach': 'Individualized approach recommended.', 'follow_up_recommendations': ['*11. Limitations and Uncertainties:**', \"This assessment is based on currently available information.  The final diagnosis, staging, and optimal treatment plan will be determined after the completion of the recommended investigations and the MDT discussion.  The absence of detailed guideline information limits the precision of guideline-specific recommendations.  Uncertainties remain regarding the exact histological subtype, the complete extent of nodal involvement, and the patient's ultimate response to treatment.\"]}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "8b811dda-c3da-40ef-89fd-93fa506806ec_SpecialistAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"medical_history\": [\\n    {\\n      \"condition\": \"Type 2 Diabetes\",\\n      \"diagnosed\": \"2015-06-15\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Metformin 1000mg BID\",\\n      \"control\": \"Good, HbA1c 6.8%\"\\n    },\\n    {\\n      \"condition\": \"Hypertension\",\\n      \"diagnosed\": \"2016-03-22\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Lisinopril 20mg daily\",\\n      \"control\": \"Well-controlled, BP avg 128/78\"\\n    },\\n    {\\n      \"condition\": \"Osteoarthritis\",\\n      \"diagnosed\": \"2018-11-30\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"PRN NSAIDs\",\\n      \"affected_joints\": [\\n        \"knees\",\\n        \"hands\"\\n      ]\\n    }\\n  ],\\n  \"ehr_analysis\": {\\n    \"summary\": \"Based on the reported symptoms and weight loss, the patient\\'s performance status is likely ECOG 2-3.  Further assessment using a validated tool like the ECOG performance status scale is needed for accurate staging and treatment planning.  The significant weight loss and fatigue indicate a decline in her functional capacity.\",\\n    \"details\": {\\n      \"summary\": \"Based on the reported symptoms and weight loss, the patient\\'s performance status is likely ECOG 2-3.  Further assessment using a validated tool like the ECOG performance status scale is needed for accurate staging and treatment planning.  The significant weight loss and fatigue indicate a decline in her functional capacity.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"**  Treatment will depend entirely on the histological diagnosis, staging, and the patient\\'s performance status.  Options might range from surgery (if localized), chemotherapy, targeted therapy, radiation therapy, or palliative care.  Her comorbidities will need to be carefully considered when choosing treatment modalities and dosages to minimize potential drug interactions and adverse events.  A multidisciplinary team (MDT) approach involving oncologists, pulmonologists, radiologists, pathologists, and potentially other specialists, is crucial for optimal patient management.\",\\n        \"comorbidity_impact\": \"** The patient has well-controlled Type 2 Diabetes Mellitus (T2DM) and hypertension, managed with Metformin and Lisinopril respectively.  She also has osteoarthritis affecting her knees and hands. These comorbidities will impact treatment choices and require careful monitoring for potential drug interactions and adverse events.  Specifically, renal function needs monitoring due to the use of Metformin and Lisinopril.\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"**EHR Analysis Agent Report - Patient ID: MDT2024001**\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:** The patient, a 62-year-old Caucasian female, presents with a persistent cough (onset January 15th, 2024) initially characterized as moderate to severe, progressing to include blood-tinged sputum.  Concomitant symptoms include significant unintentional weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats.  This constellation of symptoms warrants serious concern, particularly given the age and presence of other comorbidities.\\\\n\\\\n* **Comorbidities:** The patient has well-controlled Type 2 Diabetes Mellitus (T2DM) and hypertension, managed with Metformin and Lisinopril respectively.  She also has osteoarthritis affecting her knees and hands. These comorbidities will impact treatment choices and require careful monitoring for potential drug interactions and adverse events.  Specifically, renal function needs monitoring due to the use of Metformin and Lisinopril.\\\\n\\\\n* **Social and Functional Factors:** The patient is a retired teacher, suggesting a potentially decreased level of physical activity compared to her previous occupation.  Her retirement status may also influence adherence to treatment regimens and access to support systems.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Primary Complaint:** Persistent cough with hemoptysis.\\\\n* **Physical Exam Findings:**  Significant findings include decreased breath sounds in the right upper lobe, suggestive of a possible lung lesion or consolidation, and right supraclavicular lymphadenopathy, which is highly suggestive of underlying malignancy.\\\\n* **Lab Results:**  Complete Blood Count (CBC) shows normal hemoglobin, white blood cell count, and platelets, ruling out overt anemia or significant infection.  Basic metabolic panel is largely unremarkable, suggesting normal renal and liver function.  However, further investigations are needed.\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:**  62 years old places her within a higher risk group for several malignancies.\\\\n* **Smoking History:** Former smoker (quit 10 years ago) significantly increases the risk of lung cancer. Although she quit 10 years ago, the risk remains elevated compared to a never-smoker.\\\\n* **Symptoms:** The combination of cough (with hemoptysis), weight loss, fatigue, night sweats, and lymphadenopathy are highly suggestive of malignancy, most likely lung cancer.\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nBased on the reported symptoms and weight loss, the patient\\'s performance status is likely ECOG 2-3.  Further assessment using a validated tool like the ECOG performance status scale is needed for accurate staging and treatment planning.  The significant weight loss and fatigue indicate a decline in her functional capacity.\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\nThe clinical presentation strongly suggests the possibility of lung cancer.  Further investigation is urgently required, including:\\\\n\\\\n* **Chest X-Ray/CT Scan:** To visualize the lung parenchyma and confirm the presence and extent of any lesions or adenopathy.\\\\n* **Bronchoscopy with Bronchoalveolar Lavage (BAL) and Biopsy:** To obtain tissue samples for definitive histological diagnosis and to rule out other causes of the symptoms.  This is the highest priority investigation.\\\\n* **PET-CT Scan:** To assess for distant metastases and stage the disease.\\\\n* **Further Blood Tests:**  Consider serum tumor markers (CEA, CYFRA 21-1) and possibly a more extensive metabolic panel to evaluate for paraneoplastic syndromes.\\\\n\\\\n**Differential Diagnosis:**  While lung cancer is the most likely diagnosis, other possibilities must be considered and ruled out, including:\\\\n\\\\n* **Tuberculosis:** Requires appropriate microbiological testing.\\\\n* **Lung Infection (Pneumonia, Lung Abscess):**  Requires further investigation with imaging and sputum analysis.\\\\n* **Sarcoidosis:** Less likely given the presentation but needs to be considered.\\\\n\\\\n**Treatment Planning:**  Treatment will depend entirely on the histological diagnosis, staging, and the patient\\'s performance status.  Options might range from surgery (if localized), chemotherapy, targeted therapy, radiation therapy, or palliative care.  Her comorbidities will need to be carefully considered when choosing treatment modalities and dosages to minimize potential drug interactions and adverse events.  A multidisciplinary team (MDT) approach involving oncologists, pulmonologists, radiologists, pathologists, and potentially other specialists, is crucial for optimal patient management.\\\\n\\\\n\\\\n**Limitations and Uncertainties:**  This analysis is based on the limited information provided.  A complete clinical evaluation, including detailed history taking, physical examination, and further investigations, is essential to confirm the diagnosis and formulate a definitive treatment plan.\\\\n\\\\n\\\\n**Next Steps:**  Immediate referral to a pulmonologist and oncologist for further evaluation and management is strongly recommended.  The patient should be informed about the possible diagnoses and the need for further investigations.  Patient education and shared decision-making are vital components of patient-centered care.\"\\n    }\\n  },\\n  \"imaging_analysis\": {\\n    \"summary\": \"**Imaging Analysis Report - Patient ID: MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Report - Patient ID: MDT2024001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"** 3.8 x 3.2 cm (CT Chest).\",\\n        \"nodal_status\": \"** If invasive procedures are needed for tissue sampling of mediastinal lymph nodes.\",\\n        \"metastatic_status\": \"** M0 (no evidence of distant metastases).\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The findings are highly suspicious for primary lung malignancy.  Limited spatial resolution prevents precise characterization.\",\\n          \"* **CT Chest (2024-02-05):** Confirms a 3.8 x 3.2 cm spiculated mass in the right upper lobe, consistent with a malignant neoplasm.  Multiple enlarged right hilar and mediastinal lymph nodes are present. No evidence of distant metastases is identified. Mild emphysematous changes are noted in the upper lobes.\",\\n          \"* **PET-CT (2024-02-12):**  The right upper lobe mass shows a maximum standardized uptake value (SUVmax) of 12.4, indicating significant FDG avidity consistent with malignancy.  FDG-avid right hilar and mediastinal lymph nodes are present, with a maximum SUVmax of 8.2. No evidence of distant metastatic disease is detected.\",\\n          \"* **Primary Lesion:** 3.8 x 3.2 cm (CT Chest).\",\\n          \"The primary lesion is located in the right upper lobe, close to the hilum, explaining the associated hilar lymphadenopathy.  The mediastinal lymph node involvement suggests locoregional spread.  The absence of distant metastases on PET-CT is reassuring, but this needs confirmation.  The mild emphysema may impact surgical resectability, though this should be assessed post-biopsy.\"\\n        ]\\n      },\\n      \"treatment_implications\": []\\n    }\\n  },\\n  \"pathology_analysis\": {\\n    \"summary\": \"**Pathology Analysis Report - Patient ID: MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Pathology Analysis Report - Patient ID: MDT2024001**\",\\n      \"histology\": \"**\",\\n      \"molecular_profile\": {\\n        \"key_mutations\": \"**  While KRAS G12C is the key driver mutation, additional molecular testing may be considered based on treatment response and disease progression, to identify any potential secondary mutations.\",\\n        \"immunotherapy_markers\": \"** The high PD-L1 expression (80%) suggests a potential benefit from immunotherapy with PD-1 or PD-L1 inhibitors (e.g., pembrolizumab, nivolumab). This could be used as a monotherapy or in combination with chemotherapy or targeted therapy.\",\\n        \"other_markers\": {}\\n      },\\n      \"therapeutic_implications\": [\\n        \"The provided data does not include information on the grade and differentiation of the adenocarcinoma.  Further pathological assessment of the biopsy specimen, including a detailed review by a pathologist experienced in lung cancer grading (e.g., using the WHO classification), is crucial to determine the grade and differentiation. This will significantly influence prognosis and treatment decisions.\",\\n        \"**5. Therapeutic Targets:**\",\\n        \"Based on the available data, the following therapeutic targets are identified:\",\\n        \"* **KRAS G12C:**  The presence of a *KRAS* G12C mutation makes this patient a candidate for targeted therapy with a KRAS G12C inhibitor (e.g., sotorasib, adagrasib).  These are highly effective in patients with this specific mutation.\",\\n        \"* **PD-L1:** The high PD-L1 expression (80%) suggests a potential benefit from immunotherapy with PD-1 or PD-L1 inhibitors (e.g., pembrolizumab, nivolumab). This could be used as a monotherapy or in combination with chemotherapy or targeted therapy.\",\\n        \"The patient is a candidate for targeted therapy with a KRAS G12C inhibitor and/or immunotherapy with a PD-1/PD-L1 inhibitor.  The choice of treatment will depend on several factors including the patient\\'s overall health, performance status (ECOG), and the presence of any other comorbidities.  The treatment plan should be individualized and determined by a multidisciplinary team.\",\\n        \"* **Further Molecular Testing:**  While KRAS G12C is the key driver mutation, additional molecular testing may be considered based on treatment response and disease progression, to identify any potential secondary mutations.\",\\n        \"* **ECOG Performance Status:**  Formal assessment using the ECOG performance status scale is needed to accurately determine the patient\\'s functional capacity and to guide treatment decisions.\",\\n        \"**Disclaimer:** This report is based on the provided data.  A complete clinical evaluation, including detailed history taking, physical examination, and further investigations, is essential to confirm the diagnosis and formulate a definitive treatment plan.  This report should be considered as part of a larger multidisciplinary discussion and does not constitute a final treatment plan.\"\\n      ]\\n    }\\n  },\\n  \"guideline_recommendations\": [\\n    {\\n      \"guideline\": \"**  Guidelines for managing Type 2 Diabetes, Hypertension, and Osteoarthritis must be followed to minimize drug interactions and adverse events.  Renal function monitoring is especially important due to the use of Metformin and Lisinopril.\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"*2. Evidence-Based Treatment Options:**\",\\n        \"**First-line:**\",\\n        \"**Targeted therapy:**  A KRAS G12C inhibitor (sotorasib or adagrasib) is a strong contender as a first-line treatment due to the presence of the KRAS G12C mutation.  (High evidence level).\",\\n        \"**Immunotherapy:**  Pembrolizumab or nivolumab are also strong candidates due to the high PD-L1 expression.  This could be used as monotherapy or in combination with chemotherapy. (High evidence level).\"\\n      ]\\n    },\\n    {\\n      \"guideline\": \"**  Combining a KRAS G12C inhibitor with immunotherapy or chemotherapy might be considered, although the optimal combination strategy needs further evaluation based on the most recent guidelines and clinical trial data. (Evidence level: Moderate to High depending on the specific regimen).\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"**Second-line (if first-line therapy fails):**  Various chemotherapy regimens, other targeted therapies, and combinations are available depending on the response to initial therapy and disease progression.  (Evidence level: Moderate to High, depending on the regimen).\",\\n        \"*3. Clinical Trial Eligibility:**\",\\n        \"*4. Special Considerations:**\",\\n        \"**Comorbidities:**  The patient\\'s comorbidities (diabetes, hypertension, osteoarthritis) require careful consideration when choosing treatment regimens and dosages.  Close monitoring of renal function, blood glucose levels, and blood pressure is essential.\",\\n        \"**Performance Status:**  A formal ECOG performance status assessment is crucial to guide treatment decisions and determine the patient\\'s ability to tolerate intensive therapies.\",\\n        \"**Patient Preferences:**  Shared decision-making is vital.  The patient\\'s preferences, values, and goals of care must be integrated into the treatment plan.\",\\n        \"*5. Documentation of Deviations:**\",\\n        \"*Recommendations:**\",\\n        \"**Refer the patient to a multidisciplinary team (MDT)** including pulmonologists, oncologists, pathologists, and potentially other specialists for comprehensive evaluation and treatment planning.\",\\n        \"**Perform a formal ECOG performance status assessment.**\",\\n        \"**Conduct a thorough review of the latest guidelines** for the management of KRAS G12C-mutated and PD-L1-positive NSCLC to determine the optimal treatment strategy.\",\\n        \"**Search for ongoing clinical trials** that the patient might be eligible for.\",\\n        \"**Carefully manage the patient\\'s comorbidities** to minimize adverse events and optimize treatment efficacy.\",\\n        \"**Engage in shared decision-making** with the patient to ensure the treatment plan aligns with her preferences and goals.\",\\n        \"*Disclaimer:** This analysis is based on the information provided.  A complete clinical evaluation, including detailed history taking, physical examination, and further investigations, is essential for a definitive diagnosis and treatment plan.  This report should be considered as part of a larger multidisciplinary discussion and does not constitute a final treatment plan.\"\\n      ]\\n    }\\n  ]\\n}', 'task': 'Synthesize all available information and provide an expert clinical assessment including treatment recommendations, risk stratification, and special considerations. Consider both patient-specific factors and guideline recommendations.'}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'overall_assessment': '**', 'treatment_considerations': [\"This 62-year-old female presents with a concerning constellation of symptoms highly suggestive of advanced lung adenocarcinoma.  The imaging (chest X-ray, CT chest, PET-CT) reveals a 3.8 x 3.2 cm right upper lobe mass with significant FDG avidity, hilar and mediastinal lymphadenopathy, and no evidence of distant metastases.  Pathology confirms a KRAS G12C mutation and high PD-L1 expression (80%).  Her ECOG performance status needs formal assessment, but based on her symptoms (significant weight loss, fatigue, etc.), it's likely ECOG 2-3.  Comorbidities include well-controlled Type 2 Diabetes Mellitus, hypertension, and osteoarthritis, which will influence treatment selection and require close monitoring.\", '**4. Treatment Options:**', '* **Targeted therapy:** A KRAS G12C inhibitor (sotorasib or adagrasib) is a highly effective first-line option based on current guidelines and evidence.', '* **Immunotherapy:** Pembrolizumab or nivolumab, given the high PD-L1 expression, are strong candidates, either as monotherapy or in combination with chemotherapy.  Combination therapy with a KRAS G12C inhibitor and immunotherapy should be discussed, considering the latest clinical trial data to optimize efficacy.', '* **Second-line (if first-line therapy fails):**  Various chemotherapy regimens, other targeted therapies, and combinations will be considered based on the response to initial therapy and disease progression.'], 'risk_assessment': '**', 'proposed_approach': 'Individualized approach recommended.', 'follow_up_recommendations': ['*Disclaimer:** This assessment is based on the information provided.  A complete clinical evaluation is essential for a definitive diagnosis and treatment plan.  This report should be considered as part of a larger multidisciplinary discussion and does not constitute a final treatment plan.']}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "17abfed3-0bbe-47f9-b550-eb661cdf5691_SpecialistAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"medical_history\": [\\n    {\\n      \"condition\": \"Type 2 Diabetes\",\\n      \"diagnosed\": \"2015-06-15\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Metformin 1000mg BID\",\\n      \"control\": \"Good, HbA1c 6.8%\"\\n    },\\n    {\\n      \"condition\": \"Hypertension\",\\n      \"diagnosed\": \"2016-03-22\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Lisinopril 20mg daily\",\\n      \"control\": \"Well-controlled, BP avg 128/78\"\\n    },\\n    {\\n      \"condition\": \"Osteoarthritis\",\\n      \"diagnosed\": \"2018-11-30\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"PRN NSAIDs\",\\n      \"affected_joints\": [\\n        \"knees\",\\n        \"hands\"\\n      ]\\n    }\\n  ],\\n  \"ehr_analysis\": {\\n    \"summary\": \"Based on the reported symptoms (fatigue, weight loss, decreased appetite) and the severity of the cough, a preliminary assessment suggests a performance status of ECOG 2-3.  A more thorough assessment using validated tools like the ECOG Performance Status scale is necessary for accurate staging and treatment planning.  The presence of comorbidities (diabetes, hypertension, osteoarthritis) may further impact her functional capacity and tolerance to treatment.\",\\n    \"details\": {\\n      \"summary\": \"Based on the reported symptoms (fatigue, weight loss, decreased appetite) and the severity of the cough, a preliminary assessment suggests a performance status of ECOG 2-3.  A more thorough assessment using validated tools like the ECOG Performance Status scale is necessary for accurate staging and treatment planning.  The presence of comorbidities (diabetes, hypertension, osteoarthritis) may further impact her functional capacity and tolerance to treatment.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"\",\\n        \"comorbidity_impact\": \"** The patient has well-controlled Type 2 Diabetes (on Metformin), well-controlled Hypertension (on Lisinopril), and Osteoarthritis affecting her knees and hands. These comorbidities will need careful consideration during treatment planning due to potential drug interactions and impact on overall tolerance.\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"## EHR Analysis Agent Report: Patient MDT2024001\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:** The patient, a 62-year-old Caucasian female, presents with a persistent cough (onset January 15th, 2024) initially characterized as moderate to severe, progressing to include blood-tinged sputum.  Significant weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats further indicate a concerning clinical picture.  The temporal relationship between these symptoms strongly suggests a serious underlying condition, possibly malignancy.\\\\n\\\\n* **Comorbidities:** The patient has well-controlled Type 2 Diabetes (on Metformin), well-controlled Hypertension (on Lisinopril), and Osteoarthritis affecting her knees and hands. These comorbidities will need careful consideration during treatment planning due to potential drug interactions and impact on overall tolerance.\\\\n\\\\n* **Social and Functional Factors:** The patient is a retired teacher, suggesting a potentially stable social support network but also potential limitations in physical activity and tolerance for intensive treatment based on her pre-existing osteoarthritis.\\\\n\\\\n* **Risk Factors:**  Former smoker (quit 10 years ago) is a significant risk factor for lung cancer.  Age (62) also places her in a higher risk category for various malignancies.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Primary Complaint:** Persistent cough with hemoptysis.\\\\n* **Physical Examination:**  Suggestive findings include decreased breath sounds in the right upper lobe and right supraclavicular lymphadenopathy, highly suspicious for lung malignancy.\\\\n* **Laboratory Results:**  The complete blood count is unremarkable, excluding overt anemia. Liver function tests (ALT and AST) are mildly elevated, which warrants further investigation but could be secondary to other factors such as medication or underlying inflammation. Albumin levels are within normal range. Creatinine is normal, suggesting no significant renal impairment.\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:** 62 years\\\\n* **Smoking history:** Former smoker\\\\n* **Symptoms:** Cough with hemoptysis, weight loss, fatigue, night sweats, decreased appetite, lymphadenopathy\\\\n* **Physical Exam:** Decreased breath sounds, lymphadenopathy\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nBased on the reported symptoms (fatigue, weight loss, decreased appetite) and the severity of the cough, a preliminary assessment suggests a performance status of ECOG 2-3.  A more thorough assessment using validated tools like the ECOG Performance Status scale is necessary for accurate staging and treatment planning.  The presence of comorbidities (diabetes, hypertension, osteoarthritis) may further impact her functional capacity and tolerance to treatment.\\\\n\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\nThe clinical presentation strongly suggests the possibility of lung cancer.  The combination of hemoptysis, weight loss, fatigue, night sweats, and lymphadenopathy warrants urgent further investigation.  The next steps should include:\\\\n\\\\n* **Imaging:**  High-resolution computed tomography (HRCT) of the chest is crucial to visualize the lung lesions, assess their extent, and evaluate for lymph node involvement.  Further imaging may be needed depending on the HRCT findings (e.g., PET-CT).\\\\n* **Bronchoscopy:**  This procedure is indicated for tissue sampling to confirm the diagnosis and determine the histological subtype of the tumor.  Bronchoalveolar lavage (BAL) may also be beneficial.\\\\n* **Biopsy:**  If bronchoscopy is non-diagnostic, a CT-guided biopsy or surgical biopsy may be necessary.\\\\n* **Staging:**  Once a diagnosis is confirmed, a comprehensive staging workup is necessary to determine the extent of the disease and guide treatment decisions. This may include additional imaging (e.g., brain MRI, bone scan) and blood tests (e.g., tumor markers).\\\\n\\\\n**Treatment Planning:**\\\\n\\\\nTreatment options will depend heavily on the histological subtype, stage of the cancer, and the patient\\'s overall performance status and comorbidities.  Potential treatment modalities include surgery, chemotherapy, radiation therapy, targeted therapy, or immunotherapy, either alone or in combination.  Careful consideration must be given to the potential interactions between cancer treatments and her existing medications for diabetes and hypertension.  Multidisciplinary team (MDT) discussion involving oncologists, pulmonologists, radiologists, pathologists, and potentially other specialists is essential for optimal patient care.\\\\n\\\\n**Limitations and Uncertainties:**\\\\n\\\\nThe analysis is based on the information provided.  Further investigations are crucial to confirm the diagnosis and determine the appropriate treatment strategy.  The patient\\'s performance status requires further evaluation.  The impact of comorbidities on treatment tolerance remains to be fully assessed.\\\\n\\\\n\\\\n**Conclusion:**\\\\n\\\\nThe patient presents with a high suspicion of lung cancer.  Urgent further investigations, including imaging and biopsy, are essential.  A multidisciplinary team approach is crucial for optimal diagnosis and management.  Close monitoring of her comorbidities and careful consideration of their impact on treatment choices are vital for patient-centered care.\"\\n    }\\n  },\\n  \"imaging_analysis\": {\\n    \"summary\": \"**Imaging Analysis Report: Patient MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Report: Patient MDT2024001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"** 3.8 x 3.2 cm (CT Chest)\",\\n        \"nodal_status\": \"** Multiple enlarged right hilar and mediastinal lymph nodes (CT Chest and PET-CT).  Precise nodal size not specified but significant FDG avidity suggests substantial involvement.\",\\n        \"metastatic_status\": \"** A bone scan may be considered to exclude bone metastases, particularly if there are clinical findings suggestive of bone involvement (e.g., bone pain).\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The finding is highly suggestive of a primary lung malignancy.  Resolution is limited, preventing precise characterization of the mass.\",\\n          \"* **CT Chest (2024-02-05):**  Confirms a 3.8 x 3.2 cm spiculated mass in the right upper lobe, consistent with malignancy.  Multiple enlarged right hilar and mediastinal lymph nodes are identified.  No evidence of distant metastases is seen. Mild emphysematous changes are noted in the upper lobes.\",\\n          \"* **PET-CT (2024-02-12):**  Shows an SUVmax of 12.4 in the right upper lobe mass, indicating high metabolic activity consistent with malignancy.  FDG-avid right hilar and mediastinal lymph nodes are present, with an SUVmax of 8.2, suggesting metastatic involvement.  No evidence of distant metastatic disease is found.\",\\n          \"* **Primary Lesion:** 3.8 x 3.2 cm (CT Chest)\",\\n          \"Based on the imaging findings, the patient presents with a large primary lung mass in the right upper lobe with significant regional lymph node involvement (N2). There is no evidence of distant metastasis (M0).  Therefore, a preliminary assessment based on imaging alone suggests a Stage IIIA (T2-3 N2 M0) non-small cell lung cancer (NSCLC).  This staging is provisional and requires confirmation with histopathological diagnosis and clinical staging.\"\\n        ]\\n      },\\n      \"treatment_implications\": []\\n    }\\n  },\\n  \"pathology_analysis\": {\\n    \"summary\": \"**Pathology Analysis Report: Patient MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Pathology Analysis Report: Patient MDT2024001**\",\\n      \"histology\": \"**\",\\n      \"molecular_profile\": {\\n        \"key_mutations\": \"** While KRAS G12C is the main driver mutation identified, additional molecular profiling may be considered to identify other potential targetable alterations.\",\\n        \"immunotherapy_markers\": \"80%.\",\\n        \"other_markers\": {}\\n      },\\n      \"therapeutic_implications\": [\\n        \"The provided data does not specify the grade or differentiation of the adenocarcinoma.  Further pathological review of the biopsy specimen, including assessment of nuclear pleomorphism, mitotic rate, and architectural features, is necessary to determine the grade.  This information is crucial for prognosis and treatment planning.\",\\n        \"PD-L1 expression is 80%, a high level indicating potential responsiveness to immunotherapy.  This finding is crucial for treatment consideration.\",\\n        \"**5. Therapeutic Targets:**\",\\n        \"Based on the molecular and biomarker findings, the following therapeutic targets are identified:\",\\n        \"* **KRAS G12C:** The presence of this mutation makes the patient eligible for targeted therapy with KRAS G12C inhibitors (e.g., sotorasib, adagrasib).  These are highly effective in a subset of *KRAS* G12C-mutated lung adenocarcinomas.\",\\n        \"* **PD-L1:** The high PD-L1 expression (80%) suggests a strong likelihood of benefit from immunotherapy with a PD-1 or PD-L1 inhibitor (e.g., pembrolizumab, nivolumab).  Immunotherapy may be used as a first-line treatment or in combination with chemotherapy or targeted therapy.\",\\n        \"The patient is a candidate for targeted therapy with a KRAS G12C inhibitor and/or immunotherapy with a PD-1/PD-L1 inhibitor.  The choice of treatment will depend on factors such as the patient\\'s overall health, performance status (ECOG score needs to be formally assessed), comorbidities, and the results of staging investigations.  A multidisciplinary team discussion is essential to optimize treatment strategy.  Combination therapies should be considered.\",\\n        \"* **Comprehensive staging:**  This is crucial to determine the extent of disease and guide treatment planning.  This should include a detailed assessment of the primary tumor (size, location, invasion), regional lymph node involvement (N stage), and distant metastases (M stage).  Imaging studies (CT chest, PET-CT, brain MRI, bone scan) are necessary.\",\\n        \"* **Further molecular testing:** While KRAS G12C is the main driver mutation identified, additional molecular profiling may be considered to identify other potential targetable alterations.\",\\n        \"* **ECOG performance status assessment:**  A formal assessment of the patient\\'s performance status using the ECOG Performance Status scale is essential for treatment planning and determining her suitability for various treatment regimens.\",\\n        \"The analysis is based on currently available data.  The grade and differentiation of the adenocarcinoma require further pathological assessment.  The definitive staging and prognosis depend on the results of the recommended additional investigations.  The optimal treatment strategy will be determined through a multidisciplinary team discussion, considering all clinical and pathological information, as well as the patient\\'s preferences and comorbidities.\"\\n      ]\\n    }\\n  },\\n  \"guideline_recommendations\": [\\n    {\\n      \"guideline\": \"**\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"*3. Special Populations Considerations:**\",\\n        \"*4. Evidence Levels:**\",\\n        \"The evidence supporting the treatment recommendations stems from numerous randomized controlled trials (RCTs) and meta-analyses, representing high-level evidence.  Specific evidence levels will be cited for each recommendation below.\",\\n        \"*5. Clinical Trial Options:**\",\\n        \"*Treatment Recommendations:**\"\\n      ]\\n    }\\n  ]\\n}', 'task': 'Synthesize all available information and provide an expert clinical assessment including treatment recommendations, risk stratification, and special considerations. Consider both patient-specific factors and guideline recommendations.'}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'overall_assessment': '** This report represents my expert opinion based on the information provided.  It is crucial to conduct a thorough in-person evaluation and incorporate the results of all pending investigations before finalizing the treatment plan.  This report should not be considered a substitute for a comprehensive clinical assessment by an oncologist and the MDT.', 'treatment_considerations': [\"Patient MDT2024001 is a 62-year-old Caucasian female with a history of well-controlled Type 2 diabetes, hypertension, and osteoarthritis presenting with a persistent cough, hemoptysis, weight loss, fatigue, and night sweats.  Imaging (CT chest, PET-CT) and pathology findings strongly suggest Stage IIIA (T2-3 N2 M0) adenocarcinoma of the right upper lung lobe, harboring a *KRAS* G12C mutation and demonstrating 80% PD-L1 expression.  This presents a complex clinical scenario requiring a multidisciplinary approach to optimize treatment and manage comorbidities. The patient's ECOG performance status needs formal assessment, which will significantly influence treatment decisions.  Her comorbidities (diabetes, hypertension, osteoarthritis) require careful consideration to minimize potential adverse effects and drug interactions.\", '* **Molecular Profile:**  *KRAS* G12C mutation offers a targetable pathway, and high PD-L1 expression suggests potential responsiveness to immunotherapy.', '* **Age:** 62 years  impacts treatment tolerance and potential long-term effects.', '* **Comorbidities:**  Well-controlled Type 2 diabetes (Metformin), hypertension (Lisinopril), and osteoarthritis.  These will influence treatment selection and require close monitoring for potential interactions and adverse events.', '* **Smoking History:** Former smoker (quit 10 years ago)  a significant risk factor but may not be directly influencing current treatment options.'], 'risk_assessment': '**', 'proposed_approach': 'Individualized approach recommended.', 'follow_up_recommendations': ['**Supportive care:**  Ongoing management of symptoms and comorbidities is crucial.', '**Quality of life assessment:**  Regular assessment of quality of life is recommended to guide treatment decisions and provide optimal patient-centered care.', '**Re-staging:**  After a course of treatment, restaging will be necessary to assess response and determine the next steps in management.', '*11. Limitations and Uncertainties:**', \"The analysis is based on the available data.  Further investigations (bone scan to complete staging) are still needed.  The final treatment decision will depend on the results of these investigations and the MDT discussion.  The long-term prognosis remains uncertain and will depend on the patient's response to treatment.\"]}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "767eda57-9a56-43d0-8bfb-22978cccd6b7_SpecialistAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"medical_history\": [\\n    {\\n      \"condition\": \"Type 2 Diabetes\",\\n      \"diagnosed\": \"2015-06-15\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Metformin 1000mg BID\",\\n      \"control\": \"Good, HbA1c 6.8%\"\\n    },\\n    {\\n      \"condition\": \"Hypertension\",\\n      \"diagnosed\": \"2016-03-22\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Lisinopril 20mg daily\",\\n      \"control\": \"Well-controlled, BP avg 128/78\"\\n    },\\n    {\\n      \"condition\": \"Osteoarthritis\",\\n      \"diagnosed\": \"2018-11-30\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"PRN NSAIDs\",\\n      \"affected_joints\": [\\n        \"knees\",\\n        \"hands\"\\n      ]\\n    }\\n  ],\\n  \"ehr_analysis\": {\\n    \"summary\": \"Based on the presented information, a preliminary assessment suggests a Karnofsky Performance Status (KPS) score of 60-70%. This is an estimation based on the reported fatigue, weight loss, and the severity of her symptoms.  A more comprehensive assessment is needed including a detailed functional assessment to accurately determine her performance status.  This is crucial for determining treatment suitability and tolerance.\",\\n    \"details\": {\\n      \"summary\": \"Based on the presented information, a preliminary assessment suggests a Karnofsky Performance Status (KPS) score of 60-70%. This is an estimation based on the reported fatigue, weight loss, and the severity of her symptoms.  A more comprehensive assessment is needed including a detailed functional assessment to accurately determine her performance status.  This is crucial for determining treatment suitability and tolerance.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"\",\\n        \"comorbidity_impact\": \"**  The patient\\'s comorbidities need to be carefully managed throughout the diagnostic and treatment process.  Close monitoring of blood glucose and blood pressure is essential.  The choice of treatment modalities needs to account for potential drug interactions and the overall health status of the patient.\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"**EHR Analysis Agent Report - Patient ID: MDT2024001**\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:** The patient, a 62-year-old Caucasian female, presents with a persistent cough (onset January 15, 2024) initially described as moderate to severe, progressing to include blood-tinged sputum.  This is accompanied by significant unintentional weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats \\\\u2013 all highly suggestive of a serious underlying condition, potentially malignancy.\\\\n\\\\n* **Comorbidities:** The patient has well-controlled Type 2 Diabetes (on Metformin), well-controlled Hypertension (on Lisinopril), and Osteoarthritis affecting her knees and hands.  These comorbidities will need careful consideration during treatment planning due to potential drug interactions and the added burden on overall health.\\\\n\\\\n* **Social and Functional Factors:** The patient is a retired teacher, suggesting a potentially stable social support system but also a potential impact on her ability to tolerate intensive treatment regimens.  Further social history is needed to fully assess her support network and functional capacity.\\\\n\\\\n* **Risk Factors:**  Former smoker (quit 10 years ago) \\\\u2013 a significant risk factor for lung cancer.  Age (62) also places her within a higher risk group for various malignancies. The combination of these factors significantly increases the likelihood of a serious underlying pathology.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Presenting Complaint:** Persistent cough with hemoptysis, weight loss, fatigue, decreased appetite, and night sweats.  These symptoms strongly suggest a possible malignancy, particularly lung cancer.\\\\n\\\\n* **Physical Examination:**  Decreased breath sounds in the right upper lobe and right supraclavicular lymphadenopathy strongly support the suspicion of lung cancer.  Vital signs are generally stable, although the slightly elevated blood pressure (132/82) warrants monitoring, especially given her existing hypertension.\\\\n\\\\n* **Laboratory Results:**  The complete blood count (CBC) shows normal hemoglobin, WBC, and platelets, which doesn\\'t rule out malignancy but doesn\\'t provide strong evidence for infection or significant anemia.  Liver function tests (ALT and AST) are mildly elevated, requiring further investigation to determine the cause.  Albumin is within the normal range.\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:** 62 years\\\\n* **Smoking history:** Former smoker (10 years quit)\\\\n* **Symptoms:** Persistent cough with hemoptysis, weight loss, fatigue, anorexia, night sweats.\\\\n* **Physical Exam:** Decreased breath sounds in the right upper lobe, right supraclavicular lymphadenopathy.\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nBased on the presented information, a preliminary assessment suggests a Karnofsky Performance Status (KPS) score of 60-70%. This is an estimation based on the reported fatigue, weight loss, and the severity of her symptoms.  A more comprehensive assessment is needed including a detailed functional assessment to accurately determine her performance status.  This is crucial for determining treatment suitability and tolerance.\\\\n\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\nThe clinical picture strongly suggests the need for further investigation to rule out lung cancer.  The next steps should include:\\\\n\\\\n* **Imaging:** A chest CT scan with contrast is crucial to evaluate the extent of any lung lesions and to assess for mediastinal lymphadenopathy.  Further imaging modalities (PET-CT) may be indicated depending on the CT findings.\\\\n\\\\n* **Bronchoscopy:**  Bronchoscopy with bronchoalveolar lavage (BAL) and biopsy would be essential for obtaining tissue samples for histopathological examination, confirming the diagnosis and determining the type and stage of cancer.\\\\n\\\\n* **Further Laboratory Investigations:**  Consideration of tumor markers (e.g., CEA, CYFRA 21-1) should be given, although these should not be solely relied upon for diagnosis.  Further investigation into the mildly elevated liver enzymes is also necessary.\\\\n\\\\n* **Multidisciplinary Team (MDT) Discussion:** This case requires immediate discussion within an MDT involving pulmonology, oncology, radiology, and potentially thoracic surgery to plan the optimal diagnostic and treatment strategy.\\\\n\\\\n* **Comorbidity Management:**  The patient\\'s comorbidities need to be carefully managed throughout the diagnostic and treatment process.  Close monitoring of blood glucose and blood pressure is essential.  The choice of treatment modalities needs to account for potential drug interactions and the overall health status of the patient.\\\\n\\\\n**Limitations and Uncertainties:**\\\\n\\\\nThis analysis is based on the limited information provided.  A complete clinical picture requires a thorough physical examination, detailed review of imaging studies, and histopathological confirmation of any suspected malignancy.  The KPS score is a preliminary estimate.\\\\n\\\\n\\\\n**Patient-Centered Care:**\\\\n\\\\nIt\\'s crucial to involve the patient in all decision-making processes, ensuring she understands the potential diagnoses, treatment options, and their associated risks and benefits.  Open communication and addressing her concerns are paramount throughout her journey.\"\\n    }\\n  },\\n  \"imaging_analysis\": {\\n    \"summary\": \"**Imaging Analysis Report - Patient ID: MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Report - Patient ID: MDT2024001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"** HRCT can provide more detailed information about the primary tumor, its relationship to surrounding structures, and the extent of any pleural involvement, which could impact the T-stage.\",\\n        \"nodal_status\": \"** This procedure is essential for obtaining tissue samples for histopathological diagnosis, confirming the type of lung cancer (e.g., adenocarcinoma, squamous cell carcinoma, etc.) and determining the precise extent of lymph node involvement.  EBUS allows for targeted sampling of mediastinal nodes, improving diagnostic accuracy compared to conventional mediastinoscopy.\",\\n        \"metastatic_status\": \"\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The finding is highly suspicious for a primary lung malignancy.  Resolution is limited, preventing precise characterization.\",\\n          \"* **CT Chest (2024-02-05):**  Confirms a 3.8 x 3.2 cm spiculated mass in the right upper lobe, consistent with malignancy.  Multiple enlarged right hilar and mediastinal lymph nodes are present.  No evidence of distant metastases is identified. Mild emphysematous changes are noted in the upper lobes.\",\\n          \"* **PET-CT (2024-02-12):**  Shows a right upper lobe mass with a maximum standardized uptake value (SUVmax) of 12.4, indicating high metabolic activity consistent with malignancy.  FDG-avid right hilar and mediastinal lymph nodes are present, with a maximum SUVmax of 8.2.  No evidence of distant metastatic disease is seen.\",\\n          \"* **Primary Lesion:** 3.8 x 3.2 cm (CT Chest)\",\\n          \"The primary lesion is located in the right upper lobe, close to the hilum.  The involvement of hilar and mediastinal lymph nodes suggests locoregional spread. The relationship of the tumor to major vessels and the extent of pleural involvement needs further clarification through higher-resolution imaging or bronchoscopy with endobronchial ultrasound (EBUS).\"\\n        ]\\n      },\\n      \"treatment_implications\": []\\n    }\\n  },\\n  \"pathology_analysis\": {\\n    \"summary\": \"**Pathology Analysis Report - Patient ID: MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Pathology Analysis Report - Patient ID: MDT2024001**\",\\n      \"histology\": \"**\",\\n      \"molecular_profile\": {\\n        \"key_mutations\": \"** While the *KRAS* G12C mutation is a key finding, it\\'s prudent to consider broader next-generation sequencing (NGS) panels to detect other potentially actionable mutations.\",\\n        \"immunotherapy_markers\": \"**Recommendations for Additional Testing:**\",\\n        \"other_markers\": {}\\n      },\\n      \"therapeutic_implications\": [\\n        \"*Pathological Diagnosis:**\"\\n      ]\\n    }\\n  },\\n  \"guideline_recommendations\": [\\n    {\\n      \"guideline\": \"**\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"*3. Special Populations and Considerations:**\",\\n        \"*4. Evidence Levels and Treatment Options:**\",\\n        \"**Definitive Diagnosis:**  The next step is obtaining tissue via bronchoscopy with endobronchial ultrasound (EBUS) guided biopsy to confirm the diagnosis and determine the histological subtype (adenocarcinoma, squamous cell carcinoma, etc.) and molecular profile (including EGFR, ALK, ROS1, KRAS mutations, PD-L1 expression, etc.). This is crucial for guiding treatment selection.\",\\n        \"**Staging:**  Once a diagnosis is confirmed, a comprehensive staging evaluation is required, including a full-body PET-CT scan and potentially further imaging based on initial findings.  This information will determine the precise stage (I-IV) according to TNM classification.\",\\n        \"**Treatment Options (pending staging and molecular profile):**\",\\n        \"**Stage III NSCLC:** Treatment options may include concurrent chemoradiotherapy followed by potential adjuvant immunotherapy.\",\\n        \"**Stage IV NSCLC:** Treatment options may include systemic therapy (chemotherapy, targeted therapy, immunotherapy, or combinations thereof).  Specific choices will depend on the histological subtype and molecular profile.  If a *KRAS* G12C mutation is present, targeted therapy with sotorasib or adagrasib would be a treatment consideration.  If PD-L1 expression is high, immunotherapy (e.g., pembrolizumab or atezolizumab) may be the preferred approach.\",\\n        \"**Comorbidity Management:**  Tight glycemic control will be maintained throughout the treatment process.  Blood pressure will be monitored closely, and medication adjustments may be required.\",\\n        \"*5. Clinical Trial Eligibility:**\",\\n        \"The patient\\'s characteristics (advanced stage, specific molecular markers) make her potentially eligible for several clinical trials investigating novel therapies for NSCLC.  A comprehensive search of ongoing trials is recommended, considering the patient\\'s performance status and comorbidities.\"\\n      ]\\n    },\\n    {\\n      \"guideline\": \"**\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"*7. Recommendations:**\",\\n        \"**Immediate Bronchoscopy with EBUS-guided biopsy:**  To obtain tissue for definitive diagnosis and molecular profiling.\",\\n        \"**Comprehensive Staging:**  Including full-body PET-CT scan.\",\\n        \"**Multidisciplinary Team (MDT) Discussion:**  To develop a personalized treatment plan based on the diagnosis, staging, and molecular findings.\",\\n        \"**Close Monitoring of Comorbidities:**  Throughout the diagnostic and treatment process.\",\\n        \"**Exploration of Clinical Trial Eligibility:**  To access potentially beneficial novel therapies.\",\\n        \"**Patient-Centered Communication:**  To ensure shared decision-making and address the patient\\'s concerns and preferences.\",\\n        \"*8. Limitations and Uncertainties:**\",\\n        \"The recommendations are based on the currently available information.  Further data from the biopsy and staging will refine the diagnosis and guide treatment.  Treatment decisions will be further optimized after MDT discussion and considering the patient\\'s preferences.\",\\n        \"*Code Usage:**\"\\n      ]\\n    }\\n  ]\\n}', 'task': 'Synthesize all available information and provide an expert clinical assessment including treatment recommendations, risk stratification, and special considerations. Consider both patient-specific factors and guideline recommendations.'}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'overall_assessment': '**', 'treatment_considerations': ['This 62-year-old female presents with a concerning constellation of symptoms (persistent cough with hemoptysis, weight loss, fatigue, anorexia, night sweats) and physical findings (decreased breath sounds in the right upper lobe, right supraclavicular lymphadenopathy) highly suggestive of lung cancer.  Imaging (CXR, CT chest, PET-CT) confirms a 3.8 x 3.2 cm spiculated mass in the right upper lobe with involvement of hilar and mediastinal lymph nodes, strongly indicating a locally advanced or potentially metastatic disease.  While distant metastases are not yet identified on imaging, the presence of mediastinal nodal involvement suggests at least stage III disease.  The preliminary Karnofsky Performance Status (KPS) of 60-70% indicates a moderate level of functional impairment, which needs further clarification through a formal assessment.  Her comorbidities (Type 2 Diabetes, Hypertension, Osteoarthritis) require careful consideration in treatment planning.  A definitive diagnosis and molecular profiling are crucial for optimal management.', '* **Performance Status:** Estimated KPS 60-70%, requiring formal assessment to guide treatment intensity.', '* **Comorbidities:** Well-controlled Type 2 Diabetes, Hypertension, and Osteoarthritis. These will influence treatment choice and require close monitoring.', '**4. Treatment Options:**', '* **Stage III (if confirmed):** Concurrent chemoradiotherapy (CRT) followed by potential adjuvant immunotherapy (e.g., pembrolizumab if PD-L1 positive) based on current NCCN guidelines.  Surgical resection may be considered if imaging and pathology reveal resectable disease.'], 'risk_assessment': '', 'proposed_approach': '* **Stage III (if confirmed):** Concurrent chemoradiotherapy (CRT) followed by potential adjuvant immunotherapy (e.g., pembrolizumab if PD-L1 positive) based on current NCCN guidelines.  Surgical resection may be considered if imaging and pathology reveal resectable disease.', 'follow_up_recommendations': ['**Immediate Bronchoscopy with EBUS-guided biopsy:**  To obtain tissue for definitive diagnosis and molecular profiling.', '**Comprehensive Staging:** Full-body PET-CT scan to accurately determine the disease extent.', '**Multidisciplinary Team (MDT) Discussion:** To develop a personalized treatment plan based on the diagnosis, staging, and molecular findings.', '**Close Monitoring of Comorbidities:** Throughout the diagnostic and treatment process.', '**Regular imaging:**  To assess response to therapy and detect disease recurrence.', '*9. Limitations and Uncertainties:**', 'This assessment is based on currently available information.  The definitive diagnosis, histological subtype, molecular profile, and precise staging are still pending.  Treatment recommendations will be refined once these data are available and after discussion within a multidisciplinary team.  The KPS score is a preliminary estimate.', '*10. Patient-Centered Care:**', 'Open communication with the patient is crucial, ensuring she understands the diagnostic process, treatment options, risks, and benefits.  Shared decision-making will be paramount, respecting her preferences and values.  Active listening and addressing her concerns are essential throughout her journey.']}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "5aa60ea2-2268-457a-81a2-b2fb5dca805e_SpecialistAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"medical_history\": [\\n    {\\n      \"condition\": \"Type 2 Diabetes\",\\n      \"diagnosed\": \"2015-06-15\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Metformin 1000mg BID\",\\n      \"control\": \"Good, HbA1c 6.8%\"\\n    },\\n    {\\n      \"condition\": \"Hypertension\",\\n      \"diagnosed\": \"2016-03-22\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Lisinopril 20mg daily\",\\n      \"control\": \"Well-controlled, BP avg 128/78\"\\n    },\\n    {\\n      \"condition\": \"Osteoarthritis\",\\n      \"diagnosed\": \"2018-11-30\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"PRN NSAIDs\",\\n      \"affected_joints\": [\\n        \"knees\",\\n        \"hands\"\\n      ]\\n    }\\n  ],\\n  \"ehr_analysis\": {\\n    \"summary\": \"A full performance status assessment using a validated tool like the ECOG (Eastern Cooperative Oncology Group) performance status scale is needed.  Based on the presented information, a preliminary assessment suggests a performance status of 2 or possibly 3, given the reported fatigue, weight loss, and moderate to severe symptom burden.  A more thorough evaluation is crucial for appropriate treatment planning.\",\\n    \"details\": {\\n      \"summary\": \"A full performance status assessment using a validated tool like the ECOG (Eastern Cooperative Oncology Group) performance status scale is needed.  Based on the presented information, a preliminary assessment suggests a performance status of 2 or possibly 3, given the reported fatigue, weight loss, and moderate to severe symptom burden.  A more thorough evaluation is crucial for appropriate treatment planning.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"\",\\n        \"comorbidity_impact\": \"**\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"**EHR Analysis Agent Report: Patient MDT2024001**\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:** The patient, a 62-year-old Caucasian female, presents with a persistent cough (onset 2024-01-15) progressing to include blood-tinged sputum, unintentional weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats. This constellation of symptoms warrants serious concern for malignancy, particularly lung cancer.\\\\n\\\\n* **Medical History:**  The patient has a history of well-controlled Type 2 Diabetes (Metformin 1000mg BID, HbA1c 6.8%), well-controlled Hypertension (Lisinopril 20mg daily, BP 128/78), and Osteoarthritis affecting her knees and hands.  These comorbidities will need consideration in treatment planning due to potential drug interactions and impact on overall tolerance.  Her history of smoking (former smoker, quit 10 years ago) is a significant risk factor for lung cancer.\\\\n\\\\n* **Social and Functional Factors:**  The patient is retired, suggesting a potentially decreased functional capacity compared to someone actively employed. This should be assessed further to determine her ability to tolerate potential treatment regimens.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Primary Complaint:** Persistent cough with hemoptysis.\\\\n* **Physical Exam:**  Significant findings include decreased breath sounds in the right upper lobe, suggestive of a space-occupying lesion, and right supraclavicular lymphadenopathy, highly suggestive of metastatic disease.\\\\n* **Laboratory Results:**  The complete blood count (CBC) shows normal hemoglobin, white blood cell count, and platelets, not providing definitive evidence of malignancy but not ruling it out.  Liver function tests (LFTs) are mildly elevated (ALT 28 U/L, AST 32 U/L), which could be due to various factors including medication or underlying disease and requires further investigation.\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:** 62 years old (increased risk of malignancy).\\\\n* **Gender:** Female (lung cancer incidence is lower in females, but this doesn\\'t negate the possibility).\\\\n* **Smoking History:** Former smoker, though cessation 10 years prior still increases risk.\\\\n* **Symptoms:** Hemoptysis, weight loss, fatigue, night sweats \\\\u2013 classic symptoms suggestive of lung cancer.\\\\n* **Physical Exam Findings:** Decreased breath sounds and supraclavicular lymphadenopathy are highly concerning for malignancy.\\\\n\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nA full performance status assessment using a validated tool like the ECOG (Eastern Cooperative Oncology Group) performance status scale is needed.  Based on the presented information, a preliminary assessment suggests a performance status of 2 or possibly 3, given the reported fatigue, weight loss, and moderate to severe symptom burden.  A more thorough evaluation is crucial for appropriate treatment planning.\\\\n\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\nThe clinical presentation strongly suggests the possibility of lung cancer.  The right supraclavicular lymphadenopathy indicates potential metastatic spread.  Further investigations are urgently required, including:\\\\n\\\\n* **Chest X-ray:** To further evaluate the right upper lobe findings.\\\\n* **Computed Tomography (CT) Scan of the Chest, Abdomen, and Pelvis:** To fully stage the disease and detect any metastatic spread.\\\\n* **Bronchoscopy with Bronchoalveolar Lavage (BAL) and Biopsy:** To obtain tissue for definitive diagnosis and histopathological analysis.  This is the most crucial step.\\\\n* **Positron Emission Tomography (PET) Scan:** To further assess the extent of disease and guide treatment planning.\\\\n\\\\n**Comorbidities and Treatment Implications:**\\\\n\\\\nThe patient\\'s comorbidities (diabetes, hypertension, osteoarthritis) will influence treatment choices.  Careful consideration is needed to select therapies that minimize adverse effects while effectively managing the cancer.  Renal function should be monitored closely due to the use of Metformin and potential nephrotoxicity from other medications.  The use of NSAIDs for osteoarthritis needs to be carefully considered in light of potential interactions with other medications and impact on bleeding risk.\\\\n\\\\n**Medication Interactions:**  Potential drug interactions between the current medications and any future cancer treatments (chemotherapy, targeted therapy, immunotherapy) must be carefully considered and managed by a pharmacist experienced in oncology.\\\\n\\\\n**Conclusion:**\\\\n\\\\nThis patient requires urgent specialist referral to a pulmonologist and oncologist for comprehensive evaluation and management.  The high suspicion for lung cancer necessitates prompt investigation and multidisciplinary discussion to develop a patient-centered treatment plan that considers her comorbidities and performance status.  The information provided is insufficient for definitive diagnosis or treatment recommendations; further investigations are crucial.  This analysis is for informational purposes only and does not constitute medical advice.\"\\n    }\\n  },\\n  \"imaging_analysis\": {\\n    \"summary\": \"**Imaging Analysis Agent Report: Patient MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Agent Report: Patient MDT2024001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"** 3.8 x 3.2 cm (CT Chest)\",\\n        \"nodal_status\": \"**  Given the mediastinal lymphadenopathy, EBUS or mediastinoscopy with lymph node biopsy is strongly recommended for precise nodal staging. This will help to determine the extent of lymph node involvement and refine the N classification.\",\\n        \"metastatic_status\": \"**  While the PET-CT did not show evidence of brain metastasis, an MRI of the brain is often recommended in staging lung cancer to rule out occult CNS involvement.\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The impression of a highly suspicious primary lung malignancy is consistent with subsequent imaging.\",\\n          \"* **CT Chest (2024-02-05):**  Confirms a 3.8 x 3.2 cm spiculated mass in the right upper lobe, characteristic of malignancy.  Multiple enlarged right hilar and mediastinal lymph nodes are present. No evidence of distant metastases is identified. Mild emphysematous changes are noted in the upper lobes.\",\\n          \"* **PET-CT (2024-02-12):**  The right upper lobe mass shows an SUVmax of 12.4, indicating high metabolic activity consistent with malignancy. FDG-avid right hilar and mediastinal lymph nodes are present with an SUVmax of 8.2, confirming their involvement.  No evidence of distant metastatic disease is observed.\",\\n          \"* **Primary Lesion:** 3.8 x 3.2 cm (CT Chest)\",\\n          \"Based on the available imaging, the patient presents with a large primary lung mass in the right upper lobe, with involvement of regional lymph nodes (hilar and mediastinal).  There is no evidence of distant metastases.  This strongly suggests a Stage IIIA Non-Small Cell Lung Cancer (NSCLC) according to the current TNM staging system (8th edition).  However, this is a preliminary assessment based on imaging alone.  Further information, including tissue biopsy and pathological analysis, is required for definitive staging.  The precise T, N, and M classifications require further investigation.  The size of the primary tumor suggests a T2 or possibly a T3 classification, and N2 classification is likely given the mediastinal lymph node involvement.  The absence of distant metastases suggests an M0 classification.\",\\n          \"The primary lesion is located in the right upper lobe, close to the hilum and major vascular structures.  The involvement of hilar and mediastinal lymph nodes indicates significant regional spread.  The location of the tumor will influence surgical options and potential complications. The mild emphysema may impact surgical feasibility and post-operative respiratory function.  The presence of right supraclavicular lymphadenopathy (noted in the physical exam) raises concern for potential N3 disease. This finding requires further investigation with additional imaging or biopsy.\"\\n        ]\\n      },\\n      \"treatment_implications\": []\\n    }\\n  },\\n  \"pathology_analysis\": {\\n    \"summary\": \"**Pathology Analysis Agent Report: Patient MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Pathology Analysis Agent Report: Patient MDT2024001**\",\\n      \"histology\": \"**\",\\n      \"molecular_profile\": {\\n        \"key_mutations\": \"**4. Biomarker Status:**\",\\n        \"immunotherapy_markers\": \"**  Could identify another potential biomarker for immunotherapy response.\",\\n        \"other_markers\": {}\\n      },\\n      \"therapeutic_implications\": [\\n        \"The provided data does not specify the grade or differentiation of the adenocarcinoma.  Further histopathological review of the biopsy specimen, including assessment of nuclear atypia, mitotic rate, and architectural features, is necessary to determine the grade (e.g., well-differentiated, moderately differentiated, poorly differentiated) and assign a specific differentiation subtype (e.g., acinar, papillary, lepidic, solid). This information is crucial for prognostication and treatment planning.\",\\n        \"Molecular testing reveals a *KRAS* G12C mutation.  *EGFR*, *ALK*, and *ROS1* are wild-type/negative for rearrangement.  The presence of the *KRAS* G12C mutation is significant, as it identifies a specific targetable driver mutation.\",\\n        \"PD-L1 expression is 80%.  This high level of expression suggests that the patient may benefit from immunotherapy, specifically PD-1/PD-L1 inhibitors.  However, the clinical benefit of immunotherapy in KRAS-mutated lung adenocarcinoma is generally less robust compared to other subtypes, and response rates can be variable.\",\\n        \"**5. Therapeutic Targets:**\",\\n        \"The *KRAS* G12C mutation is a key therapeutic target.  Sotorasib and adagrasib are FDA-approved targeted therapies specifically designed to inhibit KRAS G12C.  These should be considered as first-line treatment options, given the high PD-L1 expression, combination therapy with immunotherapy (e.g., pembrolizumab or atezolizumab) could also be explored.  However, the efficacy of this combination needs to be carefully weighed against potential toxicity.\",\\n        \"* **Targeted Therapy:** Sotorasib or adagrasib are primary treatment considerations due to the *KRAS* G12C mutation.\",\\n        \"* **Immunotherapy:**  Given the high PD-L1 expression, the addition of immunotherapy (e.g., pembrolizumab or atezolizumab) should be evaluated, potentially in combination with targeted therapy.  However, this requires careful consideration of potential increased toxicity and the overall benefit-risk profile.\",\\n        \"* **Chemotherapy:**  While less likely to be first-line in this case given the availability of targeted therapy, chemotherapy may be considered as an alternative or in combination if targeted therapy fails or is poorly tolerated.\",\\n        \"* **Close Monitoring:**  Careful monitoring of response to therapy and potential adverse events is essential.\",\\n        \"1. **Complete histopathological review:**  To determine the grade and subtype of the adenocarcinoma. This will refine prognostication and treatment selection.\",\\n        \"2. **Comprehensive genomic profiling:**  While KRAS G12C is identified, broader genomic testing may reveal additional mutations or alterations that could influence treatment decisions or predict response to therapy.  This is particularly important given the relatively lower response rates of immunotherapy in KRAS-mutated lung adenocarcinoma.\",\\n        \"3. **Assessment of tumor mutational burden (TMB):**  Could be useful in selecting patients who might benefit from immunotherapy.\",\\n        \"4. **Microsatellite instability (MSI) testing:**  Could identify another potential biomarker for immunotherapy response.\",\\n        \"5. **Further staging investigations:**  As indicated in the EHR and imaging reports, EBUS/mediastinoscopy with lymph node biopsy, and brain MRI are crucial to definitively stage the disease. This will influence treatment decisions and prognosis.\",\\n        \"The current analysis is based on the information provided.  Further investigations and multidisciplinary discussion are required to develop a comprehensive and personalized treatment plan. The absence of detailed information regarding performance status, comorbidities, and treatment preferences limits the scope of this analysis.  The efficacy of any treatment modality remains dependent on individual patient factors and response.\"\\n      ]\\n    }\\n  },\\n  \"guideline_recommendations\": [\\n    {\\n      \"guideline\": \"** This will guide staging, treatment selection (surgery, chemotherapy, targeted therapy, immunotherapy), and supportive care.  The specific recommendations will depend on the final pathological staging (following EBUS/mediastinoscopy and brain MRI) and performance status (ECOG PS).\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"**FDA-approved treatments for *KRAS* G12C-mutated NSCLC:**  This will inform the choice of targeted therapy (sotorasib or adagrasib).\"\\n      ]\\n    },\\n    {\\n      \"guideline\": \"**  The patient\\'s diabetes, hypertension, and osteoarthritis require careful consideration when selecting and administering treatment to minimize adverse effects and drug interactions.\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"*2. Evidence-Based Treatment Options:**\",\\n        \"**First-line treatment:**  Given the *KRAS* G12C mutation, the first-line treatment should be a KRAS G12C inhibitor (sotorasib or adagrasib).  The high PD-L1 expression warrants consideration of combining this targeted therapy with immunotherapy (e.g., pembrolizumab or atezolizumab) \\\\u2013 this decision should be made based on a thorough risk-benefit assessment considering potential toxicity.\",\\n        \"**Surgical resection:**  Surgical resection might be considered if the disease is deemed resectable after definitive staging.  Given the size and location of the tumor, as well as the presence of mediastinal lymphadenopathy, this is less likely. EBUS-TBNA or mediastinoscopy is required to fully assess resectability.\",\\n        \"**Chemotherapy:**  Chemotherapy is less likely to be first-line in this specific scenario due to the availability of targeted therapy.  It could be considered as a salvage therapy if the targeted therapy and/or immunotherapy fail.\",\\n        \"**Radiation therapy:**  Radiation therapy may have a role in palliative care or as part of a combined modality approach, depending on the disease extent and patient response to other treatments.\",\\n        \"*3. Clinical Trial Eligibility:**\",\\n        \"The patient\\'s *KRAS* G12C mutation, high PD-L1 expression, and advanced stage of disease make her potentially eligible for several clinical trials investigating novel therapies for NSCLC, including combination therapies and immunotherapies. A comprehensive search of ongoing clinical trials is recommended.\",\\n        \"*4. Special Considerations:**\",\\n        \"**Comorbidities:**  Careful management of the patient\\'s diabetes, hypertension, and osteoarthritis is crucial.  Close monitoring of renal function is necessary due to metformin use and potential nephrotoxicity from other medications.  The use of NSAIDs should be carefully considered given the bleeding risk and potential interactions.\",\\n        \"**Performance Status:**  A formal ECOG performance status assessment is essential for determining treatment tolerance and selecting appropriate therapies.\",\\n        \"**Patient Preferences:**  The treatment plan should be individualized to the patient\\'s preferences and values.\",\\n        \"*5. Documentation of Deviations:**\",\\n        \"*Recommendations:**\",\\n        \"**Urgent referral to a pulmonologist and oncologist:** For comprehensive evaluation and multidisciplinary discussion.\",\\n        \"**Complete staging:**  EBUS-TBNA or mediastinoscopy with lymph node biopsy and brain MRI are needed to accurately stage the disease.\",\\n        \"**Definitive tissue diagnosis:**  Confirmation of adenocarcinoma and assessment of tumor grade and subtype.\",\\n        \"**Comprehensive molecular profiling:** To confirm the *KRAS* G12C mutation and assess for other potential therapeutic targets.\",\\n        \"**Treatment plan development:**  A multidisciplinary team should develop a patient-centered treatment plan considering the *KRAS* G12C mutation, high PD-L1 expression, comorbidities, and performance status.  This plan should include first-line treatment with a KRAS G12C inhibitor (sotorasib or adagrasib), possibly combined with immunotherapy, and exploration of clinical trial eligibility.\",\\n        \"**Close monitoring:**  Regular monitoring of disease progression, treatment response, and adverse effects.\",\\n        \"*Limitations:**\"\\n      ]\\n    }\\n  ]\\n}', 'task': 'Synthesize all available information and provide an expert clinical assessment including treatment recommendations, risk stratification, and special considerations. Consider both patient-specific factors and guideline recommendations.'}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'overall_assessment': '**', 'treatment_considerations': [\"Patient MDT2024001 is a 62-year-old female with a concerning presentation strongly suggestive of advanced non-small cell lung cancer (NSCLC), likely adenocarcinoma, based on imaging and pathology findings.  The key features are a large (3.8 x 3.2 cm) right upper lobe mass, mediastinal lymphadenopathy,  a confirmed *KRAS* G12C mutation, and high PD-L1 expression (80%).  While the PET-CT scan didn't reveal distant metastases, the supraclavicular lymphadenopathy raises concern for potential N3 involvement.  This requires further staging with EBUS/mediastinoscopy and brain MRI.  Her comorbidities (Type 2 diabetes, hypertension, osteoarthritis) and likely ECOG performance status of 2-3 (requiring formal assessment) will significantly influence treatment decisions.  The patient's history of smoking further increases her risk.\", '* **Molecular Profile:** *KRAS* G12C mutation is a key driver mutation and a crucial therapeutic target.  High PD-L1 expression suggests potential benefit from immunotherapy.', '* **Age:** 62 years old  impacts treatment tolerance and potential long-term effects.', '* **Comorbidities:** Well-controlled Type 2 diabetes, hypertension, and osteoarthritis  require careful medication management to minimize drug interactions and adverse events. Renal function must be closely monitored due to metformin and potential nephrotoxicity from other medications.', '* **Performance Status:**  Requires formal ECOG performance status assessment to guide treatment selection and predict tolerance.  Preliminary assessment suggests ECOG PS 2-3.'], 'risk_assessment': '**', 'proposed_approach': 'Individualized approach recommended.', 'follow_up_recommendations': ['**Urgent referral to a pulmonologist and oncologist:** For comprehensive evaluation and multidisciplinary discussion.', '**Complete staging:** EBUS-TBNA or mediastinoscopy with lymph node biopsy and brain MRI are needed to accurately stage the disease.', '**Definitive tissue diagnosis:**  Confirmation of adenocarcinoma and assessment of tumor grade and subtype.', '**Comprehensive molecular profiling:**  To confirm the *KRAS* G12C mutation and assess for other potential therapeutic targets (e.g., TMB, MSI).', '**Treatment plan development:**  A multidisciplinary team should develop a patient-centered treatment plan.', '**Regular monitoring:**  Close monitoring of disease progression, treatment response, and adverse effects.', '*Limitations:**  This assessment is based on the information provided.  The absence of a formal ECOG performance status assessment and the need for further staging investigations limit the certainty of the conclusions.  Individual patient response to treatment can vary.', 'This report is for informational purposes only and does not constitute medical advice.  A comprehensive multidisciplinary team discussion is necessary to develop a personalized treatment plan for this patient.']}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "e353a1be-3ac3-42f1-a660-bad66a2e58e2_SpecialistAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"medical_history\": [\\n    {\\n      \"condition\": \"Type 2 Diabetes\",\\n      \"diagnosed\": \"2015-06-15\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Metformin 1000mg BID\",\\n      \"control\": \"Good, HbA1c 6.8%\"\\n    },\\n    {\\n      \"condition\": \"Hypertension\",\\n      \"diagnosed\": \"2016-03-22\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Lisinopril 20mg daily\",\\n      \"control\": \"Well-controlled, BP avg 128/78\"\\n    },\\n    {\\n      \"condition\": \"Osteoarthritis\",\\n      \"diagnosed\": \"2018-11-30\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"PRN NSAIDs\",\\n      \"affected_joints\": [\\n        \"knees\",\\n        \"hands\"\\n      ]\\n    }\\n  ],\\n  \"ehr_analysis\": {\\n    \"summary\": \"This analysis provides a preliminary assessment based on the available information. Further investigations are essential for definitive diagnosis and treatment planning.  Regular monitoring and adjustments to the treatment plan will be necessary based on the patient\\'s response.\",\\n    \"details\": {\\n      \"summary\": \"This analysis provides a preliminary assessment based on the available information. Further investigations are essential for definitive diagnosis and treatment planning.  Regular monitoring and adjustments to the treatment plan will be necessary based on the patient\\'s response.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"\",\\n        \"comorbidity_impact\": \"**  The patient\\'s comorbidities will need careful consideration during treatment planning.  The potential for drug interactions between cancer therapies and her current medications (Metformin, Lisinopril, and PRN NSAIDs) must be assessed.  Close monitoring of blood glucose and blood pressure will be crucial during and after any cancer treatment.\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"**EHR Analysis Agent Report: Patient ID MDT2024001**\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:** The patient, a 62-year-old Caucasian female, presents with a persistent cough, initially noted on 2024-01-15, progressing to include blood-tinged sputum.  This is accompanied by significant unintentional weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats \\\\u2013 all highly suggestive of a serious underlying condition, possibly malignancy.\\\\n\\\\n* **Comorbidities:** The patient has well-controlled Type 2 Diabetes Mellitus (T2DM) and hypertension, managed with Metformin and Lisinopril respectively.  She also has osteoarthritis affecting her knees and hands, managed with PRN NSAIDs. These comorbidities will need careful consideration during treatment planning, as they may influence treatment tolerability and potential drug interactions.\\\\n\\\\n* **Social and Functional Factors:** The patient is a retired teacher, suggesting a previously active lifestyle.  Her current symptoms, however, significantly impair her functional status.  Further assessment of her daily living activities and social support network is necessary.\\\\n\\\\n* **Risk Factors:**  Her history of smoking (former smoker, quit 10 years ago) increases her risk for various respiratory malignancies.  Age and gender are also relevant risk factors for lung cancer.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Primary Complaint:** Persistent cough with occasional hemoptysis.\\\\n* **Physical Examination:**  Significant findings include decreased breath sounds in the right upper lobe and right supraclavicular lymphadenopathy \\\\u2013 strongly suggestive of lung pathology, potentially malignancy.\\\\n* **Laboratory Results:**  The complete blood count (CBC) shows normal hemoglobin, WBC, and platelets, although this does not rule out malignancy.  Liver function tests (LFTs) are mildly elevated (ALT 28 U/L, AST 32 U/L), which warrants further investigation.  Albumin is within the normal range. Renal function is normal.\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:** 62 years (increased risk for lung cancer)\\\\n* **Gender:** Female (lung cancer risk is lower than in males but still significant)\\\\n* **Smoking History:** Former smoker (significant risk factor)\\\\n* **Symptoms:**  Cough with hemoptysis, weight loss, fatigue, anorexia, night sweats (highly suggestive of malignancy)\\\\n* **Physical Exam:** Decreased breath sounds, lymphadenopathy (highly suggestive of malignancy)\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nBased on the presented information, a preliminary assessment suggests a performance status (PS) somewhere between ECOG 2-3.  The patient\\'s significant weight loss, fatigue, and symptomatic cough significantly impair her daily activities. A more formal assessment using the ECOG performance status scale is crucial for accurate staging and treatment planning.\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\nThe clinical presentation strongly suggests a possible lung malignancy.  The right supraclavicular lymphadenopathy is a particularly concerning finding, suggesting advanced disease.  Further investigations are urgently required, including:\\\\n\\\\n* **Chest X-ray/CT Scan:** To confirm the suspected lung pathology and assess the extent of the disease.\\\\n* **Bronchoscopy with Bronchoalveolar Lavage (BAL) and Biopsy:**  To obtain tissue for histopathological examination and cytological analysis for definitive diagnosis and staging.\\\\n* **PET-CT Scan:**  To evaluate for distant metastases and guide treatment planning.\\\\n* **Thoracic Surgery Consultation:** If indicated based on imaging and biopsy results.\\\\n* **Oncology Consultation:** For management and treatment planning.\\\\n\\\\n**Comorbidity Management:**  The patient\\'s comorbidities will need careful consideration during treatment planning.  The potential for drug interactions between cancer therapies and her current medications (Metformin, Lisinopril, and PRN NSAIDs) must be assessed.  Close monitoring of blood glucose and blood pressure will be crucial during and after any cancer treatment.\\\\n\\\\n**Limitations and Uncertainties:**  The diagnosis remains presumptive until confirmed by histopathological examination.  The severity of the underlying condition and its responsiveness to treatment are currently unknown.\\\\n\\\\n**Patient-Centered Care:**  A comprehensive discussion with the patient regarding the potential diagnosis, investigations, and treatment options is paramount.  Shared decision-making will be essential throughout the process, ensuring that the patient\\'s preferences and values are respected.  Psychological support should also be offered to address the emotional impact of the suspected diagnosis.\\\\n\\\\n\\\\nThis analysis provides a preliminary assessment based on the available information. Further investigations are essential for definitive diagnosis and treatment planning.  Regular monitoring and adjustments to the treatment plan will be necessary based on the patient\\'s response.\"\\n    }\\n  },\\n  \"imaging_analysis\": {\\n    \"summary\": \"**Imaging Analysis Agent Report: Patient ID MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Agent Report: Patient ID MDT2024001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"** 3.8 x 3.2 cm (CT Chest)\",\\n        \"nodal_status\": \"**  Potentially feasible depending on the resectability of the tumor and the extent of lymph node involvement as confirmed by biopsy.  Surgical feasibility will be significantly influenced by the precise extent of nodal involvement and the proximity of the tumor to critical structures.\",\\n        \"metastatic_status\": \"\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The findings are highly suspicious for a primary lung malignancy.  The resolution is limited, preventing precise characterization of the mass.\",\\n          \"* **CT Chest (2024-02-05):** Confirms a 3.8 x 3.2 cm spiculated mass in the right upper lobe, consistent with malignancy.  Multiple enlarged right hilar and mediastinal lymph nodes are present, suggesting nodal involvement.  No evidence of distant metastases is identified. Mild emphysematous changes are noted in the upper lobes.\",\\n          \"* **PET-CT (2024-02-12):**  Shows a right upper lobe mass with a maximum standardized uptake value (SUVmax) of 12.4, indicating high metabolic activity characteristic of malignancy.  FDG-avid right hilar and mediastinal lymph nodes are present, with an SUVmax of 8.2, confirming nodal involvement. No evidence of distant metastatic disease is seen.\",\\n          \"* **Primary lesion:** 3.8 x 3.2 cm (CT Chest)\",\\n          \"Based on the imaging findings, the patient presents with a large primary lung mass in the right upper lobe with significant regional lymph node involvement (N2).  There is no evidence of distant metastases (M0).  Therefore, a preliminary imaging-based staging assessment suggests **Stage IIIA** non-small cell lung cancer (NSCLC) according to the TNM staging system (T3N2M0).  This is a provisional staging; confirmation requires histopathological examination of the tumor tissue.\"\\n        ]\\n      },\\n      \"treatment_implications\": []\\n    }\\n  },\\n  \"pathology_analysis\": {\\n    \"summary\": \"**Pathology Analysis Agent Report: Patient ID MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Pathology Analysis Agent Report: Patient ID MDT2024001**\",\\n      \"histology\": \"**\",\\n      \"molecular_profile\": {\\n        \"key_mutations\": \"** Although the KRAS G12C mutation is a key driver mutation, additional molecular testing may be considered depending on treatment response and the development of resistance.\",\\n        \"immunotherapy_markers\": \"** While targeted therapy and immunotherapy are preferred in this setting, chemotherapy regimens may be considered either as initial treatment or in combination with other modalities if the targeted therapies are ineffective or poorly tolerated.\",\\n        \"other_markers\": {}\\n      },\\n      \"therapeutic_implications\": [\\n        \"The provided data does not specify the grade or differentiation of the adenocarcinoma.  Further pathological review of the biopsy specimen, including assessment of nuclear pleomorphism, mitotic rate, and the presence of necrosis, is necessary to determine the grade.  This information is crucial for prognosis and treatment planning.\",\\n        \"Molecular testing reveals a *KRAS* G12C mutation.  *EGFR*, *ALK*, and *ROS1* are all wild-type (no rearrangement detected).  The presence of a *KRAS* G12C mutation is a significant finding, as it identifies a specific therapeutic target.\",\\n        \"PD-L1 expression is 80%, indicating a high level of expression. This is highly significant as it suggests potential responsiveness to immunotherapy.\",\\n        \"**5. Therapeutic Targets:**\",\\n        \"The patient\\'s molecular profile and biomarker status suggest several potential therapeutic targets:\",\\n        \"* **KRAS G12C Inhibition:** The presence of the *KRAS* G12C mutation makes her a candidate for treatment with a KRAS G12C inhibitor, such as sotorasib or adagrasib. These are targeted therapies specifically designed to inhibit the activity of the mutated KRAS protein.\",\\n        \"* **Immunotherapy:** The high PD-L1 expression (80%) strongly suggests that she may benefit from immunotherapy, either as a single agent or in combination with chemotherapy or targeted therapy.  Pembrolizumab or other PD-1/PD-L1 inhibitors are potential options.\",\\n        \"* **Chemotherapy:** While targeted therapy and immunotherapy are preferred in this setting, chemotherapy regimens may be considered either as initial treatment or in combination with other modalities if the targeted therapies are ineffective or poorly tolerated.\",\\n        \"The patient is a strong candidate for treatment with a KRAS G12C inhibitor and/or immunotherapy.  The choice of specific agents and treatment strategy should be determined by a multidisciplinary team (MDT) considering the patient\\'s overall health, performance status, and comorbidities.  Close monitoring of treatment response and potential side effects is crucial.\",\\n        \"* **Complete pathological assessment of the biopsy:**  This is essential to determine the grade and differentiation of the adenocarcinoma.  This will refine prognostication and treatment planning.\",\\n        \"* **Further molecular testing:** Although the KRAS G12C mutation is a key driver mutation, additional molecular testing may be considered depending on treatment response and the development of resistance.\",\\n        \"* **Assessment of other biomarkers:**  Consideration of other biomarkers, such as tumor mutational burden (TMB) and microsatellite instability (MSI) status, could further guide treatment decisions, particularly in the context of immunotherapy.\",\\n        \"* **Comprehensive Geriatric Assessment:** Given the patient\\'s age and comorbidities, a comprehensive geriatric assessment should be performed to optimize treatment planning and minimize potential toxicities.\",\\n        \"**Disclaimer:** This report is based on the information provided.  A definitive diagnosis and treatment plan require a comprehensive multidisciplinary evaluation.  This analysis should be considered a preliminary assessment to inform further investigations and discussions within the MDT.\"\\n      ]\\n    }\\n  },\\n  \"guideline_recommendations\": [\\n    {\\n      \"guideline\": \"**\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"*3. Special Populations Considerations:**\",\\n        \"*4. Evidence Levels:**\",\\n        \"*5. Clinical Trial Eligibility:**\",\\n        \"*Recommendations:**\"\\n      ]\\n    },\\n    {\\n      \"guideline\": \"**\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"**Initial Treatment:**  The presence of a *KRAS* G12C mutation and high PD-L1 expression strongly suggests a combination of a KRAS G12C inhibitor (sotorasib or adagrasib) and a PD-1/PD-L1 inhibitor (e.g., pembrolizumab) as a first-line treatment approach. This is supported by high-level evidence from clinical trials.\",\\n        \"**Surgery:**  Surgical resection might be considered if the tumor is deemed resectable after further assessment, potentially followed by adjuvant therapy.  This decision will depend on the extent of nodal involvement and the proximity of the tumor to critical structures.\",\\n        \"**Chemotherapy:**  If targeted therapy and immunotherapy prove ineffective or poorly tolerated, chemotherapy regimens may be considered.\",\\n        \"*2. Evidence Levels:**\",\\n        \"KRAS G12C inhibitors + immunotherapy: Level 1 evidence.\",\\n        \"Surgery (if resectable): Level 1 evidence for early-stage disease, but requires careful consideration of stage IIIA disease and patient comorbidities.\",\\n        \"Chemotherapy: Level 1 evidence for certain regimens, but generally considered less effective than targeted therapy and immunotherapy in this setting.\",\\n        \"*3. Clinical Trial Considerations:**\",\\n        \"*4. Special Considerations:**\",\\n        \"**Comorbidity Management:**  Careful management of the patient\\'s T2DM, hypertension, and osteoarthritis is crucial to minimize treatment-related toxicity and ensure optimal tolerability. Regular monitoring of blood glucose and blood pressure is essential.\",\\n        \"**Geriatric Assessment:**  A comprehensive geriatric assessment is recommended to evaluate her frailty and functional status, optimizing treatment decisions based on her overall health.\",\\n        \"**Psychosocial Support:**  The patient should receive psychological support to cope with the emotional impact of her diagnosis and treatment.\",\\n        \"*5. Documentation of Deviations:**\",\\n        \"*Limitations and Uncertainties:**\",\\n        \"This analysis is based on currently available information.  Further investigations, a multidisciplinary team discussion, and the patient\\'s participation in shared decision-making are essential for developing an individualized treatment plan.  The exact prognosis and response to treatment remain uncertain until further assessment and monitoring.  The information provided from the `guideline_reference` tool would significantly improve the precision of these recommendations.  I am unable to access external websites or specific medical guidelines databases.\"\\n      ]\\n    }\\n  ]\\n}', 'task': 'Synthesize all available information and provide an expert clinical assessment including treatment recommendations, risk stratification, and special considerations. Consider both patient-specific factors and guideline recommendations.'}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'overall_assessment': '**', 'treatment_considerations': ['This 62-year-old female presents with a highly suggestive clinical picture of advanced non-small cell lung cancer (NSCLC), likely stage IIIA (T3N2M0) based on imaging.  The persistent cough with hemoptysis, significant weight loss, fatigue, and right supraclavicular lymphadenopathy are alarming signs.  Imaging confirms a 3.8 x 3.2 cm right upper lobe mass with significant hilar and mediastinal lymph node involvement.  Importantly, pathology reveals a *KRAS* G12C mutation and high PD-L1 expression (80%), offering targeted therapeutic options.  Her comorbidities (Type 2 Diabetes, Hypertension, Osteoarthritis) require careful consideration in treatment planning.  A comprehensive geriatric assessment is warranted to optimize treatment and minimize toxicity.', '* **Molecular Profile:** *KRAS* G12C mutation, high PD-L1 expression (80%), *EGFR*, *ALK*, and *ROS1* wild-type.  This profile significantly influences treatment selection.', '* **Age:** 62 years   influences treatment choice and toxicity considerations.', '* **Comorbidities:** Well-controlled Type 2 Diabetes, Hypertension, and Osteoarthritis.  These necessitate careful medication management and monitoring to avoid drug interactions and minimize adverse events.', '**4. Treatment Options & Risk-Benefit Analysis:**'], 'risk_assessment': '**', 'proposed_approach': 'Individualized approach recommended.', 'follow_up_recommendations': ['**Treatment response assessment:**  Response to treatment should be assessed regularly using RECIST criteria.', '**Toxicity management:**  Proactive management of treatment-related toxicities is essential to ensure patient safety and well-being.', '**Supportive care:**  Ongoing provision of supportive care, including pain management, nutritional support, and psychological support, is necessary.', '*9. Limitations and Uncertainties:**', 'This assessment is based on the available data.  Further investigations, including a complete pathological assessment and a multidisciplinary team discussion, are crucial for finalizing the treatment plan.  The exact prognosis and response to treatment are uncertain until further assessment and monitoring.  The absence of specific guideline references limits the precision of some recommendations.  Access to a comprehensive guideline database would enhance the accuracy and completeness of this report.', '*10.  Recommendation Summary:**']}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "8106dfd8-6bd9-49a3-b9bd-51a1e7623fb3_SpecialistAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"medical_history\": [\\n    {\\n      \"condition\": \"Type 2 Diabetes\",\\n      \"diagnosed\": \"2015-06-15\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Metformin 1000mg BID\",\\n      \"control\": \"Good, HbA1c 6.8%\"\\n    },\\n    {\\n      \"condition\": \"Hypertension\",\\n      \"diagnosed\": \"2016-03-22\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Lisinopril 20mg daily\",\\n      \"control\": \"Well-controlled, BP avg 128/78\"\\n    },\\n    {\\n      \"condition\": \"Osteoarthritis\",\\n      \"diagnosed\": \"2018-11-30\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"PRN NSAIDs\",\\n      \"affected_joints\": [\\n        \"knees\",\\n        \"hands\"\\n      ]\\n    }\\n  ],\\n  \"ehr_analysis\": {\\n    \"summary\": \"Based on the presented information, a preliminary assessment suggests a performance status (PS) of ECOG 2-3. The patient is experiencing significant symptoms (fatigue, weight loss, cough) impacting her daily activities.  A more precise assessment would require a detailed functional assessment.\",\\n    \"details\": {\\n      \"summary\": \"Based on the presented information, a preliminary assessment suggests a performance status (PS) of ECOG 2-3. The patient is experiencing significant symptoms (fatigue, weight loss, cough) impacting her daily activities.  A more precise assessment would require a detailed functional assessment.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"\",\\n        \"comorbidity_impact\": \"**\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"**EHR Analysis Agent Report: Patient MDT2024001**\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:** The patient, a 62-year-old Caucasian female, presents with a persistent cough (onset January 15th, 2024) initially described as moderate to severe, progressing to include blood-tinged sputum.  Concomitant symptoms of unintentional weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats suggest a significant underlying pathology.  The temporal relationship between these symptoms strongly points towards a concerning systemic illness.\\\\n\\\\n* **Medical History:**  The patient has a history of well-controlled Type 2 Diabetes (since 2015) managed with Metformin, well-controlled Hypertension (since 2016) managed with Lisinopril, and Osteoarthritis (since 2018) managed with PRN NSAIDs.  These comorbidities will need careful consideration during treatment planning.\\\\n\\\\n* **Social and Functional Factors:** The patient is a retired teacher, suggesting a potential for reduced social interaction and physical activity compared to her previous employment. This factor could influence her tolerance of treatment and rehabilitation.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Primary Complaint:** Persistent cough with hemoptysis.\\\\n* **Physical Examination:**  Significant findings include decreased breath sounds in the right upper lobe, suggestive of a possible consolidation or mass, and right supraclavicular lymphadenopathy, raising strong suspicion for malignancy.\\\\n* **Laboratory Results:**  The complete blood count (CBC) shows normal hemoglobin, white blood cell count, and platelet count, which is not entirely reassuring given the clinical presentation; further investigation is required.  Liver function tests (LFTs) are mildly elevated (AST 32, ALT 28), which warrants further investigation and could indicate liver metastasis or other systemic effects. Albumin is within normal limits. Creatinine is normal.\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:** 62 years old \\\\u2013 increased risk for various malignancies.\\\\n* **Smoking History:** Former smoker (quit 10 years ago) \\\\u2013 significant risk factor for lung cancer and other respiratory malignancies. The duration since quitting is relevant, as the risk remains elevated even after cessation.\\\\n* **Weight Loss:**  Significant unintentional weight loss (5kg in 3 months) strongly suggests a serious underlying medical condition, potentially malignancy.\\\\n* **Symptoms:** The constellation of symptoms (cough with hemoptysis, weight loss, fatigue, night sweats) is highly suggestive of lung cancer.\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nBased on the presented information, a preliminary assessment suggests a performance status (PS) of ECOG 2-3. The patient is experiencing significant symptoms (fatigue, weight loss, cough) impacting her daily activities.  A more precise assessment would require a detailed functional assessment.\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\nThe clinical picture strongly suggests a possible malignancy, most likely lung cancer.  The right upper lobe findings, supraclavicular lymphadenopathy, and systemic symptoms necessitate urgent further investigation.\\\\n\\\\n**Further Investigations:**\\\\n\\\\n* **Imaging:** High-resolution computed tomography (HRCT) of the chest is crucial to evaluate the extent of lung involvement, assess for mediastinal lymphadenopathy, and identify potential metastatic disease.\\\\n* **Biopsy:**  Bronchoscopy with endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) or other appropriate biopsy techniques to obtain tissue for histopathological examination and molecular testing is essential for diagnosis and staging.  This is the highest priority.\\\\n* **Further Lab Investigations:**  Consider serum tumor markers (CEA, CYFRA 21-1, NSE), depending on the imaging results.\\\\n\\\\n\\\\n**Comorbidity Impact on Treatment:**\\\\n\\\\nThe patient\\'s comorbidities (diabetes, hypertension, osteoarthritis) need careful consideration when planning treatment.  The presence of diabetes and hypertension may influence the choice of chemotherapy regimens and require close monitoring for potential adverse effects. Osteoarthritis may impact the patient\\'s ability to tolerate certain treatments and will require appropriate pain management.\\\\n\\\\n**Treatment Planning:**\\\\n\\\\nTreatment planning will depend on the definitive diagnosis, stage of disease, and the patient\\'s performance status.  Options could include surgery, chemotherapy, radiation therapy, targeted therapy, or immunotherapy, potentially in combination.  A multidisciplinary team (MDT) approach involving oncologists, pulmonologists, radiologists, pathologists, and other specialists is crucial for optimal management.\\\\n\\\\n**Limitations and Uncertainties:**\\\\n\\\\nThis analysis is based on limited information.  The absence of detailed imaging and pathology results prevents a definitive diagnosis and precise staging.  A complete MDT discussion is necessary to formulate a comprehensive treatment plan.\\\\n\\\\n**Conclusion:**\\\\n\\\\nThis patient requires urgent further investigation to confirm the suspicion of lung cancer.  A multidisciplinary approach is crucial for optimal patient care, considering the patient\\'s comorbidities and performance status.  Patient-centered care should guide all treatment decisions.\"\\n    }\\n  },\\n  \"imaging_analysis\": {\\n    \"summary\": \"**Imaging Analysis Report: Patient MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Report: Patient MDT2024001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"** 3.8 x 3.2 cm (CT Chest); SUVmax 12.4 (PET-CT)\",\\n        \"nodal_status\": \"** N2 (ipsilateral mediastinal lymph node involvement) given the involvement of hilar and mediastinal lymph nodes.\",\\n        \"metastatic_status\": \"If there is clinical suspicion of other metastases not detected by the initial PET-CT, further CT imaging of the abdomen and pelvis may be considered.\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The finding is highly suggestive of a primary lung malignancy.  Limited in its ability to fully characterize the extent of disease.\",\\n          \"* **CT Chest (2024-02-05):**  Confirms a 3.8 x 3.2 cm spiculated mass in the right upper lobe, consistent with a primary lung cancer.  Multiple enlarged right hilar and mediastinal lymph nodes are present.  No evidence of distant metastases is identified. Mild emphysematous changes are noted in the upper lobes. This is a more detailed assessment than the chest x-ray, but still lacks the metabolic information provided by PET-CT.\",\\n          \"* **PET-CT (2024-02-12):**  Shows a right upper lobe mass with a maximum standardized uptake value (SUVmax) of 12.4, indicative of high metabolic activity characteristic of malignancy.  FDG-avid right hilar and mediastinal lymph nodes are present, with a maximum SUVmax of 8.2, confirming their malignant nature. No evidence of distant metastatic disease is found. This study provides crucial functional information confirming the malignancy and extent of nodal involvement.\",\\n          \"* **Primary lesion:** 3.8 x 3.2 cm (CT Chest); SUVmax 12.4 (PET-CT)\",\\n          \"The primary lesion is located in the right upper lobe, close to the hilum.  The involvement of hilar and mediastinal lymph nodes suggests locoregional spread. The lack of distant metastases on PET-CT is reassuring.  The mild emphysema might influence surgical planning.  The right supraclavicular lymphadenopathy noted on physical exam needs correlation with imaging findings (it may be a result of lymphatic drainage from the primary tumor, or may represent a separate finding requiring further assessment).\"\\n        ]\\n      },\\n      \"treatment_implications\": []\\n    }\\n  },\\n  \"pathology_analysis\": {\\n    \"summary\": \"**Pathology Analysis Agent Report: Patient MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Pathology Analysis Agent Report: Patient MDT2024001**\",\\n      \"histology\": \"**\",\\n      \"molecular_profile\": {\\n        \"key_mutations\": \"Key mutations not specified\",\\n        \"immunotherapy_markers\": \"**  While PD-L1 is informative, additional biomarker testing might be considered depending on the treatment approach, potentially including microsatellite instability (MSI) status.  This information can inform treatment choices and predict response to therapy.\",\\n        \"other_markers\": {}\\n      },\\n      \"therapeutic_implications\": [\\n        \"*Recommendations for Additional Testing:**\",\\n        \"**Complete histopathological review:**  To determine the grade and differentiation of the adenocarcinoma.  This will improve prognostication and guide treatment decisions.\",\\n        \"**Comprehensive staging workup:**  Including a detailed assessment of the extent of disease using imaging (CT chest, abdomen, pelvis; PET-CT), and potentially other investigations such as brain MRI, bone scan, depending on initial imaging results.  This is crucial for accurate staging and treatment planning.\"\\n      ]\\n    }\\n  },\\n  \"guideline_recommendations\": [\\n    {\\n      \"guideline\": \"**\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"The primary guidelines relevant to this case are those for the management of non-small cell lung cancer (NSCLC), specifically adenocarcinoma, as this is the most likely diagnosis based on the available data.  These guidelines are typically published by organizations like the National Comprehensive Cancer Network (NCCN), European Society for Medical Oncology (ESMO), and others.  Unfortunately, I cannot directly access and interpret external guidelines using the `guideline_reference` tool as it lacks the necessary functionality to retrieve and process guideline content.  My recommendations will therefore be based on general knowledge of best practices for NSCLC management.\"\\n      ]\\n    },\\n    {\\n      \"guideline\": \"**\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"*3. Special Populations and Evidence Levels:**\",\\n        \"This patient does not fall into any specific special population category that would significantly alter guideline recommendations.  However, her comorbidities require careful consideration to minimize treatment-related toxicity.  The evidence levels for treatment recommendations are generally high, based on numerous randomized controlled trials comparing different treatment modalities for NSCLC.\",\\n        \"*4. Evidence-Based Treatment Options:**\",\\n        \"**Chemotherapy:**  Platinum-based doublet chemotherapy (e.g., cisplatin or carboplatin combined with a taxane like paclitaxel or docetaxel) is a standard first-line treatment for advanced NSCLC.\",\\n        \"**Immunotherapy:**  If the patient\\'s tumor expresses PD-L1, immunotherapy (e.g., pembrolizumab, atezolizumab) may be considered as a first-line treatment or in combination with chemotherapy.  This requires further biomarker testing.\",\\n        \"**Targeted Therapy:**  If specific driver mutations are identified (e.g., EGFR, ALK, ROS1), targeted therapy may be an option.  This also necessitates comprehensive molecular profiling.\",\\n        \"**Radiation Therapy:**  Radiation therapy may be used for local control of the primary tumor or to manage symptoms.\",\\n        \"**Surgery:**  Surgery is unlikely to be curative given the advanced stage of disease and nodal involvement.  However, if the response to chemotherapy and/or immunotherapy is excellent, a surgical resection might be considered.\",\\n        \"*5. Clinical Trial Eligibility:**\",\\n        \"The patient may be eligible for clinical trials investigating novel therapies for advanced NSCLC.  Eligibility criteria vary widely depending on the specific trial, but factors such as age, performance status, disease stage, and molecular profile are typically considered.  Referral to an oncologist experienced in clinical trials is recommended.\"\\n      ]\\n    },\\n    {\\n      \"guideline\": \"**\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"*7. Recommendations:**\",\\n        \"**Urgent completion of diagnostic workup:**  This includes a complete histopathological review with immunohistochemistry (IHC) for PD-L1 and comprehensive molecular profiling (looking for driver mutations such as EGFR, ALK, ROS1, etc.).  A thorough staging workup with imaging (CT chest, abdomen, pelvis; PET-CT) is also crucial.\",\\n        \"**Multidisciplinary team (MDT) discussion:**  The case should be discussed in an MDT setting involving oncologists, thoracic surgeons, pulmonologists, radiologists, and pathologists to formulate an optimal treatment plan.\",\\n        \"**Treatment planning based on the results of the workup:**  The treatment plan should be individualized based on the patient\\'s pathology, stage, performance status, and comorbidities.  This may involve chemotherapy, immunotherapy, targeted therapy, radiation therapy, or a combination thereof.\",\\n        \"**Consideration of clinical trial participation:**  The patient should be discussed for potential enrollment in relevant clinical trials.\",\\n        \"**Close monitoring for treatment-related toxicity and management of comorbidities:**  Careful management of the patient\\'s diabetes, hypertension, and osteoarthritis is crucial throughout the treatment process.\",\\n        \"*Limitations and Uncertainties:**\",\\n        \"This analysis is based on the information provided.  A definitive diagnosis and staging can only be made after the complete diagnostic workup is completed.  The recommendations are subject to change based on the results of further investigations.  The absence of the specific guideline content prevents a precise comparison of the proposed plan to those guidelines.\"\\n      ]\\n    }\\n  ]\\n}', 'task': 'Synthesize all available information and provide an expert clinical assessment including treatment recommendations, risk stratification, and special considerations. Consider both patient-specific factors and guideline recommendations.'}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'overall_assessment': '**', 'treatment_considerations': ['Patient MDT2024001 is a 62-year-old female with a concerning clinical presentation highly suggestive of advanced non-small cell lung cancer (NSCLC), most likely adenocarcinoma, given the imaging findings and symptoms.  The patient presents with a persistent cough, hemoptysis, significant weight loss, fatigue, and night sweats.  Physical examination reveals decreased breath sounds in the right upper lobe and right supraclavicular lymphadenopathy.  Imaging (CT chest and PET-CT) demonstrates a 3.8 x 3.2 cm mass in the right upper lobe with involvement of hilar and mediastinal lymph nodes (N2), consistent with stage IIIB or IV disease.  The absence of detectable distant metastases on PET-CT is a positive prognostic factor.  However,  a complete histopathological examination with immunohistochemistry (IHC) for PD-L1 and comprehensive molecular profiling (EGFR, ALK, ROS1 mutations) are crucial for definitive diagnosis, subtyping, and guiding treatment selection.  Her comorbidities (Type 2 Diabetes, Hypertension, Osteoarthritis) require careful consideration in treatment planning and monitoring.  Her ECOG performance status is estimated at 2-3, indicating moderate to severe symptom burden affecting daily activities.  A detailed functional assessment is warranted to refine this.', '**2. Treatment Recommendations:**', '* **Urgent Bronchoscopy with EBUS-TBNA:** To obtain tissue for histopathological examination, including IHC for PD-L1 and comprehensive molecular profiling.  This is the highest priority to confirm diagnosis and guide therapy.', '* **If PD-L1 positive and no driver mutations:**  First-line immunotherapy (e.g., pembrolizumab, atezolizumab) may be considered.', '* **If PD-L1 negative or driver mutations present (EGFR, ALK, ROS1):**  First-line targeted therapy (e.g., EGFR-TKIs, ALK-TKIs, ROS1-TKIs) or platinum-based doublet chemotherapy (e.g., cisplatin/carboplatin plus a taxane) may be more appropriate.  The choice will depend on the specific molecular profile and patient factors.'], 'risk_assessment': '**', 'proposed_approach': '**  To monitor tumor response to treatment.  Frequency will depend on the treatment approach and response.', 'follow_up_recommendations': ['**Regular physical examinations:**  To assess symptom progression and detect new complications.']}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "b5654b5a-e88a-4c1c-89e6-0567ad3163ae_SpecialistAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"medical_history\": [\\n    {\\n      \"condition\": \"Type 2 Diabetes\",\\n      \"diagnosed\": \"2015-06-15\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Metformin 1000mg BID\",\\n      \"control\": \"Good, HbA1c 6.8%\"\\n    },\\n    {\\n      \"condition\": \"Hypertension\",\\n      \"diagnosed\": \"2016-03-22\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Lisinopril 20mg daily\",\\n      \"control\": \"Well-controlled, BP avg 128/78\"\\n    },\\n    {\\n      \"condition\": \"Osteoarthritis\",\\n      \"diagnosed\": \"2018-11-30\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"PRN NSAIDs\",\\n      \"affected_joints\": [\\n        \"knees\",\\n        \"hands\"\\n      ]\\n    }\\n  ],\\n  \"ehr_analysis\": {\\n    \"summary\": \"The diagnosis remains presumptive until confirmed by histopathological examination.  The severity of the patient\\'s comorbidities and their impact on treatment tolerance requires further assessment.  The patient\\'s functional status needs to be fully evaluated to determine her ability to tolerate potentially intensive treatment regimens.\",\\n    \"details\": {\\n      \"summary\": \"The diagnosis remains presumptive until confirmed by histopathological examination.  The severity of the patient\\'s comorbidities and their impact on treatment tolerance requires further assessment.  The patient\\'s functional status needs to be fully evaluated to determine her ability to tolerate potentially intensive treatment regimens.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"\",\\n        \"comorbidity_impact\": \"** The patient has well-controlled Type 2 Diabetes Mellitus (T2DM) and Hypertension, managed with Metformin and Lisinopril respectively.  She also has Osteoarthritis affecting her knees and hands, managed with PRN NSAIDs.  These comorbidities will need careful consideration during treatment planning due to potential drug interactions and increased risk of complications.\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"**EHR Analysis Agent Report - Patient ID: MDT2024001**\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:** The patient, a 62-year-old Caucasian female, presents with a persistent cough (onset January 15th, 2024) initially described as moderate to severe, now complicated by occasional blood-tinged sputum.  This is accompanied by significant weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats \\\\u2013 all highly suggestive of a serious underlying pathology, potentially malignancy.\\\\n\\\\n* **Comorbidities:** The patient has well-controlled Type 2 Diabetes Mellitus (T2DM) and Hypertension, managed with Metformin and Lisinopril respectively.  She also has Osteoarthritis affecting her knees and hands, managed with PRN NSAIDs.  These comorbidities will need careful consideration during treatment planning due to potential drug interactions and increased risk of complications.\\\\n\\\\n* **Social and Functional Factors:** The patient is a retired teacher, suggesting a previously active lifestyle, now potentially impacted by her current illness.  Her functional status needs further assessment.\\\\n\\\\n* **Risk Factors:**  Former smoker (quit 10 years ago) increases the risk of respiratory malignancy.  Age (62) also places her in a higher risk category for various cancers.  The combination of weight loss, cough, hemoptysis, and lymphadenopathy raises significant concern for lung cancer.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Symptoms:**  Persistent cough with hemoptysis, unintentional weight loss, fatigue, decreased appetite, and night sweats are highly suggestive of malignancy, particularly lung cancer.\\\\n\\\\n* **Physical Exam:** Decreased breath sounds in the right upper lobe and right supraclavicular lymphadenopathy strongly support the suspicion of lung cancer.  Vital signs are relatively stable, although the slightly elevated blood pressure (132/82) requires monitoring.\\\\n\\\\n* **Laboratory Results:**  The complete blood count (CBC) shows normal hemoglobin, WBC, and platelet counts, which doesn\\'t definitively rule out malignancy but does not reveal overt cytopenias.  The basic metabolic panel (BMP) is largely unremarkable, showing normal creatinine, slightly elevated AST (32 U/L) and ALT (28 U/L) which could be related to the underlying condition or medications.  Albumin is within the normal range.  Further investigations are needed.\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:** 62 years\\\\n* **Gender:** Female (lung cancer is more common in males, but this doesn\\'t preclude the diagnosis)\\\\n* **Smoking history:** Former smoker\\\\n* **Symptoms:**  Highly suggestive of lung cancer (cough, hemoptysis, weight loss, fatigue, night sweats, lymphadenopathy)\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nA more detailed assessment is needed using tools like the Eastern Cooperative Oncology Group (ECOG) performance status scale or the Karnofsky Performance Status scale.  Based on the presented information, a preliminary assessment suggests a performance status of 2-3 (moderate to severe limitations in activity).  Further evaluation is crucial for accurate staging and treatment planning.\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\nThe clinical picture strongly suggests the need for urgent further investigation to determine the cause of the patient\\'s symptoms.  This should include:\\\\n\\\\n* **Chest X-ray:** To confirm the physical exam findings.\\\\n* **CT scan of the chest and abdomen/pelvis:**  To stage the potential lung cancer and identify any metastases.\\\\n* **Bronchoscopy with bronchoalveolar lavage (BAL) and biopsy:** To obtain tissue samples for histopathological examination and cytology.  This is crucial for definitive diagnosis.\\\\n* **PET scan:** To assess for distant metastases.\\\\n* **Further blood tests:**  Tumor markers (e.g., CEA, CYFRA 21-1) should be considered.\\\\n\\\\n**Treatment planning will depend heavily on the results of these investigations.**  The presence of comorbidities (T2DM and hypertension) needs to be carefully managed to minimize treatment-related adverse effects.  The impact of the patient\\'s performance status on treatment tolerance will also be a key factor.  A multidisciplinary team (MDT) meeting involving oncologists, radiologists, pathologists, and potentially pulmonologists is essential for optimal treatment planning.  This MDT approach will ensure patient-centered care, balancing the potential benefits and risks of various treatment options while considering the patient\\'s overall health and preferences.\\\\n\\\\n\\\\n**Limitations and Uncertainties:**\\\\n\\\\nThe diagnosis remains presumptive until confirmed by histopathological examination.  The severity of the patient\\'s comorbidities and their impact on treatment tolerance requires further assessment.  The patient\\'s functional status needs to be fully evaluated to determine her ability to tolerate potentially intensive treatment regimens.\"\\n    }\\n  },\\n  \"imaging_analysis\": {\\n    \"summary\": \"**Imaging Analysis Report - Patient ID: MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Report - Patient ID: MDT2024001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"** 3.8 x 3.2 cm (CT Chest).\",\\n        \"nodal_status\": \"** To obtain tissue samples for histopathological diagnosis and to directly assess mediastinal lymph node involvement. This is crucial for definitive staging and treatment planning.\",\\n        \"metastatic_status\": \"** Although the PET-CT did not show bony metastases, this could be considered if bone pain or elevated alkaline phosphatase is present.\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The finding is highly suggestive of a primary lung malignancy.  Limited in its ability to fully characterize the lesion or assess for distant metastases.\",\\n          \"* **CT Chest (2024-02-05):**  Reveals a 3.8 x 3.2 cm spiculated mass in the right upper lobe, consistent with malignancy.  Multiple enlarged right hilar and mediastinal lymph nodes are present. No evidence of distant metastases is identified. Mild emphysematous changes are noted in the upper lobes.\",\\n          \"* **PET-CT (2024-02-12):** Confirms the presence of a highly FDG-avid right upper lobe mass (SUVmax 12.4), indicating high metabolic activity characteristic of malignancy.  FDG-avid right hilar and mediastinal lymph nodes (SUVmax 8.2) are also present, confirming lymph node involvement. No evidence of distant metastatic disease is detected.\",\\n          \"* **Primary Lesion:** 3.8 x 3.2 cm (CT Chest).\",\\n          \"Based on the imaging findings, the patient presents with a large primary lung mass in the right upper lobe with involvement of regional lymph nodes (hilar and mediastinal).  There is no evidence of distant metastases based on the available imaging.  This strongly suggests a Stage IIIA Non-Small Cell Lung Cancer (NSCLC) according to the 8th edition TNM staging system.  However, this is a presumptive staging based on imaging alone and requires confirmation by histopathological examination of tissue obtained via biopsy.  The exact T, N, and M classifications need confirmation through tissue diagnosis and potentially further staging investigations.\",\\n          \"The primary lesion is located in the right upper lobe, close to the hilum.  The involvement of hilar and mediastinal lymph nodes suggests locoregional spread.  The relationship of the tumor to major vessels and the trachea requires further assessment, potentially via bronchoscopy and endobronchial ultrasound (EBUS) or mediastinoscopy.  The mild emphysema may influence surgical planning.\",\\n          \"* **Further CT evaluation:** A high resolution CT scan might help to further define the extent of the lesion and the relationship with adjacent structures.\"\\n        ]\\n      },\\n      \"treatment_implications\": []\\n    }\\n  },\\n  \"pathology_analysis\": {\\n    \"summary\": \"**Pathology Analysis Agent Report - Patient ID: MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Pathology Analysis Agent Report - Patient ID: MDT2024001**\",\\n      \"histology\": \"**  A detailed review of the microscopic slides to determine the precise histological subtype and grade of the adenocarcinoma. This will refine the prognosis and inform treatment decisions.\",\\n      \"molecular_profile\": {\\n        \"key_mutations\": \"Key mutations not specified\",\\n        \"immunotherapy_markers\": \"**  Given the high PD-L1 expression, immunotherapy with a PD-1 or PD-L1 inhibitor (e.g., pembrolizumab, nivolumab, atezolizumab) should be strongly considered, potentially in combination with chemotherapy or a KRAS G12C inhibitor.  The optimal combination strategy would require discussion within the MDT.\",\\n        \"other_markers\": {\\n          \"EGFR\": \"** Wild type \\\\u2013 This excludes the use of EGFR tyrosine kinase inhibitors (TKIs) as a first-line treatment option.\",\\n          \"ALK\": \"** No rearrangement \\\\u2013 This excludes ALK TKIs.\",\\n          \"ROS1\": \"** No rearrangement \\\\u2013 This excludes ROS1 TKIs.\",\\n          \"KRAS\": \"**  Sotorasib or adagrasib are strong candidates for first-line treatment.  Response rates to these agents are not 100%, and careful monitoring for toxicity and response is essential.\"\\n        }\\n      },\\n      \"therapeutic_implications\": [\\n        \"The provided data does not include information on the grade and differentiation of the adenocarcinoma.  This information is crucial for prognosis and treatment planning and should be obtained from the microscopic examination of the biopsy.  The presence of a KRAS mutation suggests a potentially more aggressive phenotype, but this needs to be correlated with histological grading.\",\\n        \"* **EGFR:** Wild type \\\\u2013 This excludes the use of EGFR tyrosine kinase inhibitors (TKIs) as a first-line treatment option.\",\\n        \"* **KRAS:** G12C mutation detected \\\\u2013 This is a significant finding.  The presence of a KRAS G12C mutation identifies a specific therapeutic target.  Sotorasib and adagrasib are FDA-approved therapies targeting this mutation.\",\\n        \"* **PD-L1:** 80% expression \\\\u2013 This high PD-L1 expression suggests the patient may benefit from immunotherapy, either as a monotherapy or in combination with chemotherapy or targeted therapy.  The exact threshold for immunotherapy eligibility can vary depending on the specific assay used and treatment guidelines.\",\\n        \"**5. Therapeutic Targets:**\",\\n        \"Based on the molecular and biomarker data, the primary therapeutic targets are the KRAS G12C mutation and the high PD-L1 expression.\",\\n        \"* **KRAS G12C-targeted therapy:**  Sotorasib or adagrasib are strong candidates for first-line treatment.  Response rates to these agents are not 100%, and careful monitoring for toxicity and response is essential.\",\\n        \"* **Immunotherapy:**  Given the high PD-L1 expression, immunotherapy with a PD-1 or PD-L1 inhibitor (e.g., pembrolizumab, nivolumab, atezolizumab) should be strongly considered, potentially in combination with chemotherapy or a KRAS G12C inhibitor.  The optimal combination strategy would require discussion within the MDT.\",\\n        \"* **Chemotherapy:**  Depending on the patient\\'s overall health, performance status, and response to targeted therapy, chemotherapy might be considered as a component of combination therapy.  However, given the availability of targeted therapy for the KRAS mutation, chemotherapy might not be the first-line choice in this case.\",\\n        \"1. **Histological review:**  A detailed review of the microscopic slides to determine the precise histological subtype and grade of the adenocarcinoma. This will refine the prognosis and inform treatment decisions.\",\\n        \"2. **Comprehensive genomic profiling:**  While KRAS G12C has been identified, broader genomic profiling might reveal additional targetable mutations or alterations that could influence treatment choices.  This is particularly relevant given the presence of other negative molecular markers.  This testing could reveal other genomic alterations that may be actionable\",\\n        \"3. **Assessment of performance status:** A formal assessment using the ECOG or Karnofsky performance scale is necessary to evaluate the patient\\'s fitness for various treatment regimens.\",\\n        \"4. **Further staging investigations:**  While imaging suggests a Stage IIIA, the exact TNM staging requires confirmation through histopathological examination of lymph nodes (obtained via mediastinoscopy or EBUS) and assessment of distant metastasis.  This is critical for accurate staging and treatment planning.  Further imaging (e.g., high resolution CT) may also be beneficial in refining the extent of local disease.\",\\n        \"The current analysis is based on limited data. The absence of detailed histological information and the need for further staging investigations represent significant limitations.  Treatment decisions must be made within the context of a comprehensive MDT discussion, considering the patient\\'s overall health, comorbidities, and preferences.  The response to therapy will require close monitoring.\"\\n      ]\\n    }\\n  },\\n  \"guideline_recommendations\": [\\n    {\\n      \"guideline\": \"Clinical Practice Guidelines\",\\n      \"version\": \"Current\",\\n      \"category\": \"Treatment Recommendations\",\\n      \"recommendations\": [\\n        \"Based on the provided data, the patient presents with a highly suspicious case of advanced Non-Small Cell Lung Cancer (NSCLC), likely stage IIIA, given the imaging findings.  However, definitive diagnosis and staging require histopathological confirmation of the tumor type, grade, and lymph node status.  The presence of a KRAS G12C mutation and high PD-L1 expression significantly impacts treatment decisions.\",\\n        \"* **National Comprehensive Cancer Network (NCCN) Guidelines for Lung Cancer:**  This is the primary guideline to determine treatment strategies for NSCLC, considering the stage, histology, and molecular profile.  Specific recommendations will depend on the final pathological diagnosis and staging.\",\\n        \"* **American Society of Clinical Oncology (ASCO) Guidelines for Lung Cancer:**  ASCO guidelines provide additional perspectives and recommendations for lung cancer management.\",\\n        \"**2. Guideline-based Treatment Options:**\",\\n        \"Given the KRAS G12C mutation and high PD-L1 expression, the following treatment approaches are indicated based on current guidelines, pending final pathology and staging:\",\\n        \"* **KRAS G12C-targeted therapy:** Sotorasib or adagrasib are FDA-approved first-line options for KRAS G12C-mutated NSCLC.  The choice between these two depends on factors such as potential side effects and patient-specific considerations.  (Evidence Level: 1A - High-quality randomized controlled trials demonstrating significant benefit)\",\\n        \"* **Immunotherapy:**  Due to the high PD-L1 expression (80%), immunotherapy with a PD-1 or PD-L1 inhibitor (e.g., pembrolizumab, nivolumab, atezolizumab) is strongly recommended, potentially as a monotherapy or in combination with chemotherapy or targeted therapy.  The optimal approach needs discussion within an MDT. (Evidence Level: 1A - High-quality randomized controlled trials showing benefit in similar patient populations)\",\\n        \"* **Chemotherapy:**  While targeted therapy and immunotherapy are preferred in this scenario, chemotherapy might be considered as part of a combination regimen, particularly if the patient does not respond adequately to initial targeted therapy or immunotherapy.  (Evidence Level: 1B -  High-quality randomized controlled trials showing benefit in some contexts)\",\\n        \"Given the patient\\'s characteristics (advanced NSCLC, KRAS G12C mutation, high PD-L1 expression), she may be eligible for several clinical trials investigating novel therapies targeting KRAS or PD-L1, or evaluating combination strategies.  A comprehensive search of clinical trials relevant to her specific molecular profile and stage should be undertaken. (Evidence Level: Varies by trial, but potentially 1A for trials with positive results)\",\\n        \"* **Comorbidities:**  The patient\\'s well-controlled Type 2 Diabetes and Hypertension require careful monitoring and management to minimize treatment-related complications and potential drug interactions.\",\\n        \"* **Performance Status:** A formal performance status assessment (ECOG or Karnofsky) is crucial to determine the patient\\'s ability to tolerate intensive treatment regimens.\",\\n        \"* **Age:**  While age is a factor, it should not preclude consideration of aggressive treatment options if the patient\\'s performance status allows.\",\\n        \"* **Patient Preferences:**  Treatment decisions should always be made in close collaboration with the patient, respecting her values and preferences.\",\\n        \"There are no deviations from standard practice at this stage.  The recommendations are entirely in line with current evidence-based guidelines.  However, the plan is contingent upon the final pathological diagnosis and staging.\",\\n        \"1. **Obtain definitive pathology report:** This is paramount for accurate staging and treatment selection.\",\\n        \"3. **Multidisciplinary Team (MDT) Meeting:**  An MDT meeting is essential to discuss the case, integrate all findings, and formulate a personalized treatment plan that considers the patient\\'s overall health, preferences, and the available treatment options.\",\\n        \"4. **Clinical trial search:**  A comprehensive search for relevant clinical trials should be performed.\",\\n        \"The Guideline Agent will continue to monitor this case and provide updates as new information becomes available.  The treatment plan will be refined based on the results of the above steps.\"\\n      ]\\n    }\\n  ]\\n}', 'task': 'Synthesize all available information and provide an expert clinical assessment including treatment recommendations, risk stratification, and special considerations. Consider both patient-specific factors and guideline recommendations.'}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'overall_assessment': '**', 'treatment_considerations': ['**Performance Status:**  Requires formal assessment (ECOG/Karnofsky) to guide treatment intensity.  Preliminary assessment suggests ECOG 2-3 based on symptoms.', '**Comorbidities:** Well-controlled Type 2 Diabetes and Hypertension, Osteoarthritis.  These require careful monitoring and management to minimize treatment-related complications and drug interactions.', '**Smoking History:** Former smoker (10 years quit)  increases baseline risk.', '**Social/Functional Status:** Retired teacher; functional status needs evaluation to assess treatment tolerance and quality of life impact.', '*4. Treatment Options:**'], 'risk_assessment': '**', 'proposed_approach': '* **First-line treatment:**  Sotorasib or adagrasib (KRAS G12C inhibitors) are strong candidates, given the presence of the KRAS G12C mutation.  The choice will depend on individual patient factors and potential side effects.', 'follow_up_recommendations': ['**Multidisciplinary Team (MDT) Meeting:**  Immediate MDT meeting to review the case, discuss treatment options, and develop a personalized treatment plan.', '**Regular Monitoring:**  Close monitoring of treatment response, toxicity, and comorbidities throughout treatment.', '**Supportive Care:**  Provision of supportive care to manage treatment-related side effects and maintain quality of life.', '**Re-evaluation:**  Regular re-evaluation of the treatment plan based on response and tolerance.', '*Disclaimer:** This assessment is based on the information provided.  A comprehensive in-person evaluation is necessary for a definitive diagnosis and treatment plan.  This report does not constitute medical advice and should not be used as a substitute for professional medical care.']}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "bc853e41-3a79-46de-a831-06ad686e53db_SpecialistAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"medical_history\": [\\n    {\\n      \"condition\": \"Type 2 Diabetes\",\\n      \"diagnosed\": \"2015-06-15\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Metformin 1000mg BID\",\\n      \"control\": \"Good, HbA1c 6.8%\"\\n    },\\n    {\\n      \"condition\": \"Hypertension\",\\n      \"diagnosed\": \"2016-03-22\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Lisinopril 20mg daily\",\\n      \"control\": \"Well-controlled, BP avg 128/78\"\\n    },\\n    {\\n      \"condition\": \"Osteoarthritis\",\\n      \"diagnosed\": \"2018-11-30\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"PRN NSAIDs\",\\n      \"affected_joints\": [\\n        \"knees\",\\n        \"hands\"\\n      ]\\n    }\\n  ],\\n  \"ehr_analysis\": {\\n    \"summary\": \"This patient requires urgent specialist referral to a pulmonologist and oncologist for prompt diagnostic evaluation and treatment planning.  A multidisciplinary team approach (MDT) involving oncology, radiology, pathology, and potentially other specialists is essential for optimal management of this case.  The possibility of lung cancer is highly probable, and prompt action is crucial.  This analysis is based on the limited information provided and further clinical assessment is mandatory.\",\\n    \"details\": {\\n      \"summary\": \"This patient requires urgent specialist referral to a pulmonologist and oncologist for prompt diagnostic evaluation and treatment planning.  A multidisciplinary team approach (MDT) involving oncology, radiology, pathology, and potentially other specialists is essential for optimal management of this case.  The possibility of lung cancer is highly probable, and prompt action is crucial.  This analysis is based on the limited information provided and further clinical assessment is mandatory.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"\",\\n        \"comorbidity_impact\": \"**\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"**EHR Analysis Agent Report: Patient ID MDT2024001**\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:** The patient, a 62-year-old Caucasian female, presents with a persistent cough (onset January 15, 2024) progressing to include blood-tinged sputum, unintentional weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats.  This constellation of symptoms warrants serious concern, particularly given the presence of right supraclavicular lymphadenopathy.\\\\n\\\\n* **Medical History:** The patient has a history of well-controlled Type 2 Diabetes (Metformin 1000mg BID, HbA1c 6.8%), well-controlled Hypertension (Lisinopril 20mg daily, BP 128/78), and Osteoarthritis affecting her knees and hands.  These comorbidities will need careful consideration in treatment planning.\\\\n\\\\n* **Social and Functional Factors:**  The patient is a retired teacher, suggesting a potentially stable social support network but also a potential impact on her ability to tolerate intensive treatment regimens due to potential fatigue and reduced physical capacity.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Primary Complaint:** Persistent cough with hemoptysis.\\\\n* **Physical Examination:**  Significant findings include decreased breath sounds in the right upper lobe and right supraclavicular lymphadenopathy, highly suggestive of a lung malignancy.\\\\n* **Laboratory Results:**  The complete blood count shows normal hemoglobin, WBC, and platelets,  ruling out overt anemia or significant infection.  Liver function tests (ALT and AST) are mildly elevated, requiring further investigation but not necessarily alarming in isolation.  The albumin level is within the normal range.  Renal function (creatinine) is normal.\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:** 62 years old, placing her within a higher risk group for lung cancer.\\\\n* **Smoking History:** Former smoker (quit 10 years ago), although past smoking significantly increases lung cancer risk.\\\\n* **Symptoms:** The combination of persistent cough, hemoptysis, weight loss, fatigue, night sweats, and lymphadenopathy strongly suggests a malignancy, most likely lung cancer.\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nBased on the presented information, a preliminary assessment of the patient\\'s performance status using the Eastern Cooperative Oncology Group (ECOG) scale would likely be 2. This is based on her reported symptoms of fatigue, weight loss, and decreased appetite, indicating that she is symptomatic and has some limitation in activity.  A more precise assessment requires a detailed functional assessment.\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\nThe clinical picture strongly suggests the need for urgent further investigation to rule out or confirm a lung malignancy.  The patient requires:\\\\n\\\\n* **Imaging:**  A chest CT scan with contrast is crucial to assess the extent of the lung lesion and evaluate for mediastinal lymph node involvement.  A PET scan may also be beneficial for staging.\\\\n* **Bronchoscopy:**  This procedure is necessary to obtain tissue samples for histopathological examination (biopsy) to confirm the diagnosis and determine the specific type of lung cancer.  This will be crucial for guiding treatment decisions.\\\\n* **Further Investigations:**  Depending on the results of the initial investigations, further tests may be necessary, such as bone scans, brain MRI, or other imaging studies to assess for metastatic disease.\\\\n\\\\n**Impact of Comorbidities on Treatment Options:**\\\\n\\\\nThe patient\\'s comorbidities (Type 2 Diabetes, Hypertension, Osteoarthritis) need careful consideration in treatment planning.  Her well-controlled diabetes and hypertension are manageable, but the Osteoarthritis may limit her tolerance to certain treatments, especially those with significant side effects.  Careful monitoring of renal function is essential, given the use of Metformin and potential nephrotoxicity from some chemotherapeutic agents.\\\\n\\\\n**Current Medications and their Interactions:**  Potential drug interactions between current medications (Metformin, Lisinopril, NSAIDs) and potential cancer treatments must be carefully evaluated by a pharmacist specializing in oncology.\\\\n\\\\n**Conclusion:**\\\\n\\\\nThis patient requires urgent specialist referral to a pulmonologist and oncologist for prompt diagnostic evaluation and treatment planning.  A multidisciplinary team approach (MDT) involving oncology, radiology, pathology, and potentially other specialists is essential for optimal management of this case.  The possibility of lung cancer is highly probable, and prompt action is crucial.  This analysis is based on the limited information provided and further clinical assessment is mandatory.\"\\n    }\\n  },\\n  \"imaging_analysis\": {\\n    \"summary\": \"**Imaging Analysis Report: Patient ID MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Report: Patient ID MDT2024001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"** T2 (\\\\u22653cm primary tumor) or T3 (primary tumor invades chest wall, diaphragm, or mediastinum); more precise T-staging requires further clinical/pathological correlation.\",\\n        \"nodal_status\": \"** N2 (ipsilateral mediastinal lymph node involvement confirmed by CT and PET-CT).\",\\n        \"metastatic_status\": \"**  A bone scan may be considered to assess for skeletal metastases, although the absence of findings on PET-CT makes this less likely.  This decision would depend on the patient\\'s clinical presentation and the oncologist\\'s assessment.\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The findings are highly suspicious for primary lung malignancy.  Resolution is limited, preventing precise characterization.\",\\n          \"* **CT Chest (2024-02-05):** Confirms a 3.8 x 3.2 cm spiculated mass in the right upper lobe.  Multiple enlarged right hilar and mediastinal lymph nodes are present.  No evidence of distant metastases is identified. Mild emphysematous changes are noted in the upper lobes. The spiculated margins of the mass are highly suggestive of malignancy.\",\\n          \"* **PET-CT (2024-02-12):**  The right upper lobe mass shows an SUVmax of 12.4, consistent with high metabolic activity characteristic of malignancy.  FDG-avid right hilar and mediastinal lymph nodes are present, with an SUVmax of 8.2, indicating significant metabolic activity.  No evidence of distant metastatic disease is detected.\",\\n          \"* **Primary lesion:** 3.8 x 3.2 cm (CT Chest)\",\\n          \"The primary lesion is located in the right upper lobe, close to the hilum, explaining the associated hilar lymphadenopathy.  The involvement of mediastinal lymph nodes suggests potential spread within the mediastinum.  The mild emphysema may impact surgical resectability and the potential for respiratory complications post-surgery.  The right supraclavicular lymphadenopathy detected on physical exam requires further investigation with imaging (e.g., ultrasound with fine-needle aspiration) to determine if it represents metastatic spread.\"\\n        ]\\n      },\\n      \"treatment_implications\": []\\n    }\\n  },\\n  \"pathology_analysis\": {\\n    \"summary\": \"**Pathology Analysis Agent Report: Patient ID MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Pathology Analysis Agent Report: Patient ID MDT2024001**\",\\n      \"histology\": \"**\",\\n      \"molecular_profile\": {\\n        \"key_mutations\": \"**4. Biomarker Status:**\",\\n        \"immunotherapy_markers\": \"**  MSI testing should be considered to rule out MSI-high status, which may also predict a good response to immunotherapy.\",\\n        \"other_markers\": {\\n          \"KRAS\": \"** While KRAS G12C is identified, comprehensive genomic profiling can identify other potential targetable alterations that could influence treatment decisions.\"\\n        }\\n      },\\n      \"therapeutic_implications\": [\\n        \"The provided data does not specify the grade and differentiation of the adenocarcinoma.  A detailed histopathological review is necessary to assess the tumor\\'s grade (based on cellular features, nuclear atypia, mitotic activity) and differentiation (level of resemblance to normal lung tissue).  This information is crucial for prognosis and treatment planning.\",\\n        \"Molecular testing reveals a *KRAS* G12C mutation.  This is a significant finding as it identifies a targetable oncogenic driver mutation.  Other tested mutations (EGFR, ALK, ROS1) are negative.\",\\n        \"* **PD-L1:**  Immunohistochemistry shows 80% PD-L1 expression. This high expression level strongly suggests that the patient may benefit from immunotherapy with PD-1/PD-L1 inhibitors.\",\\n        \"**5. Therapeutic Targets:**\",\\n        \"Based on the current data, the primary therapeutic targets are the *KRAS* G12C mutation and the high PD-L1 expression.  This suggests a potential treatment strategy involving a combination of:\",\\n        \"* **Targeted therapy:** A KRAS G12C inhibitor (sotorasib or adagrasib) is the preferred first-line targeted therapy option.\",\\n        \"* **Immunotherapy:**  A PD-1/PD-L1 inhibitor (e.g., pembrolizumab, nivolumab) could be considered as a first-line treatment or in combination with targeted therapy, given the high PD-L1 expression.  The response to immunotherapy might be synergistic with KRAS G12C inhibition.\",\\n        \"* **Complete histopathological review:**  A detailed review of the histopathology slides is crucial to determine the precise subtype (e.g., acinar, papillary, lepidic, micropapillary, solid) and grade of the adenocarcinoma. This will refine the prognosis and treatment strategy.\",\\n        \"* **Tumor mutational burden (TMB) analysis:** Assessing TMB may provide additional information regarding the patient\\'s potential response to immunotherapy.  High TMB often correlates with better responses to checkpoint inhibitors.\",\\n        \"* **Microsatellite instability (MSI) testing:**  MSI testing should be considered to rule out MSI-high status, which may also predict a good response to immunotherapy.\",\\n        \"* **Comprehensive genomic profiling:** While KRAS G12C is identified, comprehensive genomic profiling can identify other potential targetable alterations that could influence treatment decisions.\",\\n        \"This patient presents with advanced-stage lung adenocarcinoma harboring a *KRAS* G12C mutation and exhibiting high PD-L1 expression.  A multidisciplinary team discussion involving medical oncology, thoracic surgery, radiation oncology, and pulmonology is essential to develop a personalized treatment plan.  The recommended additional testing will help optimize the treatment strategy and improve patient outcomes.  The prognosis depends on the precise staging, grade, and response to therapy.\"\\n      ]\\n    }\\n  },\\n  \"guideline_recommendations\": [\\n    {\\n      \"guideline\": \"Clinical Practice Guidelines\",\\n      \"version\": \"Current\",\\n      \"category\": \"Treatment Recommendations\",\\n      \"recommendations\": [\\n        \"* **NCCN Guidelines for Lung Cancer:** These guidelines provide comprehensive recommendations on the diagnosis, staging, treatment, and follow-up of lung cancer patients, stratified by stage and molecular characteristics.  They will be crucial in determining the optimal treatment strategy, considering the patient\\'s KRAS G12C mutation and high PD-L1 expression.\",\\n        \"* **Guidelines for Management of Type 2 Diabetes, Hypertension, and Osteoarthritis:**  These guidelines are important to manage the patient\\'s comorbidities and ensure that any cancer treatment is compatible with her existing conditions and medications.  Careful monitoring and potential adjustments to her diabetes and hypertension medications may be required during and after cancer treatment.\",\\n        \"The patient\\'s advanced-stage lung adenocarcinoma with a KRAS G12C mutation and high PD-L1 expression falls within specific sections of the NCCN and MSKCC guidelines. These guidelines will inform treatment decisions regarding:\",\\n        \"* **First-line therapy:**  The KRAS G12C mutation makes her eligible for targeted therapy with a KRAS G12C inhibitor (sotorasib or adagrasib).  The high PD-L1 expression strongly suggests that immunotherapy with a PD-1/PD-L1 inhibitor (pembrolizumab or nivolumab) could be considered as a first-line treatment or in combination with targeted therapy.  The choice between these options, or a combination, will be based on a multidisciplinary discussion weighing potential benefits and side effects.\",\\n        \"* **Adjuvant/neoadjuvant therapy:** Given the advanced stage, adjuvant therapy is less likely to be considered, but neoadjuvant treatment (before surgery if considered resectable) could be discussed if the tumor is deemed potentially resectable after further assessment.\",\\n        \"The patient\\'s age (62), comorbidities (Type 2 diabetes, hypertension, osteoarthritis), and former smoking history are all important considerations.  Her comorbidities will require careful monitoring during treatment to mitigate potential adverse events and interactions with cancer therapies.  Her performance status will also need to be carefully assessed to ensure the chosen treatment regimen is tolerable.  Geriatric assessment may be beneficial.\",\\n        \"The recommendations for KRAS G12C inhibitors and PD-1/PD-L1 inhibitors are supported by high-level evidence from randomized controlled trials demonstrating significant improvements in progression-free survival and overall survival in patients with similar characteristics.\",\\n        \"**6. Recommendations:**\",\\n        \"* **Multidisciplinary Team Discussion:**  The case requires immediate discussion within an MDT to formulate a personalized treatment plan.\",\\n        \"* **First-line Treatment Options:**\",\\n        \"* **Targeted Therapy:** Sotorasib or adagrasib (KRAS G12C inhibitors).\",\\n        \"* **Immunotherapy:** Pembrolizumab or nivolumab (PD-1/PD-L1 inhibitors).\",\\n        \"* **Combination Therapy:** Combination of a KRAS G12C inhibitor and a PD-1/PD-L1 inhibitor might be considered.  The decision should be guided by the MDT discussion, considering the patient\\'s overall health, performance status, and potential side effects.\",\\n        \"* **Comorbidity Management:**  Closely monitor and manage her diabetes, hypertension, and osteoarthritis throughout the treatment process.  A pharmacist specializing in oncology should be involved to optimize medication management and minimize potential drug interactions.\",\\n        \"* **Regular Monitoring:**  Close monitoring of treatment response, adverse events, and overall health status is crucial.\",\\n        \"No deviations from standard practice are evident at this stage, provided that the recommendations above are followed.  However, deviations may arise depending on the results of further investigations and the MDT\\'s decisions.  Any deviations should be clearly documented with justifications based on the patient\\'s specific circumstances and the collective judgment of the MDT.\",\\n        \"**Limitations:**  This analysis relies on the information provided.  Further clinical assessment and additional test results are needed to refine the diagnosis, staging, and treatment plan.  The recommendations are subject to change based on new information.\"\\n      ]\\n    }\\n  ]\\n}', 'task': 'Synthesize all available information and provide an expert clinical assessment including treatment recommendations, risk stratification, and special considerations. Consider both patient-specific factors and guideline recommendations.'}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'overall_assessment': '**', 'treatment_considerations': ['This 62-year-old female presents with a highly suggestive clinical picture of advanced lung adenocarcinoma.  The persistent cough with hemoptysis, significant weight loss, fatigue, night sweats, and right supraclavicular lymphadenopathy, coupled with imaging findings (3.8 x 3.2 cm spiculated mass in the right upper lobe, mediastinal lymphadenopathy on CT and PET-CT) and pathology results (KRAS G12C mutation, 80% PD-L1 expression), strongly support this diagnosis.  The imaging suggests at least stage IIIB disease (T2-3N2M0 or potentially higher depending on further staging investigations such as bone scan), though precise staging requires further correlation with pathology.  Her well-controlled comorbidities (Type 2 Diabetes, Hypertension, Osteoarthritis) will influence treatment selection and require close monitoring.', '* **Molecular Profile:** KRAS G12C mutation (targetable), high PD-L1 expression (predictive of immunotherapy response).  Comprehensive genomic profiling is advisable to identify other potential targetable alterations.', '* **Age:** 62 years   influences treatment tolerance and potential toxicities.', '* **Comorbidities:** Well-controlled Type 2 Diabetes, Hypertension, and Osteoarthritis  require careful management to minimize treatment-related toxicities and drug interactions.', '**4. Treatment Options & Risk-Benefit Analysis:**'], 'risk_assessment': '**', 'proposed_approach': 'Individualized approach recommended.', 'follow_up_recommendations': ['*9. Limitations:**', \"This assessment is based on the available data.  Further investigations, including a detailed histopathological review, bone scan, and potentially a comprehensive genomic profile, are necessary to refine the diagnosis, staging, and treatment plan. The recommendations are subject to change based on new information and the MDT's collective judgment.\", '*Conclusion:**', \"This patient requires urgent multidisciplinary team management.  A combination therapy approach using a KRAS G12C inhibitor and a PD-1/PD-L1 inhibitor is likely the preferred first-line strategy, but this decision must be individualized based on the MDT discussion considering the patient's specific circumstances and preferences.  Close monitoring of comorbidities and potential treatment-related toxicities is crucial.  A detailed treatment plan should be developed collaboratively with the patient, incorporating her preferences and values to ensure optimal outcomes and quality of life.\"]}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "badc9c52-d9bf-4d56-a104-7200d4c2ed92_SpecialistAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"medical_history\": [\\n    {\\n      \"condition\": \"Type 2 Diabetes\",\\n      \"diagnosed\": \"2015-06-15\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Metformin 1000mg BID\",\\n      \"control\": \"Good, HbA1c 6.8%\"\\n    },\\n    {\\n      \"condition\": \"Hypertension\",\\n      \"diagnosed\": \"2016-03-22\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Lisinopril 20mg daily\",\\n      \"control\": \"Well-controlled, BP avg 128/78\"\\n    },\\n    {\\n      \"condition\": \"Osteoarthritis\",\\n      \"diagnosed\": \"2018-11-30\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"PRN NSAIDs\",\\n      \"affected_joints\": [\\n        \"knees\",\\n        \"hands\"\\n      ]\\n    }\\n  ],\\n  \"ehr_analysis\": {\\n    \"summary\": \"A full performance status assessment (e.g., using the ECOG or Karnofsky scales) is needed.  Based on the reported symptoms, a preliminary assessment suggests a performance status of 2-3 (unable to carry out light work).  A more thorough evaluation is crucial for determining treatment feasibility and selecting appropriate therapies.\",\\n    \"details\": {\\n      \"summary\": \"A full performance status assessment (e.g., using the ECOG or Karnofsky scales) is needed.  Based on the reported symptoms, a preliminary assessment suggests a performance status of 2-3 (unable to carry out light work).  A more thorough evaluation is crucial for determining treatment feasibility and selecting appropriate therapies.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"\",\\n        \"comorbidity_impact\": \"\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"**EHR Analysis Agent Report: Patient ID MDT2024001**\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:** The patient, a 62-year-old Caucasian female, presents with a concerning constellation of symptoms with an onset in January 2024.  The primary complaint is a persistent cough, initially likely non-specific, which has progressed to include blood-tinged sputum.  This, coupled with significant unintentional weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats, strongly suggests a possible malignancy. The temporal relationship between these symptoms is highly suggestive of a serious underlying condition requiring urgent investigation.\\\\n\\\\n* **Medical History:**  The patient has a history of well-controlled Type 2 Diabetes Mellitus (HbA1c 6.8%), hypertension (well-controlled on Lisinopril), and osteoarthritis. These comorbidities will need careful consideration in treatment planning, particularly regarding potential drug interactions and organ function.  Her former smoking status (quit 10 years ago) represents a significant risk factor for lung cancer.\\\\n\\\\n* **Social and Functional Factors:** The patient is a retired teacher, suggesting a potentially lower tolerance for treatment-related side effects that may interfere with her quality of life.  Her functional status needs further assessment to determine her ability to cope with potential treatments.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Presenting Complaint:** Persistent cough with hemoptysis, unintentional weight loss, fatigue, decreased appetite, and night sweats.\\\\n* **Physical Examination:**  Significant findings include decreased breath sounds in the right upper lobe, suggestive of a possible lung lesion, and right supraclavicular lymphadenopathy, raising strong suspicion for malignancy.  Vital signs are mostly stable, although the slightly elevated blood pressure (132/82) warrants monitoring.\\\\n* **Laboratory Results:**  The complete blood count (CBC) shows normal hemoglobin, WBC, and platelet counts. The basic metabolic panel shows normal creatinine, mildly elevated liver enzymes (ALT 28 U/L, AST 32 U/L), and a slightly low albumin (3.8 g/dL). The slightly elevated liver enzymes and low albumin could be related to the underlying illness or medication side effects and require further investigation.\\\\n\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:** 62 years old (increased risk for malignancy)\\\\n* **Gender:** Female (lung cancer incidence is lower in women, but still a significant risk)\\\\n* **Smoking History:** Former smoker (significant risk factor for lung cancer)\\\\n* **Weight Loss:** Significant unintentional weight loss (5kg in 3 months) \\\\u2013 a key warning sign for malignancy.\\\\n* **Hemoptysis:** Presence of blood in sputum \\\\u2013 highly suggestive of a lung pathology, potentially malignant.\\\\n* **Lymphadenopathy:** Right supraclavicular lymphadenopathy \\\\u2013 strongly suggestive of metastatic disease.\\\\n* **Fatigue, Anorexia, Night Sweats:** Constitutional symptoms supporting the suspicion of malignancy.\\\\n\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nA full performance status assessment (e.g., using the ECOG or Karnofsky scales) is needed.  Based on the reported symptoms, a preliminary assessment suggests a performance status of 2-3 (unable to carry out light work).  A more thorough evaluation is crucial for determining treatment feasibility and selecting appropriate therapies.\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\nThe clinical presentation strongly suggests the possibility of lung cancer, potentially with metastatic spread.  The right supraclavicular lymphadenopathy is particularly concerning.\\\\n\\\\n**Further Investigations:**\\\\n\\\\n* **Imaging:** High-resolution computed tomography (HRCT) of the chest is urgently indicated to evaluate the lung parenchyma and mediastinum.  Further imaging, such as PET-CT, may be necessary for staging purposes.\\\\n* **Bronchoscopy:**  To obtain tissue samples for cytological and histological examination, including biopsy of the suspicious lymph node.\\\\n* **Thoracic Surgery Consultation:**  Surgical intervention may be necessary for diagnosis and/or treatment, depending on the findings of the imaging and bronchoscopy.\\\\n* **Oncology Consultation:**  To discuss treatment options based on the diagnosis and staging of the disease.\\\\n\\\\n**Treatment Planning Considerations:**\\\\n\\\\nTreatment planning will depend heavily on the results of the further investigations, specifically the diagnosis and staging of the cancer.  Comorbidities, particularly diabetes and hypertension, will need to be carefully managed throughout the treatment process.  The patient\\'s performance status will influence the choice of treatment modality.  Close monitoring for treatment-related side effects is crucial, especially given her existing medical conditions and age.\\\\n\\\\n**Limitations and Uncertainties:**\\\\n\\\\nThis analysis is based on the limited information provided.  A definitive diagnosis cannot be made without further investigations.  The severity and extent of the disease are currently unknown.  The patient\\'s response to treatment cannot be predicted with certainty.\\\\n\\\\n**Conclusion:**\\\\n\\\\nThis patient requires urgent further investigation to determine the cause of her symptoms.  Lung cancer is a strong consideration and requires immediate attention.  A multidisciplinary team (MDT) approach involving oncology, radiology, respiratory medicine, and potentially thoracic surgery is essential for optimal patient management.\"\\n    }\\n  },\\n  \"imaging_analysis\": {\\n    \"summary\": \"**Imaging Analysis Agent Report: Patient ID MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Agent Report: Patient ID MDT2024001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"** 3.8 x 3.2 cm (CT chest)\",\\n        \"nodal_status\": \"** N2 (ipsilateral mediastinal lymph node involvement)\",\\n        \"metastatic_status\": \"** M0 (No distant metastasis)\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"The imaging findings strongly suggest a right upper lobe lung malignancy.  The initial chest X-ray demonstrated a 3.5 cm mass with associated hilar lymphadenopathy.  The subsequent CT chest confirmed a 3.8 x 3.2 cm spiculated mass in the right upper lobe, a characteristic suggestive of malignancy.  Multiple enlarged right hilar and mediastinal lymph nodes were also identified.  The PET-CT scan corroborated these findings, showing an SUVmax of 12.4 in the primary lesion and FDG-avid right hilar and mediastinal lymph nodes with an SUVmax of 8.2.  No evidence of distant metastases was found on either the CT or PET-CT scans.  Mild emphysematous changes were noted in the upper lobes on the CT chest.\",\\n          \"* **Primary lesion:** 3.8 x 3.2 cm (CT chest)\",\\n          \"The primary lesion is located in the right upper lobe, close to the hilum.  The involvement of hilar and mediastinal lymph nodes suggests local-regional spread.  The relationship of the tumor to major vessels and bronchi needs further clarification through high-resolution CT and possibly bronchoscopy.  The presence of mild emphysema may influence surgical planning and potential post-operative complications.\"\\n        ]\\n      },\\n      \"treatment_implications\": []\\n    }\\n  },\\n  \"pathology_analysis\": {\\n    \"summary\": \"**Pathology Analysis Agent Report: Patient ID MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Pathology Analysis Agent Report: Patient ID MDT2024001**\",\\n      \"histology\": \"**\",\\n      \"molecular_profile\": {\\n        \"key_mutations\": \"** The presence of the *KRAS* G12C mutation is a key biomarker indicating potential responsiveness to KRAS G12C-specific inhibitors (e.g., sotorasib, adagrasib).\",\\n        \"immunotherapy_markers\": \"** The high PD-L1 expression (80%) suggests that immunotherapy with a PD-1 or PD-L1 inhibitor could be a beneficial treatment option either as a monotherapy or in combination with other therapies.\",\\n        \"other_markers\": {}\\n      },\\n      \"therapeutic_implications\": [\\n        \"*Recommendations for Additional Testing:**\",\\n        \"1. **Complete histopathological examination:**  A full pathological review of the resected tumor specimen (if surgical resection is performed) or additional biopsies to assess tumor grade, differentiation, and lymphovascular invasion.\",\\n        \"3. **Assessment of performance status:**  Formal assessment of performance status using ECOG or Karnofsky scale is critical for treatment planning and determining treatment feasibility.\",\\n        \"4. **Further imaging (if needed):**  Depending on the extent of surgery, additional imaging may be needed for restaging.\",\\n        \"*Limitations and Uncertainties:**\",\\n        \"This analysis is based on the available data.  The grade and differentiation of the adenocarcinoma require further histological assessment.  The optimal treatment strategy requires a comprehensive multidisciplinary discussion, considering the patient\\'s overall health, performance status, and preferences.  The efficacy and tolerability of any chosen therapy will vary between individual patients.\"\\n      ]\\n    }\\n  },\\n  \"guideline_recommendations\": [\\n    {\\n      \"guideline\": \"**\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"The primary guidelines applicable to this case include the National Comprehensive Cancer Network (NCCN) Guidelines for Lung Cancer and relevant guidelines from professional organizations like the European Society for Medical Oncology (ESMO).  These guidelines will inform treatment strategies based on stage, molecular profiling, and performance status.  Specific guideline references would require access to the full NCCN and ESMO guidelines databases, which are not available in this context.  The `guideline_reference` tool lacks sufficient detail to provide specific recommendations from those guidelines.\"\\n      ]\\n    },\\n    {\\n      \"guideline\": \"**\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"*3. Special Populations Considerations:**\",\\n        \"*4. Evidence Levels:**\",\\n        \"*5. Clinical Trial Options:**\",\\n        \"*Treatment Recommendations:**\"\\n      ]\\n    },\\n    {\\n      \"guideline\": \"**  The treatment strategy should be individualized and discussed within a multidisciplinary team (MDT) setting.  Options include:\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"**KRAS G12C-targeted therapy:**  Sotorasib or adagrasib are likely to be primary considerations due to the *KRAS* G12C mutation.\",\\n        \"**Immunotherapy:**  A PD-1/PD-L1 inhibitor (e.g., pembrolizumab, nivolumab) is a strong contender given the high PD-L1 expression.  This could be used as a monotherapy or in combination with chemotherapy or targeted therapy.\"\\n      ]\\n    },\\n    {\\n      \"guideline\": \"**  Depending on performance status and other factors, chemotherapy regimens may be considered, potentially in combination with immunotherapy or targeted therapy.  The choice of regimen would be guided by NCCN guidelines.\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"**Surgery:**  Given the stage III classification, surgical resection may or may not be appropriate.  The feasibility of surgery will depend on the extent of the disease and the patient\\'s overall health. A thoracic surgery consult is essential.  Neoadjuvant or adjuvant therapy may be considered before or after surgery, depending on the MDT\\'s decision.\",\\n        \"**Radiation Therapy:** Radiation therapy, potentially stereotactic body radiotherapy (SBRT) or other modalities, might be part of the treatment plan, especially if surgery is not feasible.\"\\n      ]\\n    },\\n    {\\n      \"guideline\": \"**  The evidence levels supporting each of these treatment options will be determined by the relevant guidelines (NCCN, ESMO) and published clinical trial data.  This information is not directly accessible in the current context.\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"**Clinical Trial Considerations:**  The patient should be evaluated for eligibility in clinical trials investigating KRAS G12C inhibitors and immunotherapy, potentially in combination.\",\\n        \"**Special Considerations:**  Close monitoring of comorbidities (diabetes, hypertension) and potential drug interactions is crucial.  Supportive care should be implemented to manage treatment-related side effects and maintain quality of life.  The patient\\'s performance status will greatly influence treatment choices and intensity.\",\\n        \"**Deviations from Standard Practice:**  Any deviations from standard practice will be determined in consultation with the MDT, considering the patient\\'s specific circumstances and response to treatment.  This requires a thorough discussion within the MDT framework.\",\\n        \"*Limitations and Uncertainties:**\"\\n      ]\\n    }\\n  ]\\n}', 'task': 'Synthesize all available information and provide an expert clinical assessment including treatment recommendations, risk stratification, and special considerations. Consider both patient-specific factors and guideline recommendations.'}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'overall_assessment': '**', 'treatment_considerations': ['This 62-year-old female presents with a concerning constellation of symptoms highly suggestive of advanced lung cancer.  The persistent cough with hemoptysis, significant weight loss, fatigue, anorexia, and night sweats, coupled with physical exam findings of decreased breath sounds in the right upper lobe and right supraclavicular lymphadenopathy, paint a strong clinical picture of malignancy.  Imaging (CT chest and PET-CT) confirms a 3.8 x 3.2 cm right upper lobe mass with N2 nodal involvement (ipsilateral mediastinal lymph node involvement) and no distant metastasis (M0), consistent with Stage IIIA lung cancer. Pathology reveals a KRAS G12C mutation and high PD-L1 expression (80%), providing crucial information for targeted therapy selection.  Her comorbidities (Type 2 Diabetes, Hypertension, Osteoarthritis) and former smoking history further contribute to the risk profile.  A thorough performance status assessment using ECOG or Karnofsky scale is urgently needed to guide treatment decisions.  Based on the presented symptoms, a preliminary performance status of 2-3 is estimated, indicating moderate to severe functional impairment.', '* **Molecular Profile:** KRAS G12C mutation (positive), PD-L1 expression (80%).  These biomarkers are highly relevant to treatment selection.', '* **Age:** 62 years old   This impacts treatment tolerance and potential side effects.', '* **Comorbidities:** Well-controlled Type 2 Diabetes, Hypertension, and Osteoarthritis   These require careful management during treatment and consideration of potential drug interactions.', '* **Social History:** Retired teacher   This impacts lifestyle and potential tolerance of treatment-related fatigue and other side effects.'], 'risk_assessment': '**', 'proposed_approach': 'Individualized approach recommended.', 'follow_up_recommendations': ['Regular monitoring of vital signs, blood counts, and organ function.', 'Repeat imaging studies (CT or PET-CT) at appropriate intervals to assess response to treatment.', 'Regular assessment of performance status to evaluate treatment tolerance and efficacy.', 'Management of comorbidities.', 'Supportive care as needed.', 'Psychosocial support for the patient and her family.', '*Limitations and Uncertainties:**', 'This assessment is based on the information provided.  Further investigations may reveal additional findings that could influence treatment decisions. The response to therapy cannot be predicted with certainty.  The final treatment plan will be determined in consultation with the MDT and the patient.']}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "64a96493-71f5-48f5-99f4-9c2536318ddc_SpecialistAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"medical_history\": [\\n    {\\n      \"condition\": \"Type 2 Diabetes\",\\n      \"diagnosed\": \"2015-06-15\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Metformin 1000mg BID\",\\n      \"control\": \"Good, HbA1c 6.8%\"\\n    },\\n    {\\n      \"condition\": \"Hypertension\",\\n      \"diagnosed\": \"2016-03-22\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Lisinopril 20mg daily\",\\n      \"control\": \"Well-controlled, BP avg 128/78\"\\n    },\\n    {\\n      \"condition\": \"Osteoarthritis\",\\n      \"diagnosed\": \"2018-11-30\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"PRN NSAIDs\",\\n      \"affected_joints\": [\\n        \"knees\",\\n        \"hands\"\\n      ]\\n    }\\n  ],\\n  \"ehr_analysis\": {\\n    \"summary\": \"Based on the presented information, a preliminary assessment suggests a Karnofsky Performance Status (KPS) score of 60-70%, indicating that the patient is experiencing some symptoms and limitations in daily activities but is still largely independent.  A more thorough assessment is needed to accurately determine her performance status, taking into account her fatigue and weight loss. This will significantly impact treatment choices.\",\\n    \"details\": {\\n      \"summary\": \"Based on the presented information, a preliminary assessment suggests a Karnofsky Performance Status (KPS) score of 60-70%, indicating that the patient is experiencing some symptoms and limitations in daily activities but is still largely independent.  A more thorough assessment is needed to accurately determine her performance status, taking into account her fatigue and weight loss. This will significantly impact treatment choices.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"\",\\n        \"comorbidity_impact\": \"**  This patient requires urgent further investigation to confirm the suspected diagnosis of lung cancer and determine the appropriate treatment plan.  A multidisciplinary team (MDT) approach involving oncologists, radiologists, pathologists, and other relevant specialists is essential for optimal patient management.  Close monitoring of comorbidities is crucial throughout the treatment process.\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"## EHR Analysis Agent - Patient MDT2024001 - Structured Analysis\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:** The patient, a 62-year-old Caucasian female, presents with a persistent cough (onset January 15th, 2024) initially characterized as moderate to severe, progressing to include blood-tinged sputum.  This is accompanied by significant unintentional weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats \\\\u2013 all highly suggestive of a serious underlying condition, potentially malignancy.\\\\n\\\\n* **Comorbidities:** The patient has well-controlled Type 2 Diabetes Mellitus (T2DM) managed with Metformin, well-controlled hypertension managed with Lisinopril, and osteoarthritis affecting her knees and hands. These comorbidities will need careful consideration during treatment planning due to potential drug interactions and overall impact on treatment tolerance.\\\\n\\\\n* **Social and Functional Factors:**  The patient is a retired teacher, suggesting a potentially sedentary lifestyle post-retirement, which could influence her response to treatment and rehabilitation.  Her social support network is unknown and requires further investigation.\\\\n\\\\n* **Risk Factors:**  Former smoker (quit 10 years ago) increases the risk of lung cancer.  Age (62) also places her within a high-risk group for various malignancies.  The combination of weight loss, cough, and hemoptysis are significant red flags.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Primary Complaint:** Persistent cough with occasional blood-tinged sputum.\\\\n* **Physical Examination:**  Significant findings include decreased breath sounds in the right upper lobe, and right supraclavicular lymphadenopathy \\\\u2013 highly suggestive of malignancy, potentially lung cancer.\\\\n* **Laboratory Results:**  While the complete blood count (CBC) shows relatively normal hemoglobin, WBC, and platelet counts, these are not definitive indicators and further investigations are crucial.  Liver function tests (LFTs) are mildly elevated (ALT 28 U/L, AST 32 U/L), warranting further investigation to rule out liver metastasis or other causes.  Albumin is within the lower limit of normal.\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:** 62 years (increased risk of malignancy)\\\\n* **Smoking History:** Former smoker (increased risk of lung cancer and other respiratory diseases)\\\\n* **Weight Loss:** Significant unintentional weight loss (5kg in 3 months) \\\\u2013 a major warning sign of malignancy\\\\n* **Hemoptysis:** Blood-tinged sputum \\\\u2013 highly suggestive of lung pathology, potentially malignancy\\\\n* **Lymphadenopathy:** Right supraclavicular lymphadenopathy \\\\u2013 strongly suggests metastatic disease.\\\\n* **Decreased Breath Sounds:** Localized decrease in breath sounds points towards a potential lung lesion.\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nBased on the presented information, a preliminary assessment suggests a Karnofsky Performance Status (KPS) score of 60-70%, indicating that the patient is experiencing some symptoms and limitations in daily activities but is still largely independent.  A more thorough assessment is needed to accurately determine her performance status, taking into account her fatigue and weight loss. This will significantly impact treatment choices.\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\nThe clinical picture strongly suggests the possibility of lung cancer, given the constellation of symptoms (cough, hemoptysis, weight loss, fatigue, night sweats, lymphadenopathy, and decreased breath sounds).  Further investigations are urgently required, including:\\\\n\\\\n* **Chest X-Ray:** To visualize the right upper lobe and confirm the presence of any lung lesions.\\\\n* **CT Scan of the Chest, Abdomen, and Pelvis:** To fully stage the disease, assess for metastatic spread, and guide biopsy procedures.\\\\n* **Bronchoscopy with Bronchoalveolar Lavage (BAL) and Biopsy:** To obtain tissue samples for definitive histological diagnosis.  This is the gold standard for lung cancer diagnosis.\\\\n* **PET-CT scan:** To further stage the disease and identify any distant metastases.\\\\n* **Further blood tests:**  Consider more extensive tumor markers (e.g., CEA, CYFRA 21-1) and inflammatory markers.\\\\n\\\\n**Management of Comorbidities:**  Careful consideration must be given to the patient\\'s T2DM and hypertension when planning treatment.  The choice of chemotherapy and radiotherapy regimens needs to account for potential drug interactions and organ toxicity.  Regular monitoring of blood glucose and blood pressure will be crucial during and after treatment.\\\\n\\\\n**Treatment Planning:**  Treatment will depend heavily on the histological diagnosis and staging of the cancer.  Options may include surgery (if localized), chemotherapy, radiotherapy, targeted therapy (depending on molecular profiling of the tumor), or a combination of these modalities.  Palliative care should also be considered to manage symptoms and improve quality of life.\\\\n\\\\n**Limitations and Uncertainties:**  The diagnosis remains presumptive until confirmed by histopathological examination. The extent of disease and the best treatment strategy cannot be determined without further investigations.  The patient\\'s social support system and psychological well-being need to be assessed to provide holistic patient-centered care.\\\\n\\\\n\\\\n**Conclusion:**  This patient requires urgent further investigation to confirm the suspected diagnosis of lung cancer and determine the appropriate treatment plan.  A multidisciplinary team (MDT) approach involving oncologists, radiologists, pathologists, and other relevant specialists is essential for optimal patient management.  Close monitoring of comorbidities is crucial throughout the treatment process.\"\\n    }\\n  },\\n  \"imaging_analysis\": {\\n    \"summary\": \"**Imaging Analysis Report - Patient ID: MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Report - Patient ID: MDT2024001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"** 3.8 x 3.2 cm (CT Chest)\",\\n        \"nodal_status\": \"**  Detailed mediastinal window CT may improve the characterization of lymph node involvement.\",\\n        \"metastatic_status\": \"\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The impression of a highly suspicious primary lung malignancy is consistent with subsequent imaging.\",\\n          \"* **CT Chest (2024-02-05):** Confirms a 3.8 x 3.2 cm spiculated mass in the right upper lobe, characteristic of malignancy.  Multiple enlarged right hilar and mediastinal lymph nodes are identified. No evidence of distant metastases is noted. Mild emphysematous changes are present in the upper lobes.\",\\n          \"* **PET-CT (2024-02-12):** Shows an SUVmax of 12.4 in the right upper lobe mass, confirming its high metabolic activity consistent with malignancy.  FDG-avid right hilar and mediastinal lymph nodes are present (SUVmax 8.2).  No evidence of distant metastatic disease is observed.\",\\n          \"* **Primary Lesion:** 3.8 x 3.2 cm (CT Chest)\",\\n          \"Based on the imaging findings, the patient presents with a large primary lung mass in the right upper lobe with involvement of regional lymph nodes (hilar and mediastinal).  There is no evidence of distant metastases on PET-CT.  This strongly suggests a Stage IIIA Non-Small Cell Lung Cancer (NSCLC) according to the 8th edition TNM staging system.  Precise T and N staging requires pathological confirmation of the primary tumor characteristics and lymph node involvement.  The current imaging suggests a T2-T3 and N2 classification.  Further pathological and clinical evaluation is needed to definitively determine the final stage.\",\\n          \"The primary lesion is located in the right upper lobe, close to the hilum, explaining the associated hilar lymphadenopathy.  The involvement of mediastinal lymph nodes indicates spread beyond the hilar region.  The proximity of the tumor to major vessels and bronchi will be critical factors in determining surgical resectability.  The mild emphysema may impact surgical planning and post-operative recovery.\"\\n        ]\\n      },\\n      \"treatment_implications\": []\\n    }\\n  },\\n  \"pathology_analysis\": {\\n    \"summary\": \"**Pathology Analysis Report - Patient ID: MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Pathology Analysis Report - Patient ID: MDT2024001**\",\\n      \"histology\": \"**\",\\n      \"molecular_profile\": {\\n        \"key_mutations\": \"Key mutations not specified\",\\n        \"immunotherapy_markers\": \"80%\",\\n        \"other_markers\": {}\\n      },\\n      \"therapeutic_implications\": [\\n        \"The provided data does not specify the grade and differentiation of the adenocarcinoma.  Further histopathological examination of the biopsy specimen, including assessment of nuclear pleomorphism, mitotic rate, and architectural features, is necessary to determine the grade (e.g., well-differentiated, moderately differentiated, poorly differentiated) and the degree of differentiation. This information is crucial for prognosis and treatment planning.\",\\n        \"Molecular testing reveals a *KRAS* G12C mutation.  This is a significant finding as it identifies a specific actionable genetic alteration.  The absence of *EGFR*, *ALK*, and *ROS1* rearrangements excludes the use of tyrosine kinase inhibitors (TKIs) targeting these pathways.\",\\n        \"PD-L1 expression is 80%, which is considered a high level.  This suggests that the tumor is likely to respond to immunotherapy, specifically PD-1/PD-L1 inhibitors.\",\\n        \"**5. Therapeutic Targets:**\",\\n        \"Based on the molecular and biomarker findings, the primary therapeutic targets are:\",\\n        \"* **KRAS G12C:**  The presence of the *KRAS* G12C mutation makes this patient a candidate for targeted therapy with a KRAS G12C inhibitor (e.g., sotorasib or adagrasib). These drugs have shown significant efficacy in patients with this specific mutation.\",\\n        \"* **PD-L1 High Expression:** The high PD-L1 expression (80%) makes immunotherapy with a PD-1 or PD-L1 inhibitor (e.g., pembrolizumab, nivolumab) a strong consideration, either as a monotherapy or in combination with chemotherapy or targeted therapy.  The high PD-L1 expression is a strong predictor of response to immunotherapy.\",\\n        \"The patient is a candidate for targeted therapy with a KRAS G12C inhibitor and/or immunotherapy with a PD-1/PD-L1 inhibitor.  The choice of therapy will depend on several factors, including the patient\\'s overall health, performance status (a more thorough assessment is needed), presence of comorbidities, and the results of further staging investigations.  A multidisciplinary team (MDT) discussion is essential to determine the optimal treatment strategy.  The high PD-L1 expression suggests a good likelihood of response to immunotherapy.\",\\n        \"* **Comprehensive staging:**  Thorough clinical staging is crucial before initiating treatment. This should include contrast-enhanced CT scan of the chest, abdomen, and pelvis to assess for locoregional and distant metastases, and potentially a brain MRI to rule out CNS metastases.  The current imaging suggests stage IIIA, but final staging requires complete pathological assessment.\",\\n        \"* **Further biomarker testing:**  While PD-L1 is informative, other biomarkers relevant to treatment selection should be considered based on the MDT discussion and treatment plan.  This may include MSI (Microsatellite Instability) testing, TMB (Tumor Mutational Burden), etc.\",\\n        \"* **Assessment of performance status:** A formal Karnofsky Performance Status (KPS) or ECOG Performance Status score should be obtained to guide treatment decisions.\",\\n        \"* **Consideration of other molecular testing:**  Further genomic profiling, such as next-generation sequencing (NGS), may be considered to identify additional potential therapeutic targets.\",\\n        \"**Disclaimer:** This report is based on the provided data and represents a preliminary assessment.  A comprehensive MDT discussion with oncology, radiology, and other relevant specialists is essential for optimal patient management and treatment planning.  This analysis does not substitute for clinical judgment and should be used in conjunction with a thorough clinical evaluation.\"\\n      ]\\n    }\\n  },\\n  \"guideline_recommendations\": [\\n    {\\n      \"guideline\": \"**  The patient\\'s Type 2 Diabetes Mellitus and Hypertension require careful consideration in treatment planning to minimize drug interactions and adverse effects.  Treatment choices must be tailored to mitigate the risks associated with these comorbidities.\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"*2. Evidence-Based Treatment Options:**\",\\n        \"**KRAS G12C-targeted therapy:**  Sotorasib or adagrasib are indicated based on the *KRAS* G12C mutation.  High-level evidence supports their use in this setting.\",\\n        \"**Immunotherapy:**  Due to the high PD-L1 expression (80%), immunotherapy with a PD-1/PD-L1 inhibitor is strongly supported by high-level evidence and is likely to be highly effective.  This could be used as monotherapy or in combination with chemotherapy or targeted therapy.\",\\n        \"**Chemotherapy:**  Depending on the final stage and patient\\'s performance status, chemotherapy may be considered, potentially in combination with immunotherapy or targeted therapy.  The choice of regimen will depend on the specific circumstances and MDT recommendations.\",\\n        \"*3. Clinical Trial Eligibility:**\",\\n        \"*4. Special Considerations:**\",\\n        \"**Comorbidities:**  Careful monitoring of blood glucose and blood pressure is essential during and after treatment to manage the patient\\'s Type 2 Diabetes and Hypertension.  Treatment choices must be made to minimize potential drug interactions and adverse events.\",\\n        \"**Performance Status:**  A formal assessment of the patient\\'s performance status (KPS or ECOG) is crucial to guide treatment decisions and predict treatment tolerance.  The current estimate (60-70%) suggests some limitations but does not preclude many treatment options.\",\\n        \"**Patient Preferences:**  Shared decision-making is crucial. The patient\\'s preferences and values should be incorporated into the treatment plan.\",\\n        \"*5. Documentation of Deviations:**\",\\n        \"*Recommendations:**\",\\n        \"**Urgent MDT discussion:**  An immediate multidisciplinary meeting is essential to finalize the staging, determine the definitive treatment plan, and discuss clinical trial eligibility.\",\\n        \"**Complete pathological assessment:**  The full histopathological report, including grade and differentiation, is necessary for precise staging and treatment selection.\",\\n        \"**Further biomarker testing:**  MSI and TMB testing should be performed to further refine treatment options.\",\\n        \"**Formal performance status assessment:**  A KPS or ECOG score should be obtained to inform treatment decisions.\",\\n        \"**Clinical trial search:**  A comprehensive search for relevant clinical trials should be conducted.\",\\n        \"**Shared decision-making:**  The patient should actively participate in the decision-making process.\"\\n      ]\\n    }\\n  ]\\n}', 'task': 'Synthesize all available information and provide an expert clinical assessment including treatment recommendations, risk stratification, and special considerations. Consider both patient-specific factors and guideline recommendations.'}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'overall_assessment': '**', 'treatment_considerations': ['* **Molecular Profile:**  A *KRAS* G12C mutation is identified, a targetable mutation.  PD-L1 expression is 80%, highly suggestive of potential responsiveness to immunotherapy.  Further biomarker testing (MSI, TMB) is warranted.', '* **Performance Status:**  Preliminary KPS 60-70%, requiring formal assessment (KPS or ECOG).  Fatigue and weight loss suggest a lower end of this range, impacting treatment choices.', '* **Comorbidities:** Well-controlled Type 2 Diabetes Mellitus (HbA1c 6.8% on Metformin) and hypertension (well-controlled on Lisinopril), and osteoarthritis. These comorbidities will influence treatment selection and require close monitoring.', '**3. Treatment Options:**', '* **KRAS G12C-targeted therapy:** Sotorasib or adagrasib are indicated and represent a cornerstone of treatment.'], 'risk_assessment': '**', 'proposed_approach': '** Based on the MDT discussion and results of further investigations, the recommended treatment approach would likely include a combination of:', 'follow_up_recommendations': ['Regular monitoring of disease progression with imaging (CT scans) and blood tests.', 'Frequent assessments of performance status and management of treatment-related side effects.', 'Close monitoring of comorbidities.', 'Regular MDT reviews to adjust treatment based on response.', '*Disclaimer:** This assessment is based on the available data and represents a preliminary opinion.  A comprehensive MDT discussion and further investigations are essential for definitive diagnosis, staging, and treatment planning.  This analysis does not substitute for clinical judgment and should be used in conjunction with a thorough clinical evaluation.']}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "c84a785f-110e-4267-aa1d-33653dc6b1e9_SpecialistAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"medical_history\": [\\n    {\\n      \"condition\": \"Type 2 Diabetes\",\\n      \"diagnosed\": \"2015-06-15\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Metformin 1000mg BID\",\\n      \"control\": \"Good, HbA1c 6.8%\"\\n    },\\n    {\\n      \"condition\": \"Hypertension\",\\n      \"diagnosed\": \"2016-03-22\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Lisinopril 20mg daily\",\\n      \"control\": \"Well-controlled, BP avg 128/78\"\\n    },\\n    {\\n      \"condition\": \"Osteoarthritis\",\\n      \"diagnosed\": \"2018-11-30\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"PRN NSAIDs\",\\n      \"affected_joints\": [\\n        \"knees\",\\n        \"hands\"\\n      ]\\n    }\\n  ],\\n  \"ehr_analysis\": {\\n    \"summary\": \"This analysis is based on currently available information.  Further investigations are needed to confirm the diagnosis and determine the optimal treatment strategy.  The severity of the patient\\'s comorbidities and their impact on treatment tolerance will require further assessment.\",\\n    \"details\": {\\n      \"summary\": \"This analysis is based on currently available information.  Further investigations are needed to confirm the diagnosis and determine the optimal treatment strategy.  The severity of the patient\\'s comorbidities and their impact on treatment tolerance will require further assessment.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"\",\\n        \"comorbidity_impact\": \"** The patient has well-controlled Type 2 Diabetes Mellitus (T2DM) and Hypertension, managed with Metformin and Lisinopril respectively.  She also has Osteoarthritis affecting her knees and hands. These comorbidities will need careful consideration in treatment planning, particularly regarding potential drug interactions and organ function.\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"**EHR Analysis Agent Report - Patient ID: MDT2024001**\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:** The patient, a 62-year-old Caucasian female, presents with a persistent cough (onset January 15th, 2024), initially described as moderate to severe, progressing to include blood-tinged sputum.  This is accompanied by significant unintentional weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats \\\\u2013 all highly suggestive of a serious underlying condition, potentially malignancy.\\\\n\\\\n* **Comorbidities:** The patient has well-controlled Type 2 Diabetes Mellitus (T2DM) and Hypertension, managed with Metformin and Lisinopril respectively.  She also has Osteoarthritis affecting her knees and hands. These comorbidities will need careful consideration in treatment planning, particularly regarding potential drug interactions and organ function.\\\\n\\\\n* **Social and Functional Factors:** The patient is a retired teacher, suggesting a potentially sedentary lifestyle but also implying a degree of independence and social support.  However, the severity of her current symptoms suggests significant functional impairment.\\\\n\\\\n* **Risk Factors:**  Former smoker (quit 10 years ago) increases the risk of lung cancer. Age (62) also places her within a high-risk group for several malignancies.  The combination of weight loss, cough, hemoptysis, and lymphadenopathy raises strong suspicion for lung cancer.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Presenting Complaint:** Persistent cough with hemoptysis, weight loss, fatigue, decreased appetite, and night sweats.\\\\n* **Physical Examination:**  Significant findings include decreased breath sounds in the right upper lobe and right supraclavicular lymphadenopathy, strongly suggestive of intrathoracic pathology.  Vital signs are relatively stable, although the slightly elevated blood pressure warrants monitoring.\\\\n* **Laboratory Results:**  Complete blood count (CBC) is unremarkable, suggesting no overt anemia or infection.  Liver function tests (LFTs) show mildly elevated AST and ALT, which could be related to her medications or an underlying condition.  Further investigation is crucial.\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:** 62 years (increased risk for malignancy)\\\\n* **Smoking History:** Former smoker (increased risk for lung cancer)\\\\n* **Weight Loss:** Significant unintentional weight loss (5kg in 3 months) \\\\u2013 hallmark of malignancy.\\\\n* **Hemoptysis:** Blood-tinged sputum \\\\u2013 highly concerning for lung pathology.\\\\n* **Lymphadenopathy:** Right supraclavicular lymphadenopathy \\\\u2013 strongly suggestive of metastatic disease.\\\\n* **Fatigue, Anorexia, Night Sweats:**  Constitutional symptoms supporting a serious underlying condition.\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nBased on the reported symptoms and weight loss, a preliminary assessment suggests the patient\\'s performance status is likely ECOG 2-3.  A more formal assessment using tools like the Karnofsky Performance Scale or the Eastern Cooperative Oncology Group (ECOG) performance status scale is necessary for accurate staging and treatment planning.  This will influence the intensity of treatment options considered.\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\nThe clinical presentation strongly suggests the possibility of lung cancer.  Further investigations are urgently required:\\\\n\\\\n* **Imaging:** High-resolution computed tomography (HRCT) of the chest is paramount to assess the extent of lung involvement and identify potential metastases.  Further imaging (e.g., CT abdomen/pelvis) may be indicated based on HRCT findings.\\\\n* **Biopsy:**  Bronchoscopy with transbronchial lung biopsy or CT-guided needle biopsy is necessary to obtain tissue for histopathological examination and confirm the diagnosis, including staging and identifying specific molecular markers for targeted therapy.\\\\n* **Further Laboratory Investigations:**  Consider further blood tests (e.g., tumor markers such as CEA, CYFRA 21-1), depending on the imaging findings.\\\\n\\\\n**Treatment Planning Considerations:**\\\\n\\\\nTreatment options will depend on the histopathological diagnosis, stage of the disease, and the patient\\'s performance status and comorbidities.  Options may range from surgery, chemotherapy, radiotherapy, targeted therapy, or a combination thereof.  Close monitoring of her diabetes and hypertension will be crucial throughout the treatment process to mitigate potential adverse effects and optimize outcomes.  The presence of comorbidities will influence treatment choice and require close collaboration with other specialists (e.g., endocrinologist, cardiologist).\\\\n\\\\n**Limitations and Uncertainties:**\\\\n\\\\nThis analysis is based on currently available information.  Further investigations are needed to confirm the diagnosis and determine the optimal treatment strategy.  The severity of the patient\\'s comorbidities and their impact on treatment tolerance will require further assessment.\\\\n\\\\n**Conclusion:**\\\\n\\\\nThis patient requires urgent further investigation to confirm the suspected lung cancer. A multidisciplinary team (MDT) approach involving pulmonology, oncology, radiology, and potentially other specialists is essential for optimal patient management and treatment planning.  The patient\\'s performance status and comorbidities will significantly influence treatment decisions.  The goal is to deliver evidence-based, patient-centered care tailored to her specific needs and circumstances.\"\\n    }\\n  },\\n  \"imaging_analysis\": {\\n    \"summary\": \"**Imaging Analysis Report - Patient ID: MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Report - Patient ID: MDT2024001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"** 3.8 x 3.2 cm spiculated mass in the right upper lobe.\",\\n        \"nodal_status\": \"**  Mediastinoscopy or EBUS/EUS-guided biopsy might be necessary for definitive mediastinal lymph node staging, particularly if surgical resection is being considered.  This would allow more precise assessment of the extent of nodal involvement.\",\\n        \"metastatic_status\": \"** M0 (no distant metastases).\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The findings are highly suspicious for a primary lung malignancy.  This initial imaging provided the impetus for further investigation.\",\\n          \"* **CT Chest (2024-02-05):** Confirms a 3.8 x 3.2 cm spiculated mass in the right upper lobe, characteristic of malignancy.  Multiple enlarged right hilar and mediastinal lymph nodes are evident.  No distant metastases are identified. Mild emphysematous changes are noted in the upper lobes.\",\\n          \"* **PET-CT (2024-02-12):**  The right upper lobe mass shows an SUVmax of 12.4, consistent with high metabolic activity indicative of malignancy.  FDG-avid right hilar and mediastinal lymph nodes are present, with an SUVmax of 8.2, confirming their malignant nature. No evidence of distant metastatic disease is observed.\",\\n          \"* **Primary Lesion:** 3.8 x 3.2 cm spiculated mass in the right upper lobe.\",\\n          \"Based on the imaging findings, the patient presents with a large primary lung mass involving the right upper lobe, with involvement of regional lymph nodes (hilar and mediastinal).  There is no evidence of distant metastases based on the available imaging.  This strongly suggests a Stage IIIA Non-Small Cell Lung Cancer (NSCLC) according to the 8th edition TNM staging system.  However, definitive staging requires tissue confirmation via biopsy.  The precise T, N, and M stages will depend on histopathological findings and potential additional imaging or endoscopic procedures.\",\\n          \"The primary lesion is located in the right upper lobe, close to the hilum, explaining the associated hilar lymphadenopathy.  The mediastinal lymph node involvement suggests potential spread along lymphatic pathways.  The proximity of the tumor to major vessels and bronchi will be crucial in determining surgical resectability.  The presence of mild emphysema may impact surgical planning and potential respiratory complications post-operatively.\"\\n        ]\\n      },\\n      \"treatment_implications\": [\\n        \"The imaging findings suggest a patient who may be a candidate for multimodality therapy including surgery, chemotherapy, and/or radiation therapy.  The choice of treatment will depend on the histopathological diagnosis, molecular profiling, and the patient\\'s overall health status and performance status, taking into account her comorbidities.  A multidisciplinary team (MDT) approach involving pulmonologists, oncologists, thoracic surgeons, and other specialists (e.g., endocrinologist, cardiologist) is essential for developing a comprehensive and personalized treatment plan.  The potential impact of her comorbidities on treatment tolerance must be carefully considered.\"\\n      ]\\n    }\\n  },\\n  \"pathology_analysis\": {\\n    \"summary\": \"**Pathology Analysis Agent Report - Patient ID: MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Pathology Analysis Agent Report - Patient ID: MDT2024001**\",\\n      \"histology\": \"**  A detailed review of the histopathological slides by an experienced pathologist is crucial to determine the grade, differentiation, and any other relevant histological features. This will refine the diagnosis and help predict prognosis.\",\\n      \"molecular_profile\": {\\n        \"key_mutations\": \"Key mutations not specified\",\\n        \"immunotherapy_markers\": \"**  This strong PD-L1 expression suggests that the patient is likely to benefit from immunotherapy with a PD-1 or PD-L1 inhibitor (e.g., pembrolizumab, nivolumab, atezolizumab).  This could be used as a single agent or in combination with chemotherapy or targeted therapy.\",\\n        \"other_markers\": {}\\n      },\\n      \"therapeutic_implications\": [\\n        \"*Recommendations for Additional Testing:**\"\\n      ]\\n    }\\n  },\\n  \"guideline_recommendations\": [\\n    {\\n      \"guideline\": \"**\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"*3. Special Populations and Considerations:**\",\\n        \"*4. Evidence Levels:**\",\\n        \"*5. Clinical Trial Eligibility:**\",\\n        \"*Recommendations:**\"\\n      ]\\n    },\\n    {\\n      \"guideline\": \"**  Evidence levels for treatment options will be determined by the final diagnosis and staging, referring to the NCCN guidelines.  RCTs will form the basis of treatment recommendations.\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"**Clinical Trial Considerations:**  Active exploration of clinical trials investigating immunotherapy and other novel therapies is strongly recommended once the complete pathology and staging are available.\",\\n        \"**Special Considerations:**  Close monitoring of the patient\\'s diabetes and hypertension, and careful consideration of potential drug interactions, are crucial throughout treatment.  Collaboration with specialists managing her comorbidities is essential.\"\\n      ]\\n    },\\n    {\\n      \"guideline\": \"**  Any deviations from standard practice based on the NCCN guidelines will be fully documented in the patient\\'s medical record, justifying the decision based on the individual patient characteristics and clinical context.  This will include a clear rationale for any chosen treatment plan.\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"*Limitations and Uncertainties:**\"\\n      ]\\n    }\\n  ]\\n}', 'task': 'Synthesize all available information and provide an expert clinical assessment including treatment recommendations, risk stratification, and special considerations. Consider both patient-specific factors and guideline recommendations.'}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'overall_assessment': '**', 'treatment_considerations': ['This 62-year-old female presents with a highly suspicious clinical picture strongly suggestive of Stage IIIA Non-Small Cell Lung Cancer (NSCLC), based on imaging findings (3.8 x 3.2 cm spiculated mass in the right upper lobe with hilar and mediastinal lymphadenopathy, no distant metastases).  The clinical presentation includes persistent cough with hemoptysis, significant weight loss (5kg in 3 months), fatigue, anorexia, and night sweats.  Right supraclavicular lymphadenopathy is also present, raising concerns about potential lymphatic spread.  She has well-controlled Type 2 Diabetes Mellitus and Hypertension, and Osteoarthritis, which must be considered in treatment planning.  Definitive diagnosis and staging require tissue confirmation via biopsy (bronchoscopy with transbronchial lung biopsy or CT-guided needle biopsy) and subsequent histopathological analysis, including molecular profiling (especially PD-L1 expression).', '* **Age:** 62 years  impacts treatment tolerance and potential long-term side effects.', '* **Comorbidities:** Well-controlled Type 2 Diabetes Mellitus and Hypertension, Osteoarthritis.  These require careful consideration regarding drug interactions and potential toxicity from chemotherapy and/or radiation therapy.  Close collaboration with endocrinology and cardiology is essential.', '* **Performance Status:**  Likely ECOG 2-3 based on symptom severity and weight loss.  Formal assessment is needed to guide treatment intensity.', '**4. Treatment Options:**'], 'risk_assessment': '**', 'proposed_approach': 'Individualized approach recommended.', 'follow_up_recommendations': ['*Limitations and Uncertainties:**', 'This assessment is based on currently available information.  The final diagnosis, staging, and treatment plan will be determined after the biopsy results and MDT discussion.  The prognosis and response to treatment will vary depending on individual patient factors and tumor characteristics.  Unforeseen complications can always arise during treatment.  This report serves as a preliminary assessment and a framework for further investigation and management.']}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "cd313cb1-548e-4a94-911c-e545344262b6_SpecialistAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"medical_history\": [\\n    {\\n      \"condition\": \"Type 2 Diabetes\",\\n      \"diagnosed\": \"2015-06-15\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Metformin 1000mg BID\",\\n      \"control\": \"Good, HbA1c 6.8%\"\\n    },\\n    {\\n      \"condition\": \"Hypertension\",\\n      \"diagnosed\": \"2016-03-22\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Lisinopril 20mg daily\",\\n      \"control\": \"Well-controlled, BP avg 128/78\"\\n    },\\n    {\\n      \"condition\": \"Osteoarthritis\",\\n      \"diagnosed\": \"2018-11-30\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"PRN NSAIDs\",\\n      \"affected_joints\": [\\n        \"knees\",\\n        \"hands\"\\n      ]\\n    }\\n  ],\\n  \"ehr_analysis\": {\\n    \"summary\": \"This patient requires urgent further investigation to confirm the diagnosis and stage of the suspected lung cancer.  The multidisciplinary team (MDT) approach involving oncologists, pulmonologists, radiologists, and pathologists is essential for optimal patient management.  A comprehensive treatment plan will be developed based on the definitive diagnosis, stage, and the patient\\\\u2019s overall performance status and comorbidities.  The patient should be counseled about the potential treatment options, risks, and benefits in a patient-centered approach.  This analysis is preliminary and further information is required for a complete assessment.\",\\n    \"details\": {\\n      \"summary\": \"This patient requires urgent further investigation to confirm the diagnosis and stage of the suspected lung cancer.  The multidisciplinary team (MDT) approach involving oncologists, pulmonologists, radiologists, and pathologists is essential for optimal patient management.  A comprehensive treatment plan will be developed based on the definitive diagnosis, stage, and the patient\\\\u2019s overall performance status and comorbidities.  The patient should be counseled about the potential treatment options, risks, and benefits in a patient-centered approach.  This analysis is preliminary and further information is required for a complete assessment.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"\",\\n        \"comorbidity_impact\": \"** The patient\\'s comorbidities (diabetes, hypertension, osteoarthritis) need careful consideration when choosing a treatment plan.  The well-controlled nature of her diabetes and hypertension currently does not pose an absolute contraindication to most cancer therapies, but close monitoring will be essential.  Osteoarthritis may influence the tolerability of certain treatments, particularly those with bone marrow suppression side effects.\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"**EHR Analysis Agent Report - Patient ID: MDT2024001**\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:** The patient, a 62-year-old Caucasian female, presents with a persistent cough with occasional hemoptysis (blood-tinged sputum) since January 15th, 2024.  This is accompanied by significant unintentional weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats \\\\u2013 all highly suggestive of an underlying malignancy.\\\\n\\\\n* **Medical History:**  The patient has a history of well-controlled Type 2 Diabetes (HbA1c 6.8%), well-controlled Hypertension (average BP 128/78), and Osteoarthritis affecting her knees and hands.  These comorbidities will need to be considered when planning treatment.  Her smoking history (former smoker, quit 10 years ago) represents a significant risk factor for lung cancer.\\\\n\\\\n* **Social and Functional Factors:** The patient is retired, suggesting potential availability for treatment but also potential limitations depending on the intensity of the regimen.  Further social support assessment is required.\\\\n\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Primary Complaint:** Persistent cough with hemoptysis.\\\\n* **Physical Examination:**  Significant findings include decreased breath sounds in the right upper lobe, and right supraclavicular lymphadenopathy \\\\u2013 strongly suggestive of lung pathology, potentially malignancy.\\\\n* **Laboratory Results:**  The complete blood count (CBC) shows normal hemoglobin, white blood cell count, and platelets, ruling out overt anemia or infection at this time.  Liver function tests (ALT and AST) are mildly elevated, requiring further investigation.  Albumin is within the normal range.  Kidney function (creatinine) is normal.\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:** 62 years old (increased risk for various cancers).\\\\n* **Gender:** Female (lung cancer incidence is lower in females but increasing).\\\\n* **Smoking History:** Former smoker (significant risk factor for lung cancer).\\\\n* **Symptoms:**  The constellation of symptoms (cough, hemoptysis, weight loss, fatigue, night sweats) strongly suggests lung cancer.  The location of the lymphadenopathy further supports this suspicion.\\\\n\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nBased on the presented information, a preliminary assessment suggests a performance status of either ECOG 2 or 3.  The patient is experiencing significant fatigue, weight loss, and decreased appetite, impacting her ability to perform daily activities.  A more detailed assessment using validated tools like the ECOG performance status scale is crucial for accurate staging and treatment planning.\\\\n\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\nThe clinical presentation strongly suggests the possibility of lung cancer.  The right supraclavicular lymphadenopathy indicates potential advanced disease.  Further investigations are urgently needed:\\\\n\\\\n* **Imaging:**  High-resolution computed tomography (HRCT) of the chest is essential to delineate the extent of the lung lesion and assess for mediastinal involvement.  A chest X-ray should be reviewed if already available.\\\\n* **Bronchoscopy:**  Bronchoscopy with bronchoalveolar lavage (BAL) and biopsy is needed to obtain tissue for definitive diagnosis and molecular profiling.  This will allow for accurate staging and targeted therapy selection.  Endobronchial ultrasound (EBUS) may be necessary for mediastinal lymph node sampling.\\\\n* **PET-CT scan:**  A positron emission tomography (PET)-CT scan will be crucial for staging the disease and identifying any distant metastases.\\\\n* **Further Lab Investigations:**  Consider further investigations including CEA, CA 125, and other tumor markers based on the imaging findings.  Repeat liver function tests are warranted.\\\\n\\\\n**Comorbidities Impact on Treatment:** The patient\\'s comorbidities (diabetes, hypertension, osteoarthritis) need careful consideration when choosing a treatment plan.  The well-controlled nature of her diabetes and hypertension currently does not pose an absolute contraindication to most cancer therapies, but close monitoring will be essential.  Osteoarthritis may influence the tolerability of certain treatments, particularly those with bone marrow suppression side effects.\\\\n\\\\n**Current Medications and Interactions:**  The current medications (Metformin, Lisinopril, PRN NSAIDs) should be reviewed for potential drug interactions with any cancer therapies prescribed.\\\\n\\\\n**Conclusion:**\\\\n\\\\nThis patient requires urgent further investigation to confirm the diagnosis and stage of the suspected lung cancer.  The multidisciplinary team (MDT) approach involving oncologists, pulmonologists, radiologists, and pathologists is essential for optimal patient management.  A comprehensive treatment plan will be developed based on the definitive diagnosis, stage, and the patient\\\\u2019s overall performance status and comorbidities.  The patient should be counseled about the potential treatment options, risks, and benefits in a patient-centered approach.  This analysis is preliminary and further information is required for a complete assessment.\"\\n    }\\n  },\\n  \"imaging_analysis\": {\\n    \"summary\": \"**Imaging Analysis Report - Patient ID: MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Report - Patient ID: MDT2024001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"** T2 (3-5cm primary tumor)\",\\n        \"nodal_status\": \"**  Precise characterization of nodal involvement requires histopathological confirmation, which may alter the final N-stage.  EBUS or mediastinoscopy may be necessary for definitive staging.\",\\n        \"metastatic_status\": \"**  While the PET-CT scan showed no distant metastases, microscopic disease could be present.\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The findings are highly suggestive of a primary lung malignancy.  Resolution is limited, preventing precise characterization.\",\\n          \"* **CT Chest (2024-02-05):**  Confirms a 3.8 x 3.2 cm spiculated mass in the right upper lobe.  Multiple enlarged right hilar and mediastinal lymph nodes are present. No evidence of distant metastases is identified. Mild emphysematous changes are noted in the upper lobes.  The spiculated margins of the primary lesion are concerning for malignancy.\",\\n          \"* **PET-CT (2024-02-12):**  The right upper lobe mass demonstrates an SUVmax of 12.4, consistent with a highly metabolically active lesion.  FDG-avid right hilar and mediastinal lymph nodes are present, with an SUVmax of 8.2, indicating involvement.  No evidence of distant metastatic disease is detected.\",\\n          \"* **Primary Lesion:** 3.8 x 3.2 cm (CT Chest).\",\\n          \"The primary lesion is located in the right upper lobe, which explains the decreased breath sounds on physical examination.  The involvement of hilar and mediastinal lymph nodes suggests locoregional spread.  The right supraclavicular lymphadenopathy detected on physical examination is concerning and warrants further evaluation to confirm if it represents metastatic spread (N3).  The mild emphysema may influence treatment planning and potentially increase surgical risk.\"\\n        ]\\n      },\\n      \"treatment_implications\": [\\n        \"The imaging findings strongly suggest the need for a multidisciplinary team approach involving oncologists, thoracic surgeons, pulmonologists, and pathologists. Treatment options will depend on the confirmed histologic subtype, molecular profiling, and the patient\\'s performance status.  Potential treatment options may include surgery (potentially lobectomy or pneumonectomy) with or without adjuvant chemotherapy, or chemoradiotherapy if surgical resection is not feasible.  The patient\\'s comorbidities need to be carefully considered when selecting the optimal treatment strategy.  A detailed discussion regarding treatment options, benefits, risks, and potential side effects is crucial.\"\\n      ]\\n    }\\n  },\\n  \"pathology_analysis\": {\\n    \"summary\": \"**Pathology Analysis Report - Patient ID: MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Pathology Analysis Report - Patient ID: MDT2024001**\",\\n      \"histology\": \"**\",\\n      \"molecular_profile\": {\\n        \"key_mutations\": \"** This mutation is a targetable oncogenic driver.  Several KRAS G12C inhibitors (e.g., sotorasib, adagrasib) have demonstrated clinical efficacy in this setting. These should be considered as first-line treatment options.\",\\n        \"immunotherapy_markers\": \"**  While PD-L1 is informative, exploring other biomarkers might offer additional insights into potential treatment strategies.\",\\n        \"other_markers\": {}\\n      },\\n      \"therapeutic_implications\": [\\n        \"Given the findings:\",\\n        \"*Recommendations for Additional Testing:**\",\\n        \"1. **Comprehensive pathological review:**  A detailed review of the biopsy specimen by an experienced lung pathologist to determine the grade and differentiation of the adenocarcinoma. This is crucial for accurate staging and prognosis.\",\\n        \"3. **Staging investigations:**  The imaging suggests locally advanced disease.  Definitive staging is crucial before treatment planning. This includes:\",\\n        \"Completion of EBUS or mediastinoscopy to fully assess nodal status.\",\\n        \"Detailed review of the PET-CT scan by a radiologist experienced in oncology to confirm the absence of distant metastases.\",\\n        \"4. **Assessment of performance status:**  A formal assessment of the patient\\\\u2019s performance status (e.g., using the ECOG scale) is needed to guide treatment selection and predict treatment tolerability.\"\\n      ]\\n    }\\n  },\\n  \"guideline_recommendations\": [\\n    {\\n      \"guideline\": \"**\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"The primary guidelines applicable to this case include the National Comprehensive Cancer Network (NCCN) Guidelines for Lung Cancer and relevant guidelines from professional organizations such as the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO).  These guidelines provide recommendations for staging, diagnosis, and treatment of NSCLC, tailored to specific molecular subtypes and disease stages.  Unfortunately, the `guideline_reference` tool is insufficient to directly access and apply these guidelines.  The analysis below will rely on my internal knowledge of these guidelines.\",\\n        \"*2. Matching Patient Characteristics:**\",\\n        \"*3. Special Populations and Comorbidities:**\",\\n        \"*4. Evidence Levels:**\",\\n        \"The treatment recommendations below will be based on high-level evidence from randomized controlled trials (RCTs) and meta-analyses supporting the use of targeted therapy for KRAS G12C-mutated NSCLC.\",\\n        \"*5. Clinical Trial Options:**\",\\n        \"*6. Treatment Recommendations:**\",\\n        \"**First-line treatment:**  Given the KRAS G12C mutation, the current standard of care involves targeted therapy with either sotorasib or adagrasib.  These have demonstrated significant improvements in progression-free survival (PFS) and overall survival (OS) in patients with this specific mutation.  The choice between sotorasib and adagrasib may depend on specific factors like availability, cost, and potential side-effect profiles.  Both drugs are supported by high-level evidence from phase III clinical trials.\",\\n        \"**Combination therapy:**  Depending on response to first-line therapy, combination strategies could be considered.  The combination of a KRAS G12C inhibitor with immunotherapy (e.g., pembrolizumab) is a promising area of research.  This will require careful consideration of the patient\\'s comorbidities and performance status.\",\\n        \"**Surgical resection:**  If the final staging demonstrates resectable disease (after EBUS/mediastinoscopy), surgical resection (lobectomy or pneumonectomy) may be an option.  However, this decision should be made cautiously given the patient\\'s comorbidities and the potential risks of major thoracic surgery.  Adjuvant therapy (chemotherapy or immunotherapy) might be indicated post-surgery depending on final staging and pathological findings.\",\\n        \"**Chemoradiotherapy:**  If the disease is unresectable, chemoradiotherapy may be considered, but this would likely be a less preferred option given the availability of targeted therapy.\",\\n        \"*7. Special Considerations and Deviations from Standard Practice:**\",\\n        \"**Definitive Staging:**  EBUS or mediastinoscopy is crucial to definitively assess nodal status and confirm the stage of the disease.  This is a deviation from standard practice only if not already planned or performed.\",\\n        \"**Comorbidity Management:**  Close monitoring of diabetes and hypertension is essential during treatment.  Osteoarthritis management may need adjustment depending on the chosen therapy\\'s side effects.\",\\n        \"**Performance Status:**  A formal ECOG performance status assessment is needed to accurately guide treatment decisions and predict tolerability.\",\\n        \"**Patient-Centered Care:**  Throughout the process, the patient must be actively involved in shared decision-making, ensuring her preferences and values are considered.\",\\n        \"*8. Documentation:**\",\\n        \"All aspects of this analysis, including the rationale for treatment recommendations, potential risks and benefits, and patient preferences, should be meticulously documented in the patient\\'s medical record.  This includes details about clinical trial eligibility and any deviations from standard practice.\",\\n        \"*Limitations and Uncertainties:**\",\\n        \"This analysis relies on the information provided.  Further investigations (EBUS/mediastinoscopy, definitive pathology results, detailed performance status assessment) are necessary to refine the staging and treatment plan. The absence of complete blood count and liver function test results in the provided data limits the ability to fully assess the impact of comorbidities.  Finally, the absence of a functional `guideline_reference` tool prevents direct access to specific guideline recommendations.\"\\n      ]\\n    }\\n  ]\\n}', 'task': 'Synthesize all available information and provide an expert clinical assessment including treatment recommendations, risk stratification, and special considerations. Consider both patient-specific factors and guideline recommendations.'}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'overall_assessment': '**', 'treatment_considerations': ['This 62-year-old female presents with a highly suggestive clinical picture of advanced lung adenocarcinoma.  The persistent cough with hemoptysis, significant weight loss, fatigue, and night sweats, coupled with right upper lobe decreased breath sounds, right supraclavicular lymphadenopathy, and imaging findings (3.8 x 3.2 cm spiculated mass in the right upper lobe with hilar and mediastinal lymphadenopathy and an SUVmax of 12.4 on PET-CT), strongly support this diagnosis.  The pathology report reveals a KRAS G12C mutation, a targetable oncogenic driver.  While the PET-CT scan currently shows no distant metastases, microscopic disease cannot be definitively ruled out.  Her comorbidities (well-controlled Type 2 diabetes, hypertension, and osteoarthritis) require careful consideration in treatment planning.  A definitive assessment of nodal status via EBUS or mediastinoscopy is crucial for accurate staging.', '* **Comorbidities:** Well-controlled Type 2 diabetes, hypertension, and osteoarthritis.  These require close monitoring and may influence treatment choice and tolerability.', '* **Social Factors:** Retired teacher; further assessment of social support is needed to ensure adequate support during treatment.', '**4. Treatment Options:**', '* **First-line therapy:**  Targeted therapy with either sotorasib or adagrasib is the current standard of care based on high-level evidence from phase III clinical trials showing improved PFS and OS. The choice will depend on factors like availability, cost, and potential side effects.'], 'risk_assessment': '**', 'proposed_approach': 'Individualized approach recommended.', 'follow_up_recommendations': ['Imaging (CT scans) at regular intervals to assess response to therapy.', 'Blood tests to monitor organ function and blood counts.', 'Regular assessments of quality of life and performance status.', '*Limitations and Uncertainties:**', 'This assessment is based on the available information.  The final staging and treatment plan will depend on the results of the EBUS/mediastinoscopy, the complete pathological report including PD-L1 status, and a formal ECOG performance status assessment.  The absence of complete blood count and comprehensive liver function test results currently limits the complete assessment of comorbidity impact.  The lack of access to the specific guideline recommendations via the `guideline_reference` tool has necessitated reliance on my internal knowledge of current best practice guidelines.']}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "df786b47-cf96-4e9f-ba15-1a2c66400f83_SpecialistAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"medical_history\": [\\n    {\\n      \"condition\": \"Type 2 Diabetes\",\\n      \"diagnosed\": \"2015-06-15\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Metformin 1000mg BID\",\\n      \"control\": \"Good, HbA1c 6.8%\"\\n    },\\n    {\\n      \"condition\": \"Hypertension\",\\n      \"diagnosed\": \"2016-03-22\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Lisinopril 20mg daily\",\\n      \"control\": \"Well-controlled, BP avg 128/78\"\\n    },\\n    {\\n      \"condition\": \"Osteoarthritis\",\\n      \"diagnosed\": \"2018-11-30\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"PRN NSAIDs\",\\n      \"affected_joints\": [\\n        \"knees\",\\n        \"hands\"\\n      ]\\n    }\\n  ],\\n  \"ehr_analysis\": {\\n    \"summary\": \"Given the patient\\'s symptoms (significant fatigue, weight loss, and dyspnea implied by decreased breath sounds), a preliminary assessment suggests a **Karnofsky Performance Status (KPS) score of 60-70%**.  Further assessment is needed following more detailed investigations.  This score indicates that the patient is experiencing some limitations in daily activities.\",\\n    \"details\": {\\n      \"summary\": \"Given the patient\\'s symptoms (significant fatigue, weight loss, and dyspnea implied by decreased breath sounds), a preliminary assessment suggests a **Karnofsky Performance Status (KPS) score of 60-70%**.  Further assessment is needed following more detailed investigations.  This score indicates that the patient is experiencing some limitations in daily activities.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"\",\\n        \"comorbidity_impact\": \"**\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"## EHR Analysis Agent Report: Patient MDT2024001\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:**  The patient, a 62-year-old Caucasian female, presents with a persistent cough (onset January 15th, 2024) initially described as moderate to severe, progressing to include occasional hemoptysis.  Significant weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats are concerning constitutional symptoms suggesting a serious underlying illness. The temporal relationship between these symptoms strongly suggests a possible underlying malignancy.\\\\n\\\\n* **Medical History:** The patient has a history of well-controlled Type 2 Diabetes Mellitus (T2DM) and Hypertension, managed with Metformin and Lisinopril respectively.  She also has Osteoarthritis affecting her knees and hands.  Her past smoking history (former smoker, quit 10 years ago) represents a significant risk factor.\\\\n\\\\n* **Current Medications:** Metformin 1000mg BID, Lisinopril 20mg daily, and PRN NSAIDs.  Potential drug interactions should be considered when initiating new treatments.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Presenting Complaint:** Persistent cough with hemoptysis, weight loss, fatigue, decreased appetite, and night sweats.\\\\n* **Physical Exam:**  Significant findings include decreased breath sounds in the right upper lobe, suggestive of a possible lung lesion, and right supraclavicular lymphadenopathy, raising strong suspicion of malignancy. Vital signs are relatively stable, although the slightly elevated blood pressure (132/82) should be monitored.\\\\n* **Laboratory Results:**  Complete blood count (CBC) shows normal hemoglobin, white blood cell count, and platelets. Basic metabolic panel (BMP) reveals normal creatinine, mildly elevated liver enzymes (ALT and AST), and a slightly low albumin, which warrants further investigation.  These laboratory findings are non-specific but do not exclude malignancy.\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:** 62 years old (increased risk for various cancers).\\\\n* **Gender:** Female (certain cancers have gender predilection).\\\\n* **Smoking History:** Former smoker (significantly increases lung cancer risk).\\\\n* **Weight Loss:** Unexplained weight loss is a major red flag for malignancy.\\\\n* **Hemoptysis:** Suggestive of a possible lung lesion, particularly in the context of other symptoms.\\\\n* **Lymphadenopathy:**  Right supraclavicular lymphadenopathy is a concerning sign, often associated with metastasis.\\\\n* **Fatigue, Anorexia, Night Sweats:**  Constitutional symptoms suggestive of malignancy.\\\\n\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nGiven the patient\\'s symptoms (significant fatigue, weight loss, and dyspnea implied by decreased breath sounds), a preliminary assessment suggests a **Karnofsky Performance Status (KPS) score of 60-70%**.  Further assessment is needed following more detailed investigations.  This score indicates that the patient is experiencing some limitations in daily activities.\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\nThe constellation of symptoms and signs strongly suggests the need for urgent further investigation to rule out lung cancer, potentially involving other thoracic malignancies.  The right supraclavicular lymphadenopathy is particularly concerning, as it is often indicative of metastatic disease.\\\\n\\\\n**Recommended Investigations:**\\\\n\\\\n* **Chest X-ray:** To further evaluate the decreased breath sounds and potential lung lesion.\\\\n* **CT Chest with contrast:** To obtain detailed imaging of the lungs, mediastinum, and hilar lymph nodes.  PET-CT should be strongly considered to assess for metastatic disease.\\\\n* **Bronchoscopy with bronchoalveolar lavage (BAL) and biopsy:** To obtain tissue samples for histopathological examination.  This is crucial for definitive diagnosis.\\\\n* **Thoracentesis (if indicated):** If pleural effusion is present.\\\\n* **Mediastinoscopy or mediastinotomy (if indicated):** For biopsy of mediastinal lymph nodes.\\\\n\\\\n**Impact of Comorbidities:**\\\\n\\\\nThe patient\\'s T2DM and hypertension need to be carefully managed during any subsequent treatment.  Careful consideration should be given to the potential for drug interactions between existing medications and any new treatments (e.g., chemotherapy).  The osteoarthritis may limit tolerance to certain procedures or treatments.\\\\n\\\\n**Social and Functional Factors:**\\\\n\\\\nThe patient\\'s occupation (retired teacher) suggests she may have adequate social support. However, her functional status needs to be assessed to determine the impact of her illness on her daily life and to plan appropriate support measures.\\\\n\\\\n**Prognostic Indicators:**\\\\n\\\\nThe presence of hemoptysis, weight loss, and supraclavicular lymphadenopathy are poor prognostic indicators.  Further investigations are crucial for determining the stage and extent of the disease, which will significantly impact prognosis.\\\\n\\\\n\\\\n**Conclusion:**\\\\n\\\\nThis patient requires urgent further investigation to evaluate the strong suspicion of lung cancer or another thoracic malignancy.  A multidisciplinary team (MDT) approach involving oncology, radiology, pathology, and potentially pulmonology is crucial for optimal diagnosis, staging, and treatment planning.  The patient\\'s comorbidities and functional status must be carefully considered when developing a personalized treatment plan.  This report highlights the need for immediate action and further investigations to improve the patient\\'s outcome.  This analysis is preliminary and further information is needed for a definitive diagnosis and treatment plan.\"\\n    }\\n  },\\n  \"imaging_analysis\": {\\n    \"summary\": \"**Imaging Analysis Report: Patient MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Report: Patient MDT2024001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"** 12.4 (PET-CT)\",\\n        \"nodal_status\": \"**  These are essential for obtaining tissue samples for histopathological confirmation and definitive nodal staging.  This will be crucial for accurate T and N staging, impacting treatment decisions.  This is considered the gold standard for mediastinal lymph node staging.\",\\n        \"metastatic_status\": \"** M0 (no distant metastases)\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The findings are highly suggestive of a primary lung malignancy.  Resolution is limited, preventing precise characterization.\",\\n          \"* **CT Chest (2024-02-05):** Confirms a 3.8 x 3.2 cm spiculated mass in the right upper lobe, consistent with a malignant neoplasm.  Multiple enlarged right hilar and mediastinal lymph nodes are present, indicating regional lymph node involvement. No evidence of distant metastases is identified. Mild emphysematous changes are noted in the upper lobes.\",\\n          \"* **PET-CT (2024-02-12):**  Shows a right upper lobe mass with a maximum standardized uptake value (SUVmax) of 12.4, confirming high metabolic activity consistent with malignancy.  FDG-avid right hilar and mediastinal lymph nodes are present, with a maximum SUVmax of 8.2, indicating metabolically active disease. No evidence of distant metastatic disease is seen.\",\\n          \"* **Primary lesion:** 3.8 x 3.2 cm (CT Chest)\",\\n          \"* **SUVmax of primary lesion:** 12.4 (PET-CT)\",\\n          \"The primary lesion is located in the right upper lobe, close to the hilum.  The involvement of hilar and mediastinal lymph nodes suggests potential spread within the mediastinum.  The relationship of the tumor to the chest wall and diaphragm cannot be definitively determined from the current imaging alone.\"\\n        ]\\n      },\\n      \"treatment_implications\": [\\n        \"The imaging findings suggest a locally advanced NSCLC requiring multidisciplinary discussion and treatment planning.  Options may include surgery (potentially with neoadjuvant chemotherapy), chemoradiotherapy, or systemic therapy depending on the final pathological diagnosis, patient performance status, and comorbidities.  The multidisciplinary team (MDT) will need to consider all the available information, including the patient\\'s age, comorbidities (diabetes, hypertension, osteoarthritis), and performance status, to develop a personalized treatment plan.\",\\n        \"*8.  Patient-Centered Care Considerations:**\",\\n        \"The patient\\'s  concerns, preferences, and quality of life must be central to the treatment decision-making process.  Open communication and shared decision-making are essential for ensuring patient-centered care.\"\\n      ],\\n      \"disease_extent_formatted\": \"Primary Tumor: ** 12.4 (PET-CT). Nodal Status: **  These are essential for obtaining tissue samples for histopathological confirmation and definitive nodal staging.  This will be crucial for accurate T and N staging, impacting treatment decisions.  This is considered the gold standard for mediastinal lymph node staging.. Metastatic Status: ** M0 (no distant metastases).\",\\n      \"staging_formatted\": \"Clinical Stage: . Key Findings: * **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The findings are highly suggestive of a primary lung malignancy.  Resolution is limited, preventing precise characterization.; * **CT Chest (2024-02-05):** Confirms a 3.8 x 3.2 cm spiculated mass in the right upper lobe, consistent with a malignant neoplasm.  Multiple enlarged right hilar and mediastinal lymph nodes are present, indicating regional lymph node involvement. No evidence of distant metastases is identified. Mild emphysematous changes are noted in the upper lobes.; * **PET-CT (2024-02-12):**  Shows a right upper lobe mass with a maximum standardized uptake value (SUVmax) of 12.4, confirming high metabolic activity consistent with malignancy.  FDG-avid right hilar and mediastinal lymph nodes are present, with a maximum SUVmax of 8.2, indicating metabolically active disease. No evidence of distant metastatic disease is seen.; * **Primary lesion:** 3.8 x 3.2 cm (CT Chest); * **SUVmax of primary lesion:** 12.4 (PET-CT); The primary lesion is located in the right upper lobe, close to the hilum.  The involvement of hilar and mediastinal lymph nodes suggests potential spread within the mediastinum.  The relationship of the tumor to the chest wall and diaphragm cannot be definitively determined from the current imaging alone.\"\\n    }\\n  },\\n  \"pathology_analysis\": {\\n    \"summary\": \"**Pathology Analysis Report: Patient MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Pathology Analysis Report: Patient MDT2024001**\",\\n      \"histology\": \"**\",\\n      \"molecular_profile\": {\\n        \"key_mutations\": \"Key mutations not specified\",\\n        \"immunotherapy_markers\": \"80%.\",\\n        \"other_markers\": {\\n          \"KRAS\": \"**  Sotorasib and adagrasib are FDA-approved targeted therapies specifically designed for *KRAS* G12C-mutated lung adenocarcinomas.  These agents represent a significant advancement in treating this previously difficult-to-treat subset of lung cancer.\"\\n        }\\n      },\\n      \"therapeutic_implications\": [\\n        \"The provided data does not include information on the grade and differentiation of the adenocarcinoma.  Further pathological assessment of the biopsy specimen, including a detailed review by a pathologist experienced in lung cancer grading, is necessary to determine the grade (e.g., well-differentiated, moderately differentiated, poorly differentiated) and assess the degree of differentiation.  This information is crucial for prognosis and treatment planning.\",\\n        \"Molecular testing reveals a *KRAS* G12C mutation.  *EGFR*, *ALK*, and *ROS1* are wild-type or show no rearrangements. The presence of a *KRAS* G12C mutation is a significant finding as it identifies a specific therapeutic target.\",\\n        \"PD-L1 expression is 80%.  This high level of PD-L1 expression suggests that the patient may benefit from immunotherapy, specifically PD-1/PD-L1 inhibitors.  However, the response rate to immunotherapy can vary, and other factors should be considered in treatment selection.\",\\n        \"**5. Therapeutic Targets:**\",\\n        \"The *KRAS* G12C mutation and high PD-L1 expression identify two key therapeutic targets.\",\\n        \"* **KRAS G12C inhibitors:**  Sotorasib and adagrasib are FDA-approved targeted therapies specifically designed for *KRAS* G12C-mutated lung adenocarcinomas.  These agents represent a significant advancement in treating this previously difficult-to-treat subset of lung cancer.\",\\n        \"* **Immunotherapy (PD-1/PD-L1 inhibitors):** Given the high PD-L1 expression (80%), immunotherapy with agents like pembrolizumab, nivolumab, or atezolizumab should be strongly considered.  The high expression level increases the likelihood of a positive response to these agents.  However, response rates are not 100%.\",\\n        \"* **Combination therapy:**  Combining a KRAS G12C inhibitor with immunotherapy is a potential treatment strategy and may offer synergistic effects.  Clinical trials are investigating this combination approach.\",\\n        \"The patient is a candidate for treatment with KRAS G12C inhibitors (sotorasib or adagrasib) and/or immunotherapy (PD-1/PD-L1 inhibitors).  A combination therapy approach should be discussed within the MDT setting, considering ongoing clinical trials and the patient\\'s overall health and performance status.\",\\n        \"* **Comprehensive genomic profiling:** Although KRAS G12C is identified, broader genomic testing may uncover additional mutations that could influence treatment decisions or predict response to therapy. This could include next-generation sequencing (NGS) panels.\",\\n        \"* **Further staging investigations:**  While imaging suggests locally advanced disease (N2), surgical staging (e.g., mediastinoscopy) may be necessary to definitively determine the extent of nodal involvement before proceeding with definitive treatment.  This is crucial for accurate TNM staging.\",\\n        \"**Disclaimer:** This report is based on the available data.  The recommendations are subject to change based on further investigations and the MDT discussion.  This analysis is for informational purposes only and should not be considered a substitute for professional medical advice.  Treatment decisions should always be made in consultation with the patient and a multidisciplinary team of healthcare professionals.\"\\n      ],\\n      \"molecular_profile_formatted\": \"Key Mutations: Key mutations not specified. Immunotherapy Markers: 80%.. Other Markers: KRAS: **  Sotorasib and adagrasib are FDA-approved targeted therapies specifically designed for *KRAS* G12C-mutated lung adenocarcinomas.  These agents represent a significant advancement in treating this previously difficult-to-treat subset of lung cancer.\"\\n    }\\n  },\\n  \"guideline_recommendations\": [\\n    {\\n      \"guideline\": \"**\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"**Age (62):**  Older patients may have reduced tolerance to certain treatments.  This needs consideration in treatment selection.\"\\n      ]\\n    },\\n    {\\n      \"guideline\": \"**  While gender doesn\\'t directly affect guideline application in this case, it\\'s noted for completeness.\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"**Comorbidities (T2DM, Hypertension, Osteoarthritis):**  These comorbidities influence treatment choices and require careful monitoring for drug interactions and potential side effects.\",\\n        \"**Performance Status (Estimated 60-70% KPS):** This indicates some limitations in daily activities and impacts treatment intensity.\",\\n        \"***KRAS* G12C Mutation:** This specific mutation is a key driver of the cancer and dictates treatment options.\",\\n        \"**High PD-L1 Expression (80%):** This strongly suggests that the patient may benefit from immunotherapy.\",\\n        \"*3. Evidence-Based Treatment Options:**\",\\n        \"**KRAS G12C Inhibitors:** Sotorasib or adagrasib are FDA-approved and demonstrate significant efficacy in this patient population (Level 1 evidence).\"\\n      ]\\n    },\\n    {\\n      \"guideline\": \"** Pembrolizumab, nivolumab, or atezolizumab are supported by high-level evidence given the high PD-L1 expression.  The choice will depend on specific guideline recommendations and the patient\\'s overall health. (Level 1 evidence).\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"**Combination Therapy:** Combining a KRAS G12C inhibitor with immunotherapy is a promising approach currently under investigation in clinical trials.  This should be considered if appropriate (Level 2 evidence).\",\\n        \"*4. Clinical Trial Eligibility:**\",\\n        \"*5. Special Considerations:**\",\\n        \"**Comorbidity Management:** Close monitoring of blood glucose and blood pressure is crucial during treatment.  Careful consideration of drug interactions is necessary.\",\\n        \"**Performance Status:** Treatment intensity should be adjusted based on the patient\\'s performance status.\",\\n        \"**Toxicity Management:**  Close monitoring for and management of treatment-related adverse effects is essential.\",\\n        \"**Shared Decision-Making:**  Treatment decisions should involve the patient and her family to ensure patient-centered care.\",\\n        \"*6. Documentation of Deviations from Standard Practice:**\",\\n        \"*7. Recommendations:**\",\\n        \"**Multidisciplinary Team (MDT) Discussion:**  An urgent MDT meeting involving oncologists, pulmonologists, pathologists, and radiologists is crucial to finalize the staging and develop a personalized treatment plan.\",\\n        \"**Definitive Staging:**  Complete pathological staging, including mediastinoscopy if indicated, is needed to determine the precise TNM stage.\",\\n        \"**Treatment Plan:** Based on the complete staging and MDT discussion, a treatment plan should be developed that includes either:\",\\n        \"Sotorasib or adagrasib monotherapy.\",\\n        \"A combination of a KRAS G12C inhibitor and immunotherapy (PD-1/PD-L1 inhibitor).\",\\n        \"Participation in a relevant clinical trial.\",\\n        \"**Close Monitoring:**  Regular monitoring for treatment response, toxicity, and management of comorbidities is essential.\",\\n        \"**Supportive Care:**  Appropriate supportive care should be provided to address symptoms and improve the patient\\'s quality of life.\",\\n        \"*Disclaimer:** This analysis is based on the available information and current medical knowledge.  The recommendations are subject to change based on additional information and the MDT discussion.  This analysis should not be considered a substitute for professional medical advice.\"\\n      ]\\n    }\\n  ]\\n}', 'task': 'Synthesize all available information and provide an expert clinical assessment including treatment recommendations, risk stratification, and special considerations. Consider both patient-specific factors and guideline recommendations.'}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'overall_assessment': '**', 'treatment_considerations': ['Patient MDT2024001 is a 62-year-old female with a strong clinical suspicion of locally advanced non-small cell lung cancer (NSCLC), likely adenocarcinoma, based on the constellation of symptoms (persistent cough with hemoptysis, significant weight loss, fatigue, anorexia, night sweats), physical examination findings (decreased breath sounds in the right upper lobe, right supraclavicular lymphadenopathy), and imaging results (3.8 x 3.2 cm spiculated mass in the right upper lobe with hilar and mediastinal lymph node involvement, SUVmax 12.4 on PET-CT).  Pathology confirmed the diagnosis of adenocarcinoma with a *KRAS* G12C mutation and high PD-L1 expression (80%).  The patient has well-controlled Type 2 Diabetes Mellitus, hypertension, and osteoarthritis, which will need to be carefully managed during treatment. Her estimated KPS is 60-70%, indicating some functional limitations.', '* **Molecular Profile:** *KRAS* G12C mutation, PD-L1 expression 80%.  This profile significantly impacts treatment selection.', '* **Age:** 62 years old  influences treatment tolerance and potential long-term side effects.', '* **Performance Status:** KPS 60-70%  limits treatment intensity and necessitates supportive care planning.', '**4. Treatment Options:**'], 'risk_assessment': '**', 'proposed_approach': '**  This is less favored in the initial treatment approach given the availability of targeted and immunotherapy options.  This might be considered if the patient progresses on targeted therapy.', 'follow_up_recommendations': []}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ],
  "197997fd-9aac-4842-bb1a-583ddb7cd188_SpecialistAgent": [
    {
      "type": "human",
      "data": {
        "content": "{'context': '{\\n  \"patient_id\": \"MDT2024001\",\\n  \"demographics\": {\\n    \"age\": 62,\\n    \"gender\": \"F\",\\n    \"ethnicity\": \"Caucasian\",\\n    \"occupation\": \"Retired Teacher\",\\n    \"smoking_status\": \"Former smoker, quit 10 years ago\"\\n  },\\n  \"current_condition\": {\\n    \"primary_complaint\": \"Persistent cough with occasional blood-tinged sputum\",\\n    \"onset\": \"2024-01-15\",\\n    \"severity\": \"Moderate to severe\",\\n    \"associated_symptoms\": [\\n      \"Unintentional weight loss (5kg in 3 months)\",\\n      \"Fatigue\",\\n      \"Decreased appetite\",\\n      \"Night sweats\"\\n    ],\\n    \"physical_exam\": {\\n      \"vital_signs\": {\\n        \"temperature\": \"37.2\\\\u00b0C\",\\n        \"blood_pressure\": \"132/82\",\\n        \"heart_rate\": \"88\",\\n        \"respiratory_rate\": \"20\",\\n        \"oxygen_saturation\": \"95% on room air\"\\n      },\\n      \"chest\": \"Decreased breath sounds in right upper lobe\",\\n      \"lymph_nodes\": \"Right supraclavicular lymphadenopathy\",\\n      \"weight\": \"68 kg\",\\n      \"height\": \"165 cm\"\\n    }\\n  },\\n  \"medical_history\": [\\n    {\\n      \"condition\": \"Type 2 Diabetes\",\\n      \"diagnosed\": \"2015-06-15\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Metformin 1000mg BID\",\\n      \"control\": \"Good, HbA1c 6.8%\"\\n    },\\n    {\\n      \"condition\": \"Hypertension\",\\n      \"diagnosed\": \"2016-03-22\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"Lisinopril 20mg daily\",\\n      \"control\": \"Well-controlled, BP avg 128/78\"\\n    },\\n    {\\n      \"condition\": \"Osteoarthritis\",\\n      \"diagnosed\": \"2018-11-30\",\\n      \"status\": \"Ongoing\",\\n      \"treatment\": \"PRN NSAIDs\",\\n      \"affected_joints\": [\\n        \"knees\",\\n        \"hands\"\\n      ]\\n    }\\n  ],\\n  \"ehr_analysis\": {\\n    \"summary\": \"Based on the reported symptoms and weight loss, a preliminary assessment suggests a Karnofsky Performance Status (KPS) score of 60-70%.  A more formal assessment using ECOG or other validated tools is needed for accurate staging and treatment planning.  The patient\\'s ability to perform activities of daily living is likely impaired.\",\\n    \"details\": {\\n      \"summary\": \"Based on the reported symptoms and weight loss, a preliminary assessment suggests a Karnofsky Performance Status (KPS) score of 60-70%.  A more formal assessment using ECOG or other validated tools is needed for accurate staging and treatment planning.  The patient\\'s ability to perform activities of daily living is likely impaired.\",\\n      \"key_history_points\": [],\\n      \"current_presentation\": {\\n        \"main_symptoms\": [],\\n        \"performance_status\": \"**  Treatment will depend on the histopathological findings, staging, and the patient\\'s overall performance status.  Options may include surgery, chemotherapy, radiation therapy, targeted therapy, or immunotherapy, or a combination thereof.  A multidisciplinary team (MDT) meeting involving oncologists, surgeons, radiologists, and other relevant specialists is essential to develop a personalized treatment plan.\",\\n        \"comorbidity_impact\": \"**  The patient\\'s comorbidities (diabetes, hypertension, osteoarthritis) will influence treatment decisions.  Careful consideration needs to be given to potential drug interactions and the overall tolerance of chemotherapy or radiation therapy.  Close monitoring of blood glucose and blood pressure will be essential during treatment.\"\\n      },\\n      \"risk_factors\": [],\\n      \"clinical_implications\": [],\\n      \"raw_output\": \"## EHR Analysis Agent Report: Patient MDT2024001\\\\n\\\\n**1. Key History Points:**\\\\n\\\\n* **Chronological Progression of Symptoms:**  The patient, a 62-year-old Caucasian female, presents with a persistent cough (onset January 15th, 2024) initially described as moderate to severe, progressing to include blood-tinged sputum.  This is accompanied by significant unintentional weight loss (5kg in 3 months), fatigue, decreased appetite, and night sweats \\\\u2013 all highly suggestive of a serious underlying condition, possibly malignancy.\\\\n\\\\n* **Medical History:** The patient has a history of well-controlled Type 2 Diabetes Mellitus (since 2015), well-controlled hypertension (since 2016), and osteoarthritis (since 2018). These comorbidities will need to be considered when planning treatment.\\\\n\\\\n* **Social and Functional Factors:** The patient is a retired teacher, suggesting a previously active lifestyle.  Her current symptoms significantly impact her functional status, given the weight loss, fatigue, and severity of her respiratory symptoms.\\\\n\\\\n**2. Current Clinical Status:**\\\\n\\\\n* **Primary Complaint:** Persistent cough with hemoptysis.\\\\n* **Physical Examination:**  Significant findings include decreased breath sounds in the right upper lobe and right supraclavicular lymphadenopathy \\\\u2013 strongly suggestive of intrathoracic pathology, potentially lung cancer.  Vital signs are mostly stable, although the slightly elevated blood pressure may be stress-related or influenced by her underlying hypertension.\\\\n* **Laboratory Results:**  The complete blood count shows normal hemoglobin, WBC, and platelets, ruling out overt anemia or significant infection.  Liver function tests (ALT and AST) are mildly elevated, which warrants further investigation, but could be related to medication or the underlying condition.  Albumin is within the normal range.  Creatinine is normal.\\\\n\\\\n**3. Relevant Risk Factors:**\\\\n\\\\n* **Age:** 62 years old (increased risk for various cancers).\\\\n* **Smoking History:** Former smoker (cessation 10 years ago), still conferring increased risk.\\\\n* **Symptoms:** The constellation of symptoms (cough, hemoptysis, weight loss, fatigue, night sweats, lymphadenopathy) is highly suggestive of lung cancer.\\\\n\\\\n**4. Performance Status Assessment:**\\\\n\\\\nBased on the reported symptoms and weight loss, a preliminary assessment suggests a Karnofsky Performance Status (KPS) score of 60-70%.  A more formal assessment using ECOG or other validated tools is needed for accurate staging and treatment planning.  The patient\\'s ability to perform activities of daily living is likely impaired.\\\\n\\\\n**5. Clinical Implications:**\\\\n\\\\nThe clinical presentation strongly suggests the possibility of lung cancer.  Further investigations are urgently required, including:\\\\n\\\\n* **Imaging:**  High-resolution computed tomography (HRCT) of the chest is crucial to evaluate the extent of the lung lesion and assess for lymph node involvement.  A CT scan of the abdomen and pelvis may also be necessary to detect any metastatic disease.\\\\n* **Bronchoscopy:** This is essential for obtaining tissue samples (biopsy) for histopathological examination and cytological analysis to confirm the diagnosis and determine the specific type of lung cancer.\\\\n* **Further Laboratory Tests:**  Consider serum tumor markers (e.g., CEA, CYFRA 21-1) and further investigation into the mildly elevated liver enzymes.\\\\n\\\\n**Comorbidity Impact on Treatment:**  The patient\\'s comorbidities (diabetes, hypertension, osteoarthritis) will influence treatment decisions.  Careful consideration needs to be given to potential drug interactions and the overall tolerance of chemotherapy or radiation therapy.  Close monitoring of blood glucose and blood pressure will be essential during treatment.\\\\n\\\\n**Treatment Planning:**  Treatment will depend on the histopathological findings, staging, and the patient\\'s overall performance status.  Options may include surgery, chemotherapy, radiation therapy, targeted therapy, or immunotherapy, or a combination thereof.  A multidisciplinary team (MDT) meeting involving oncologists, surgeons, radiologists, and other relevant specialists is essential to develop a personalized treatment plan.\\\\n\\\\n**Limitations and Uncertainties:** The diagnosis remains presumptive until confirmed by histopathological examination.  The severity of the underlying condition and the patient\\'s prognosis are currently unknown and will depend on the results of further investigations.\\\\n\\\\n\\\\n**Conclusion:**\\\\n\\\\nThis patient requires urgent further investigation to confirm the suspected diagnosis of lung cancer and to determine the extent of the disease.  A comprehensive MDT approach is crucial for optimal management.  Close monitoring of her comorbidities is vital throughout the diagnostic and treatment process to minimize potential complications and ensure patient safety and well-being.\"\\n    }\\n  },\\n  \"imaging_analysis\": {\\n    \"summary\": \"**Imaging Analysis Report: Patient MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Imaging Analysis Report: Patient MDT2024001**\",\\n      \"disease_extent\": {\\n        \"primary_tumor\": \"** 3.8 x 3.2 cm (CT Chest)\",\\n        \"nodal_status\": \"**  Detailed analysis of individual lymph node size and SUVmax values on PET-CT is crucial for accurate N-staging.  This detailed information is missing from the current data.\",\\n        \"metastatic_status\": \"** Although the PET-CT did not reveal distant metastases, additional imaging of the abdomen and pelvis may be valuable for a more comprehensive evaluation, especially given the patient\\'s age and overall presentation.\"\\n      },\\n      \"staging\": {\\n        \"clinical_stage\": \"\",\\n        \"key_findings\": [\\n          \"* **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The findings are highly suggestive of a primary lung malignancy.  Limited spatial resolution prevents precise characterization.\",\\n          \"* **CT Chest (2024-02-05):**  Reveals a 3.8 x 3.2 cm spiculated mass in the right upper lobe, consistent with a malignant neoplasm.  Multiple enlarged right hilar and mediastinal lymph nodes are present. No evidence of distant metastases is identified. Mild emphysematous changes are noted in the upper lobes.\",\\n          \"* **PET-CT (2024-02-12):** Confirms the presence of a highly FDG-avid right upper lobe mass (SUVmax 12.4), indicating high metabolic activity consistent with malignancy.  FDG-avid right hilar and mediastinal lymph nodes (SUVmax 8.2) are also identified, confirming lymph node involvement.  No evidence of distant metastatic disease is detected.\",\\n          \"* **Primary Lesion:** 3.8 x 3.2 cm (CT Chest)\",\\n          \"Based on the available imaging data, the patient presents with a large primary lung mass in the right upper lobe with significant regional lymph node involvement (N2).  There is no evidence of distant metastases (M0).  Considering the size of the primary tumor (T2-T3 based on the CT findings, exact T-stage requires further pathological confirmation) and the presence of N2 disease, the imaging suggests a **Stage IIIA** non-small cell lung cancer (NSCLC) according to the 8th edition TNM staging system.  This is a preliminary assessment pending histopathological confirmation of the tumor type and further detailed lymph node staging.\",\\n          \"The primary lesion is located in the right upper lobe, close to the hilum, explaining the associated hilar lymphadenopathy.  The mediastinal lymph node involvement suggests potential spread along lymphatic pathways.  The proximity of the tumor to major vessels and bronchi should be carefully assessed pre-operatively, if surgery is considered.  The mild emphysema may impact surgical planning and should be considered.\"\\n        ]\\n      },\\n      \"treatment_implications\": [],\\n      \"disease_extent_formatted\": \"Primary Tumor: ** 3.8 x 3.2 cm (CT Chest). Nodal Status: **  Detailed analysis of individual lymph node size and SUVmax values on PET-CT is crucial for accurate N-staging.  This detailed information is missing from the current data.. Metastatic Status: ** Although the PET-CT did not reveal distant metastases, additional imaging of the abdomen and pelvis may be valuable for a more comprehensive evaluation, especially given the patient\\'s age and overall presentation..\",\\n      \"staging_formatted\": \"Clinical Stage: . Key Findings: * **Chest X-ray (2024-02-01):** Demonstrates a 3.5 cm mass in the right upper lobe with associated hilar lymphadenopathy.  The findings are highly suggestive of a primary lung malignancy.  Limited spatial resolution prevents precise characterization.; * **CT Chest (2024-02-05):**  Reveals a 3.8 x 3.2 cm spiculated mass in the right upper lobe, consistent with a malignant neoplasm.  Multiple enlarged right hilar and mediastinal lymph nodes are present. No evidence of distant metastases is identified. Mild emphysematous changes are noted in the upper lobes.; * **PET-CT (2024-02-12):** Confirms the presence of a highly FDG-avid right upper lobe mass (SUVmax 12.4), indicating high metabolic activity consistent with malignancy.  FDG-avid right hilar and mediastinal lymph nodes (SUVmax 8.2) are also identified, confirming lymph node involvement.  No evidence of distant metastatic disease is detected.; * **Primary Lesion:** 3.8 x 3.2 cm (CT Chest); Based on the available imaging data, the patient presents with a large primary lung mass in the right upper lobe with significant regional lymph node involvement (N2).  There is no evidence of distant metastases (M0).  Considering the size of the primary tumor (T2-T3 based on the CT findings, exact T-stage requires further pathological confirmation) and the presence of N2 disease, the imaging suggests a **Stage IIIA** non-small cell lung cancer (NSCLC) according to the 8th edition TNM staging system.  This is a preliminary assessment pending histopathological confirmation of the tumor type and further detailed lymph node staging.; The primary lesion is located in the right upper lobe, close to the hilum, explaining the associated hilar lymphadenopathy.  The mediastinal lymph node involvement suggests potential spread along lymphatic pathways.  The proximity of the tumor to major vessels and bronchi should be carefully assessed pre-operatively, if surgery is considered.  The mild emphysema may impact surgical planning and should be considered.\"\\n    }\\n  },\\n  \"pathology_analysis\": {\\n    \"summary\": \"**Pathology Analysis Agent Report: Patient MDT2024001**\",\\n    \"details\": {\\n      \"summary\": \"**Pathology Analysis Agent Report: Patient MDT2024001**\",\\n      \"histology\": \"**\",\\n      \"molecular_profile\": {\\n        \"key_mutations\": \"**4. Biomarker Status:**\",\\n        \"immunotherapy_markers\": \"**  MSI testing is recommended to evaluate potential response to immunotherapy, especially if TMB is low.\",\\n        \"other_markers\": {}\\n      },\\n      \"therapeutic_implications\": [\\n        \"The provided data does not specify the grade or differentiation of the adenocarcinoma.  Review of the hematoxylin and eosin (H&E)-stained slides by a pathologist is crucial to determine the grade and assess the degree of cellular differentiation. This information is vital for prognosis and treatment planning.\",\\n        \"The molecular testing reveals a *KRAS* G12C mutation.  This is a significant finding as it identifies a specific targetable oncogenic driver.  The absence of *EGFR*, *ALK*, and *ROS1* rearrangements rules out other common driver mutations in lung adenocarcinoma.\",\\n        \"The PD-L1 immunohistochemistry shows 80% expression.  This high PD-L1 expression suggests the patient may benefit from immunotherapy, specifically PD-1/PD-L1 inhibitors.\",\\n        \"**5. Therapeutic Targets:**\",\\n        \"Based on the molecular and biomarker findings, the following therapeutic targets are identified:\",\\n        \"* **KRAS G12C:**  The presence of the *KRAS* G12C mutation makes the patient eligible for treatment with specific KRAS G12C inhibitors (e.g., sotorasib, adagrasib).  These targeted therapies have shown significant efficacy in patients with this specific mutation.\",\\n        \"* **PD-L1:** The high PD-L1 expression (80%) strongly suggests that the patient may respond well to immunotherapy with PD-1/PD-L1 inhibitors (e.g., pembrolizumab, nivolumab).  The high expression level increases the likelihood of a positive response.\",\\n        \"The patient is a candidate for both targeted therapy with a KRAS G12C inhibitor and immunotherapy with a PD-1/PD-L1 inhibitor.  The optimal treatment strategy will need to be determined through a multidisciplinary team (MDT) discussion considering the patient\\'s overall health, performance status, and the presence of any comorbidities.  The high PD-L1 expression strengthens the case for immunotherapy.  A combination of targeted therapy and immunotherapy may also be considered, depending on the MDT decision.\",\\n        \"* **Detailed Review of H&E Stained Slides:**  A thorough assessment by an experienced pathologist to determine the grade and differentiation of the adenocarcinoma. This will refine the prognosis and inform treatment decisions.\",\\n        \"* **Comprehensive Lymph Node Staging:**  Detailed analysis of the lymph nodes identified on the PET-CT scan is crucial for accurate staging.  This may involve additional imaging or sampling of involved lymph nodes via mediastinoscopy or endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA).  Accurate nodal staging (N-stage) is crucial for determining the overall stage of the disease and selecting the appropriate treatment approach.\",\\n        \"* **Tumor Mutational Burden (TMB):**  Assessing TMB can provide additional insights into the patient\\'s potential response to immunotherapy.  High TMB is associated with improved response to immunotherapy.\",\\n        \"* **Microsatellite Instability (MSI) Testing:**  MSI testing is recommended to evaluate potential response to immunotherapy, especially if TMB is low.\",\\n        \"This comprehensive analysis provides a strong foundation for the MDT to develop a personalized and evidence-based treatment plan for this patient.  The information provided here should be discussed and integrated with other relevant clinical data during the MDT meeting.\"\\n      ],\\n      \"molecular_profile_formatted\": \"Key Mutations: **4. Biomarker Status:**. Immunotherapy Markers: **  MSI testing is recommended to evaluate potential response to immunotherapy, especially if TMB is low.\"\\n    }\\n  },\\n  \"guideline_recommendations\": [\\n    {\\n      \"guideline\": \"**\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"*3. Special Populations and Comorbidities:**\",\\n        \"*4. Evidence Levels:**\",\\n        \"*5. Clinical Trial Options:**\",\\n        \"*Recommendations:**\"\\n      ]\\n    },\\n    {\\n      \"guideline\": \"**\",\\n      \"version\": \"\",\\n      \"category\": \"\",\\n      \"recommendations\": [\\n        \"**Targeted Therapy:**  Sotorasib or adagrasib (KRAS G12C inhibitors) are strongly indicated based on the *KRAS* G12C mutation.\",\\n        \"**Immunotherapy:**  Pembrolizumab or nivolumab (PD-1/PD-L1 inhibitors) are indicated due to high PD-L1 expression.\",\\n        \"**Combination Therapy:**  The combination of a KRAS G12C inhibitor and a PD-1/PD-L1 inhibitor may be considered, potentially enhancing efficacy. This warrants discussion within the MDT given the ongoing research in this area.\",\\n        \"**Chemotherapy:**  Depending on the outcome of the MDT discussion and the patient\\'s response to targeted therapy and/or immunotherapy, chemotherapy may be considered as part of a combined modality approach.  The choice of chemotherapy regimen would depend on several factors, including the patient\\'s overall health and tolerance.\",\\n        \"*2. Evidence Levels:**  The evidence supporting the use of KRAS G12C inhibitors and PD-1/PD-L1 inhibitors in this patient population is high (Level 1 evidence based on large, well-designed RCTs).  The evidence for combination therapy is emerging but warrants further investigation within the MDT.\",\\n        \"*3. Clinical Trial Considerations:**  The patient should be assessed for eligibility in clinical trials investigating novel combinations of targeted therapy and immunotherapy in *KRAS* G12C-mutated NSCLC.\",\\n        \"*4. Special Considerations:**\",\\n        \"**Comorbidities:**  Careful management of the patient\\'s diabetes, hypertension, and osteoarthritis is essential.  Close monitoring of blood glucose, blood pressure, and renal function is necessary during treatment.  Drug interactions between the cancer treatments and her existing medications must be considered.\",\\n        \"**Performance Status:**  Regular assessment of the patient\\'s performance status using ECOG or KPS is vital for treatment adjustments and quality-of-life monitoring.\",\\n        \"*5. Documentation of Deviations:**  Any deviations from standard practice would need to be documented and justified based on the patient\\'s specific clinical situation, preferences, and the MDT\\\\u2019s collective decision-making process.  This would involve careful consideration of risk-benefit ratios.\",\\n        \"*Next Steps:**\",\\n        \"**MDT Meeting:**  An urgent MDT meeting involving oncologists, pulmonologists, thoracic surgeons, radiologists, pathologists, and other relevant specialists is crucial to develop a personalized treatment plan.\",\\n        \"**Comprehensive Lymph Node Staging:**  Further investigation to precisely define the nodal status (N-stage) is essential for accurate staging.  This might involve mediastinoscopy or EBUS-TBNA.\",\\n        \"**Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) Testing:**  These tests can further refine treatment strategies and predict response to immunotherapy.\"\\n      ]\\n    }\\n  ]\\n}', 'task': 'Synthesize all available information and provide an expert clinical assessment including treatment recommendations, risk stratification, and special considerations. Consider both patient-specific factors and guideline recommendations.'}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "human",
        "name": null,
        "id": null,
        "example": false
      }
    },
    {
      "type": "ai",
      "data": {
        "content": "{'overall_assessment': '**', 'treatment_considerations': ['Patient MDT2024001 is a 62-year-old Caucasian female presenting with a highly suggestive clinical picture of advanced non-small cell lung cancer (NSCLC), likely adenocarcinoma, based on the imaging and pathology findings.  The patient presents with a 3.8 x 3.2 cm right upper lobe mass, significant regional lymph node involvement (N2), and high PD-L1 expression (80%).  Crucially, molecular testing reveals a *KRAS* G12C mutation, a targetable oncogenic driver.  While distant metastases are not currently detected, the size of the primary tumor and nodal involvement place her in a high-risk category (Stage IIIA, pending definitive pathological staging).  Her comorbidities (Type 2 Diabetes, Hypertension, Osteoarthritis) will require careful consideration in treatment planning and monitoring.  Her KPS is estimated at 60-70%, indicating moderate impairment in her activities of daily living.  Further investigation is needed to precisely define the nodal status (N-stage) through mediastinoscopy or EBUS-TBNA, and to assess TMB and MSI status.', '**4. Treatment Options:**', '* **Targeted Therapy:** Sotorasib or adagrasib (KRAS G12C inhibitors) are highly indicated.', '* **Immunotherapy:** Pembrolizumab or nivolumab (PD-1/PD-L1 inhibitors) are highly indicated due to the high PD-L1 expression.', '* **Combination Therapy:**  The combination of a KRAS G12C inhibitor and a PD-1/PD-L1 inhibitor is a strong contender, offering the potential for synergistic effects.  This requires careful consideration within the MDT.'], 'risk_assessment': '**', 'proposed_approach': 'Individualized approach recommended.', 'follow_up_recommendations': ['Ongoing monitoring of comorbidities and treatment-related side effects.', 'Supportive care as needed to manage symptoms and improve quality of life.  This may include palliative care consultation.', '*11. Limitations and Uncertainties:**', \"The diagnosis and staging remain presumptive until confirmed by definitive pathology and complete lymph node staging.  The optimal treatment sequence and the patient's long-term prognosis will depend on the response to initial treatment and the results of further investigations.  The emergence of resistance to targeted therapy is also a potential long-term concern.\", 'This comprehensive assessment provides a framework for discussion within the MDT.  The final treatment plan must be individualized based on the complete data and the MDTs collective expertise.  The patients autonomy and shared decision-making are central to this process.']}",
        "additional_kwargs": {},
        "response_metadata": {},
        "type": "ai",
        "name": null,
        "id": null,
        "example": false,
        "tool_calls": [],
        "invalid_tool_calls": [],
        "usage_metadata": null
      }
    }
  ]
}